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SPECIAl. COMMUNICATION 
The following extended abstracts were presented at a Research Initiatives in 
Vascular Disease Symposium, Inflammatory and Immune Mechanisms in Vascular 
Disease, sponsored by The Lifeline Foundation; the International Society for 
Cardiovascular Surgery, North American Chapter; and The Society for Vascular 
Surgery on Feb. 19-20, 1998, in Bethesda, Md. 
INFLAMMATION AND IMMUNOLOGY- -  
CR IT ICAL  I SSUES 
IMMUNE MECHANISMS IN VASCULAR 
DISEASE 
Much interest has recently been focused on the role of the 
immune system in the pathogenesis of atherosclerosis. This 
interest is based on observations of immunoglobulins, T lym- 
phocytes, macrophages, immune-regulatory cytokines, and cel- 
lular adhesion molecules in human atherosclerotic plaques) It is 
therefore clear that the central components of the immune 
response--T cells, macrophages, and immune-regulatory 
cytokines--are present and activated in atherosclerosis. 
These observations indirectly imply that manipulation of 
the immune response could alter the development of athero- 
sclerosis. Recent animal experiments support his notion. First, 
it was shown that genetic or antibody-mediated elimination of 
T lymphocytes increase lesion formation after balloon injury in 
the rat carotic artery. 2 Second, the immunosuppressive drug 
cyclosporin A enhanced atherosclerosis in cholesterol-fed rab- 
bits. 3 Finally, it was recently demonstrated that genetically 
immunodeficient mice develop larger lesions when fed choles- 
terol. 4 This was the case both for RAG-1 knock-out mice, 
which lack mature B and T cells, and for MHC-class I knock- 
out mice, which are deficient in the CD8 subtype of T lym- 
phocytes and cannot herefore mount immune responses that 
are dependent on presentation via the secretory pathway. 
Two possible therapeutic strategies could be developed 
on the basis of these findings. First, eftkctor pathways of the 
immune response could be used to inhibit vascular disease. 
For example, recombinant cytokines might be applied to pre- 
vent restenosis after angioplasty. Support for this concept has 
been obtained in the rat balloon catheter model 5 but still 
needs to be confirmed in animal models that are more similar 
to the human disease process. 
Primary prevention strategies and treatment of clinically 
asymptomatic atherosclerosis requires drugs that can be taken 
orally and have minimal side effects. This in essence rules out 
cytokines, which are highly potent biologic response modi- 
tiers and have to be taken parenterally. Instead, the classical 
approach in preventive medicine, i. ., induction of protective 
immune responses, would be attractive. Vaccination has erad- 
icated many infectious diseases and there is now an increasing 
interest in using this approach to treat autoimmune diseases 
such as multiple sclerosis and rheumatoid arthritis. However~ 
such a strategy requires the identification of specific antigens 
involved in the pathogenesis of the particular disease. Such 
information has been lacking in atherosclerosis. 
In order to ensure the widest dissemination possible, these 
abstracts also will appear in the July issue of the Journal of 
Vascular and Interventional Radiology (published by 
Lippincott-Raven). 
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Rcccnt studies have, however, identified autoantigens in
human plaques. Low-density lipoprotein (LDL) is oxidized in 
tissues, thus transforming the native lipoprotein particle into 
an immunogen. 6 In fact, the titer of autoantibodies to oxi- 
dized LDL correlates with disease progression in man. 7 Two 
new pieces of information further highlight oxidized LDL as 
an interesting candidate antigen for prophylactic use. First, 
CD4 + T cells of human atherosclerotic plaques were found to 
react immunospecifically to oxidized LDL presented to them 
by autologous macrophages. 8 This indicates that oxidized 
LDL is not only generated but indeed elicits a cellular autoim- 
mune response in the atherosclerotic plaque. Secondly, 
immunization with oxidized LDL was found to significantly 
reduce the development of atherosclerotic lesions in choles- 
terol-fed rabbits. 9 This directly indicates that immunization 
with oxidized LDL inhibits the atherogenic process. It will 
now be important o confirm this finding in other experi- 
mental models. 
The immune response is, however, extremely complex, 
and in addition to LDL several other local antigens could be 
involved in the immune response of the atherosclerotic 
plaque. Some of these antigens may elicit aggravating rather 
than protective immune responses. Thus immunization with 
heat shock protein 60, an intracellular protein released uring 
cell injury, was found to aggravate atherosclerosis in rabbits. 10 
This emphasizes the complexity of the immune response and 
argues against general and for specific immunoprophylactic 
strategies. 
In conclusion, therefore, recent research into the immune 
response of atherosclerosis has unraveled several mechanistic 
interactions, some of which are elicited in the lesion and 
induce immune responses that may be protective. The devel- 
opment of murine models of atherosderosis permit an analysis 
of mechanisms and candidate antigens to an extent that has 
not been possible with other models. Although much more 
remains to be clarified before new therapeutic or prophylactic 
strategies are developed, the results obtained so far are encour- 
aging as they point towards a new approach to prevent or treat 
atherosclerosis. 
G6ran IC Hansson, MD, PhD 
Karolinska Institute 
Stockholm, Sweden 
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INFLAMMATORY PROCESSES IN VASCULAR 
DISEASE 
Inflammatory processes contribute to the pathobiologic mech- 
anisms of all major categories of vascular disease, including 
atherosclerosis, thrombosis, aneurysms, and, by definition, the 
various forms of arteritis. On considering inflammatory 
processes in general, it is useful to group them into two cate- 
gories: antigen-specific, and antigen-nonspecific. Antigen-spe- 
cific inflammatory responses are the basis for adaptive immu- 
nity or autoimmunity and are driven by T or B lymphocyte 
reactions to particular foreign or auto antigens. Antigen-non- 
specific inflammation is mediated by the native immune system 
without a requirement for lymphocyte activation and is char- 
acterized by stereotypical response to many different stimuli. 
An important theme in immunobiology and inflammation is
the cooperation of the adaptive and native immune systems 
such that antigen-specific responses recruit many of the effec- 
tor mechanisms that are active in antigen-nonspecific respons- 
es. This becomes readily apparent when the inflammatory 
processes in vascular walls are analyzed in detail, as discussed in 
several of the other papers in this meeting. Both antigen-spe- 
cific and antigen-nonspecific categories can be subdivided fur- 
ther into humoral and cell-mediated responses. The humoral 
response of the specific immune system is mediated by soluble 
antibodies ecreted by B lymphocytes. Serum complement 
proteins are prevalent soluble or humoral components of anti- 
gen-nonspecific inflammatory responses. A good example of 
how the humoral arms of the acquired and native immune sys- 
tems cooperate is the activation of the classical complement 
cascade by immunoglobulin G or M bound to specific antigen. 
T lymphoeytes are the cellular mediators of antigen-specific 
inflammatory esponses. CD8+ T cells respond to foreign pep- 
tide antigens displayed by class I MHC molecules on the sur- 
face of host cell types and differentiate into effector cytolytic T
lymphocytes, which can kill those antigen bearing cells. On the 
other hand, CD4 + T cells recognize foreign peptides displayed 
by class II MHC molecules on professional ntigen presenting 
cells (APCs). In response to antigen, these CD4 + T cells dif- 
ferentiate into effector helper T cells, which often work to 
eradicate the antigen by activating other cellular effcctors. 
Cellular components of typical antigen-nonspccific immune 
responses include granulocytcs, uch as polymorphonuclear 
leukocytes and eosinophils, and mononuclear phagocytes. As 
with humoral immunity, antigen-specific cell-mediated immu- 
nity often relies on the antigen-nonspecific cellular effectors. 
Thus, in delayed-type hypersensitivity responses, antigen-acti- 
vated CD4 + T cells express membrane-bound CD40-1igand 
and secreted interferon-7, both of which activate maerophages. 
Alaother important relationship between these different com- 
ponents of the immune system is the functional interplay 
between cellular and humoral effectors. For example, the 
opsonization of antigen by antibody or complement greatly 
enhances the ability of Ig Fc receptor-bearing eutrophils and 
macrophages to phagocytose those antigens. 
Atherosclerosis i , in part, an inflammatory process that 
incorporates cellular and humoral elements of both antigen- 
specific and antigen-nonspecific responses. As discussed in 
other papers in this forum, there is convincing evidence for 
both T and B lymphocyte responses to antigens present in 
atherosclerotic plaquesJ The evidence for T cell responses 
includes the demonstration of early and persistent infltration 
of both CD4 + and CD8 + T cells in developing lesions and the 
expression of surface activation markers and cytokines by 
these T cells. The antigens to which these T cells are reacting 
is thc subject of intense scrutiny, and thc search is beginning 
to bear fruit. Candidates include products of low-density 
lipoprotein (LDL) oxidation and heat shock proteins. The 
evidence for B cell responses to plaque antigens was obtained 
first by identifying plaque components that might act as anti- 
gens and then identifying circulating antibodies reactive with 
these antigens. 2 This work has indicated that oxidized LDL 
(oxLDL) represents a plaque antigen that evokes antibody 
responses. The level of circulating antibodies reactive with 
oxLDL apparently correlates with the extent of atherosclerot- 
ic disease, and the localization of these antibodies within 
lesions has also been shown. Although these findings leave tit- 
tle doubt that antigen-specific immune responses directed 
against atheroma-associated antigens do occur, the signifi- 
cance of such responses to the process of lesion development 
or stability remains unknown. In this regard, the advent of 
mouse models of atherosclcrosis, ncluding LDL receptor and 
Apo-E deficient mice, are useful in deciphering the role of 
such immune responses.3, 4 This is because such mice can be 
intercrossed with other mutant strains that lack various com- 
ponents of the specific immune system, and the effects on ath- 
erosclerotic lesion development and phenotype can be ana- 
lyzed. The evidence for antigen-nonspecific inflammation in 
atherosclerotic lesions was obtained well before lymphocyte 
responses were identified. As for cellular esponses, the influx 
of monocytes into early atherosclerotic lesions appears to be 
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an antigcn-indcpendent (nonspecific) leukocytic inflammato- 
ry response. Once in theintima, these cells are converted to 
activated macrophages that eventually become lipid-laden 
foam cells. The very early upregulation of endothelial adhe- 
sion molecules, uch as vascular cellular adhesion molocule-1, 
which enhance recruitment of mononuclear cells, is likely a 
critical event early in the process of atheroma formation that 
occurs before antigen-specific a tivation of recruited T cells. 
A poorly understood but interesting characteristic of the ath- 
erosclerotic lesions is the absence of neutrophils. This distin- 
guishes the phenotype of this native immune inflammatory 
response from most other inflammatory conditions f vessel 
walls. Antigen-nonspecific humoral effector molecules are 
also found within atherosclerotic lesions, including comple- 
ment proteins C3b and C5b-9. 
Analyses of the atherosclerotic plaque have provided signif- 
icant information on which to base hypotheses for how inflam- 
matory responses may alter the disease process. Of particular 
interest isthe way the various antigen-specific and antigen-non- 
specific effector mechanisms interact with one another, and, 
importantly, on intrinsic vascular cells to modify lesion devel 
opment. An important question ishow the leukocytes and vas- 
cular cells communicate to orchestrate the inflammatory 
response. Traditionally, small molecules such as lipid mediators 
(e.g., prostaglandins, leukotrienes) or oligopepfide derivatives 
(e.g., F-met-leu-phe) were invoked inthis regard. More recent- 
ly, protein mediators known collectively as cytokines have 
gained attention as messengers that are important in vascular 
inflammation. Cytokines are protein mediators of inflamma- 
tion, immune responses, and hcmatopoiesis and are produced 
by many different cell types. Lymphocyte-derived cytokines 
("lymphokines") and those produced by mononuclear phago- 
cytes ("monokines") are critical for bidirectional cellular inter- 
actions during immune responses. Such interactions likely 
occur in plaques,  For example, the monocytes that are recruit- 
ed to early esions accumulate oxLDL via their scavenger recep- 
tors to form foam cells. The foam cells may secrete cytoldnes 
such as tumor necrosis factor (TNF) or interleukin (IL)-I that 
further upregulate adhesion molecules on overlying endotheli- 
urn, and this would promote recruitment ofT cells. An attrac- 
tive idea is that the foam cell also acts as an antigen presenting 
cell (APC) that processes and presents modified peptides 
derived from the oxLDL to infiltrating memory CD4 + T cells. 
The activated T cells secrete cyto!dnes including TNF-~ and 
interferon-3, (IFN-7), and these cytoldnes amplify the inflam- 
matory process by further activating macrophages and 
endothelium. In addition, it is important to consider events in 
draining lymph nodes where atheroma-associated antigens may 
be collected. It is presumably atthese sites that sensitization f
naive T cells first occurs and where T cell help for B cell anti- 
body responses to the antigens occurs. These lymph 
node-based responses are also dependent on cytokine commu- 
nication APCs, T cells, and B cells. The chemokines, a family of 
relatively low molecular weight cytokines with conserved struc- 
tural characteristics, are important for stimulating chemokinesis 
of leukocytes into inflammatory lesions. Monocytes, T cells, 
and endothelium all produce chemokines that may mediate 
movement of inflammatory cells into atherosclerotic lesions. 
Cytokines ecreted by CD4 + helper T cells could have var- 
ious influences on inflammatory processes in vascular walls. In 
fact, helper T cells have been classified into distinct subsets 
based on the types ofcytokines they produce. Thl  ceils are best 
distinguished byproduction of IFN-3, and TNF-I3, whereas Th2 
cells produce IL-4, IL-5, and IL-13. The phenotype of an 
immune response may be largely determined by the dominance 
of one or the other of these subsets. Thl-dominated reactions 
typically lead to IFN-3~-dependent macrophage activation and 
B-cell production ofimmunoglobulin isotypes that fix comple- 
ment or bind Fc-receptors. The evidence for IFN- 7 production 
and macrophage activation in plaques suggests a Thl-l ike 
response. Th2 cytokines such as IL-4 can downregulate 
macrophage activation and therefore could potentially regulate 
plaque-based Thl  responses. There is tittle evidence, however, 
for the local production of IL-4 in atheromata. On the other 
hand, it ~11 be of great interest to consider the role of a dis- 
tinct, recently described T cell subset called Trl, which sup- 
presses antigen-specific immune responses and actively down- 
regulates pathologic immune responses in vivo. 6 Trl cells pro- 
duce low levels of IL-2, no IL-4, and high levels of IL-10, a 
cytokine with potent macrophage inhibitory activity. Indeed, 
IL-10 has been detected in human atherosclerotic lesions. 7 
Cytokines produced within atherosclerotic lesions can 
have potentially significant effects beyond amplifying or regu- 
lating the inflammatory processes that have initiated their pro- 
duction. Migration and intimal proliferation of smooth muscle 
cells are fundamental to atherosclerosis. Several cytokines 
elaborated within lesions influence smooth muscle prolifera- 
tion. IL-1 can stimulate ndothelial or smooth muscle cell pro- 
duction of peptide mitogens uch as platelet-derived growth 
factor or basic fibroblast grox~h factor, which, in turn, stimu- 
late smooth muscle cell growth. In contrast, IFN-3' can inhib- 
it smooth muscle cell division. Hemocompafibility of the ves- 
sel wall can be altered by cytokines elaborated by endothelium, 
macrophages, and smooth muscle cells. For example, IL-1 or 
TNF readily induce endothelial expression of tissue factor 
activity and platelet activator inhibitor-1. Thus cytokines exert 
a concerted action on endothelial cells to promote blood coag- 
ulation and inhibit fibrinolysis. Vasomotor responses are influ- 
enced by cytoldnes uch as IL-1 and interferon-3, that induce 
the expression of nitric oxide synthetases and prostaglandins. 
There is obviously a daunting complexity to the local cytokine 
networks within the vascular wall. Nonetheless, mouse models 
of atherosclerosis will be helpful in deciphering the net effects 
of different cytokines. For example, the extent of atheroscle- 
rosis in Apo-E-deflcient mice is reduced when IFN-3, receptors 
are absent. 8 This approach also promises to shed light on the 
role of cytoldnes in other forms of vascular disease. Thus in a 
mouse model of transplant-associated arterial disease the 
absence of IFN-3, prevents coronary arteriosclerosis. 9 
In summary, atherosclerosis is one example of a vascular 
disease in which both antigen-specific acquired immune 
responses and antigen-nonspeciflc native immune responses 
contribute to an inflammatory pathologic process. Both cel- 
lular and humoral effectors of inflammation are prevalent 
within lesions. Cytokines produced by vascular wall cells and 
infiltrating leukocytes are responsible for the inflammatory 
phenotype of the atheroma. In addition, these cytokines influ- 
ence other components of the disease process including fibro- 
proliferative activity, thrombosis, and vascttlar tone. Although 
many of the cellular and molecular players in this process have 
been identified, their exact roles remain unknown. Among 
other approaches, mouse models are helping to sort out the 
atheroprotective and atherogenic properties of the native and 
acquired immune systems. 
Andrew H. Lichtman, AID, PhD 
Brigham & WomenJs Hospital 
Boston~ Mass. 
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INTERACTIONS AMONG THE INFLAMMATORY 
AND ARTERY WALL CELLS AND THE 
CONNECTIVE  T ISSUE 
The advanced lesions of atherosclerosis represent the culmina- 
tion of a series of cellular and molecular events in which there 
is replication of both smooth muscle cells and macrophages, 
which had previously entered the artery wall. The interactions 
among these cells, with the overlying endothelium and T lym- 
phocytes also in the lesion, may lead to a massive fibroprolifer- 
ative response. Smooth muscle cells lay down relatively large 
amounts of connective tissue and form a fibrous cap, which 
covers the advanced lesion of atherosclerosis (or fibrous 
plaque), the deeper portions of which consist of macrophages, 
T lymphocytes, mooth muscle cells, connective tissue, necrot- 
ic debris, and varying amounts of lipids and lipoproteins. 
Terminal events, such as myocardial or cerebral infarction, are 
usually derived from secondary changes within the fibrous 
plaque that lead to the formation of an occlusive thrombus. 
These changes include fissuring, cracking, or ulceration in the 
surface of the lesion, which can become subjected to altered 
theologic forces due to the encroachment upon the lumen by 
the lesion. 
The protective response 
Examination of the earliest cellular events that occur dur- 
ing atherogenesis has demonstrated that the cells involved are 
classical components of a specialized type of chronic inflam- 
matory response that precedes migration and proliferation of 
arterial smooth muscle cells. The first observable vents 
include increased accumulation of lipid and lipoprotein parti- 
cles bcneath the endothelium, presumably due to increased 
transport and/or permeability of the lining endothelial cells. 
This is rapidly followed by attachment, adherence, and spread- 
ing of peripheral blood monocytes and T lymphocytes at sites 
throughout the arterial tree, particularly at branches and bifur- 
cations. These cells adhere due to the formation of adhesive 
cell-surface glycoproteins by the endothelium and the leulm- 
cytes, which interact in a ligand-receptor manner. Thus one of 
the earliest changes induced by hypercholesterolemia and 
hypertension appears to be altered endothelial permeability 
together with the adherence of leukocytes, representing the 
first phase of an inflammatory response. 
The leukocytes migrate across the surface of the endothe- 
liurn, probe between the junctions of the endothelial cells, and 
are chcmotactically attracted into the subendothelial space 
where they begin to accumulate within thc intima. In the pres- 
cncc of oxidized low-density lipoprotein (oxLDL) the mono- 
cytes become converted to activated macrophages and, via 
their scavenger receptors and oxLDL receptors, take up the 
modified lipoprotein particles and become foam cells. The for- 
marion of foam cells and their continued accumulation i the 
intima lead to the first ubiquitous lesion of atherosderosis, the 
fatty streak. I f  the offending agent, such as hypercholes- 
terolemia or other risk factors, continues, then the inflamma- 
tory response will also continuc. What may begin as a protec- 
tivc, inflammatory responsc an become sufficiently deleteri- 
ous to thc cells of the artery wall. 
This condition may lead to an expanded, intermediate (or 
fibrofatty) lesion that may contain multiple laycrs of smooth 
musclc, connective tissuc, macrophagcs, and T lymphocytcs. 
Eventually, if the conditions that induce the response contin- 
ue long enough, remodeling of the lesion may occur with the 
formation of a fibrous cap. The cap covers the numerous, pro- 
liferated smooth musclc cells and macrophages, together with 
varying amounts of necrotic cell debris, intracellular and 
extracellular lipid, and potentially massivc amounts of new 
connective tissue. Thc advanced lesion, or fibrous plaque, 
dmn can intrude into the artery wall. Changes in the surface 
;~aracteristics of the fibrous plaque may lead to formation of 
thrombus that can cause sudden death or that can organize 
itself and lead to further lesion progression and compromisc 
the flow at the local sitc. 
The response-to-injury hypothesis 
of  atherosclerosis 
The response-to-injury hypothesis of atherosclerosis 
states that the protective, inflammatory response followed by 
the formation of a fibroproliferative r sponse begins as a pro- 
tective mechanism, which with time and continuing insult 
may become excessive. In its excess, both the inflammation 
and the fibrous, connective tissue proliferation become, in 
themsclvcs, the disease process. This is the essence of the 
proccss of atherogenesis. 
Gene expression by the cells 
As one examines the lesions of atherosclerosis during the 
different stages of lesion formation, it becomes apparent that 
the intercellular networking, which occurs among macro- 
phages, T lymphocytes, endothelium, and smooth muscle, is 
critical to determining the direction the lesions will go. For 
example, gene expression in macrophages can lead to synthe- 
sis and secretion of many growth-stimulatory molecules (e.g., 
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platelet-derived growth factor, fibroblast growth factor, 
heparin-binding epidermal growth factor-lille growth factor, 
monocyte-colony stimulating factor, grannlocyte-monocyte 
colony stimulating factor) and growth-inhibitory molecules 
(e.g., transforming rowth factor [3, interleuldn-1, tumor 
necrosis factor a). However, the cytokines formed by 
macrophages can also induce secondary gene expression in 
smooth muscle cells for platelet-derived growth factor-AA and, 
in some cases, heparin-binding epidermal growth factor-like 
growth factor, inducing the cells to make growth-stimulatory 
molecules. Whether or not a lesion will progress, remain stat- 
ic, or undergo regression may be in part a reflection of which 
of these genes is expressed in the different cell types. 
Macrophage replication can occur through the action of 
CSFs formed by endothelium, smooth muscle, or the 
macrophages themselves. Studies have demonstrated that 
macrophage r plication occurs during all phases of lesion pro- 
gression in atherogenesis and that macrophage r plication may 
be as prominent a feature of lesion progression as is smooth 
muscle replication. Macrophages not only make cytokines and 
growth factors, but they also make numerous hydrolytic 
enzymes, in particular, metalloproteinases. Metalloproteinases 
may play critical roles in releasing smooth muscle cells from 
the inhibirory influence of connective tissue and in converting 
fibrous plaques from stable to unstable l sions. 
T lymphocytes also replicate in the lesions and may recog- 
nize antigens presented by macrophages or smooth muscle 
cells. T cells in lesions express both CD4 and CD8 antigens, 
and many of the T cells have the memory T cell phenotype, 
express VLA- 1 and HLA-DR, and have interleukin-2 receptors. 
Summary  
Thus the lcsions of atherosclerosis represent a protective, 
inflammatory-fibroproliferative response against he different 
agents that can cause the disease. If the injury continues 
chronically over a long period of time, it may become xces- 
sive and in its excess becomes the disease itself. It has been 
shown that this excessive, inflammatory, fibropro!iferative 
response can be reversed, given sufficient opportunity for the 
injurious factors to be modified. Approaches to modifying 
specific cellular interactions, growth-regulatory molecules, or 
intracellular signaling molecules may afford opportunities to 
modify these processes and lead to lesion prevention or 
regression. 
This work was supported in part by the National Heart, 
Lung, and Blood Institute, Grant HL18645, and by Bristol- 
Myers Squibb, an unrestricted grant for cardiovascular 
research. 
Russell Ross, PhD 
University of Washington School of Medicine 
Seattle, Wash. 
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through regulation of CDK2 inhibitors. Cell 1996;87: 
1069-78. 
INFLAMMATION AND IMMUNE 
MECHANISMS IN  ATHEROGENESIS  
OXIDIZED LIPIDS AS INFLAMMATORY 
AGONISTS 
The earliest event in the development of the fatty streak is the 
transport of low-density lipoprotein (LDL) into the artery 
wall. This is a concentration-dcpendent process that does not 
require receptor-mediated endocytosis.18 Tom Carew and his 
colleaguc Dawn Schwenke3, 4 demonstrated that for any given 
concentration f lipoprotein the plasma, llpoprotein retention 
in the artery wail was more important than the rate of trans- 
port into the artery wall. Kruth s and the Simionescus and their 
colleagues 6 were among the first to report changes in the 
llpoproteins that wcrc retained in the artery wall. With state- 
of-the-art ultrastructural techniques, Frank and Fogelman 7 
extended these findings and demonstrated a three-dimension- 
al cage-work of fibers and fibrils secreted by the cells of the 
artery wall into the subendothelial space. Nievelstein-Post and 
coworkersS, 9 demonstrated that when LDL was injected into a 
normal rabbit, it rapidly crossed the intact endothelium and 
became trapped in this three dimensional cage-work. The inti- 
mate association of LDL with the extracellnlar matrix of the 
subendothelial space described by Camejo and colleagues 1°
explains why higher concentrations of apo B are present in the 
artery wall than in the plasma. 10d3 
Oxidative modification of the trapped lipoprotcins was 
originally proposed in the early 1980s. 14-18 Proof that support- 
ed this proposal was published in the late 1980s. 18-21 Wirztum, 
Steinberg, and Parthasarathy 22-26 and Chisolm 27 emphasized 
that the cells of the artery wall are constantly secreting oxida- 
tive waste products into their membranes and into the suben- 
dothellal space. Parthasarathy 2s has emphasized that the ability 
of the cells of the artery wall to oxidize LDL is directly related 
to their ability to "seed" the LDL with reactive oxygen species. 
Navab and colleagues 28demonstrated in vitro using hnman 
artery wail cell coculmres that these cells were capable of creat- 
ing microcnvironments into which their oxidative waste could 
be secreted. At the same time these microenvironments exclud- 
ed aqueous antioxid0alts and allowed trapped LDL to undergo 
mild oxidation. 28 However, if the cells in the coculture were 
first treated with lipid-soluble (but not water-soluble) antioxi- 
dants, the oxidation of LDL was prevented. 28Adding antioxi- 
dants to preformed mildly oxidized LDL did not alter its bio- 
logic activity. Thus it was proposed that the anfioxidants pre- 
vented the seeding of LDL and the formation of biologically 
active mildly oxidized LDL. In contrast, once the active lipids 
were formed in LDL, antioxidants did not prevent or reverse 
their biologic activities. A number of studies have subsequently 
indicated that oral administration f lipid-sohiblc vitamins to 
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humans attenuates the in vitro oxidation of LDL isolated from 
their plasma. 29-31 
Work from this laboratory suggests that the fatty streak 
develops in response to specific oxidized phospholipids that 
are generated in LDL that is trapped in the subendothelial 
space, a2 Antio~dants that are present within both LDL and 
the microenvironments in which LDL are trapped function to 
prevent he formation of these biologically active, oxidized 
phospholipids. Enzymes associated with LDL and high-den- 
sity lipoprotein (e.g., platelet activating factor acetylhydro- 
lase) or with high-density lipoprotein alone (e.g., paraox- 
onase) destroy these biologically active lipids. The regulation 
and expression of these enzymes are determined genetically 
and are also significantly modified by environmental influ- 
ences, including the acute phase response or an atherogenic 
diet. The balance of these multiple factors leads to an induc- 
tion or suppression of the inflammatory response in the artery 
walI and thus determines the clinical course, a3 
Alan M. Fogelman, MD 
UCLA School of Medicine 
Los Angeles, Calif. 
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LEUKOCYTE-MEDIATED ENDOTHELIAL 
INJURY 
As effectors cells of the immune system, leukocytes are capa- 
ble of synthesizing and releasing a plethora of bioactive mol- 
ecules, including oxidants, eicosanoids, proteases, and 
cytokines. Although critical for host defense and repair, under 
some circumstances, leukocytes and leukocyte-derived prod- 
ucts may contribute to endothelial nd tissue injury. For 
leukocytes to cause vascular or tissue damage they must first 
adhere to the endothelium and then exit the blood stream to 
gain access to extravascular tissue. Leukocyte and endothelial 
adhesion molecules are necessary not only for adherence and 
emigration, but they participate in several other leukocyte 
functions, such as the transduction of signals that regulate 
gene expression and cell survival. Blockade of leukocyte- 
endothelial dhesive interactions has helped to elucidate the 
role of leukocytes in the genesis of vascular and tissue injury 
in experimental models of inflammatory and immunc disor- 
ders. 1 Moreover, adhesion molecules have emerged as impor- 
tant argets of therapy in a broad spectrum of human diseases. 
The most convincing evidence for leukocyte-mediated 
endothelial injury comes from studies of ischemia-reperfusion 
(I-R) injury.I, 2 1-Rinjury is potentially involved in a wide spec- 
trum of disease processes, including myocardial infarction, 
stroke, mesenteric and peripheral vascular ischemia, li b and 
digit reimplantation, compartment syndromes, thermal injury, 
and circulatory shock. A major component of I-R injury is 
believed to occur during the reperfusion phase when an inflam- 
matory response triggers neutrophil adhesion to endothelium 
and transmigration to tissue, subsequent eutrophil-mediatcd 
endothelial nd tissue injury. Blockade of ither the initial teth- 
ering/rolling adhesive interactions between endothelial P- or 
leukocyte L-selectin a d their glycoconjugate ligands or the 
subsequent firm adhesive interaction between leukocyte b 2_ 
integrins and the immunoglobulin gene superfamily ligand 
ICAM-1 has been demonstrated to attenuate vascular injury, 
manifested by plasma leakage or thrombosis, and tissue damage 
in a wide variety of animal models of I-R injury. Clinical trials 
evaluating the efficacy ofadhesion molecule blockade in reduc- 
ing organ damage are underway in hemorrhagic shock, stroke, 
and myocardial infarction. 
Blockade of leukocyte or endothelial dhesion molecules 
has also been demonstrated to be of benefit in models of 
chronic inflammatory-immune dis ases, such as allografr 
rejection, multiple sclerosis, asthma, arthritis, and inflamma- 
tory bowel disease. 1 Recently, a newperspective has emerged 
that views atherosclerosis a  achronic inflammatory-immune 
process. Like other chronic inflammatory eactions, experi- 
mental and human athcrosclerotic lesions exhibit an accumu- 
lation of mononnclear phagocytes as well as lymphocytes. 
Muchattention has been directed to the potential contribu- 
tion of these mononuclear leukocytes to lesion initiation and 
progression. In experimental models, monocyte adherence to 
endothelium and subendothelial accumulation of mononu- 
clear phagocytes are observed at the earliest stages of lesion 
formation. Mononuclear phagocytes produce multiple medi- 
ators, such as growth factors, proteases, and cytokines, that 
could contribute to the initiation a d progression ofthe arte- 
rial lesions by inducing endothelial dysfunction with altered 
permeability or vasoreactivity; by accumulating lipid and 
becoming foam cells; by promoting smooth muscle cell 
migration and proliferation; and by later destabilizing the 
plaque. Consequently, there has been a great deal of interest 
in elucidating the mechanisms of mononuclear phagocyte 
recruitment into the arterial wall. In particular, much atten- 
tion has been directed to the adhesion molecules expressed on 
endothelium during atherogenesis. Upregulated expression of 
VCAM-1, ICAM-1, E-selectin, and P-selectin has been 
demonstrated onarterial luminal endothelium in human and 
experimental lesions. 3-8 In human lesions increased expres- 
sion of adhesion molecules i even more prominent in the 
neovasculature of the intima than on arterial luminal endothe- 
lium, suggesting that leukocyte recruitment may in fact occur 
primarily through intimal neovasculamre. 9 Soluble VCAM- 1, 
presumably shed from activated ndothelium, also appears to
correlate with the extent of atherosclerosis in man.10, 31 
Limited studies have t sted antiadhesion therapy in ather- 
osclerosis-related models. Blockade of VLA-4 and CD18 or 
ICAM-1 and LFA-1 were reported to attenuate intimal 
smooth muscle cell hyperplasia in rat and rabbit models of 
arterial injury.12,13 Blockade of VLA-4 by CS-1 fibronectin 
peptide reduced accelerated allograft arteriopathy in a rabbit 
model. 14 More direct evidence for a role of endothelial cell 
adhesion molecules in atherogenesis comes from gene-target- 
ed mice with deficiencies of adhesion molecules. Using 
C57BL/6 mice fed a high-fat diet, a 50% to 75% reduction i  
fatty streak formation was observed in mice with homozygous 
mutations of ICAM-1, P-selectin, CD18, or both ICAM-1 
and CD18, or both ICAM-1 and P-selectin. is Similarly, mice 
lacking both the low density lipoprotein receptor and P- 
selectin showed a twofold reduction in fatty streak formation 
in the cusp region at early time points, although at later time 
points this difference was minimal. 16 
These in vivo studies confirm the importance ofleukocyte 
and endothelial dhesion molecules in the recruitment of 
mononuclear phagocytes into the arterial wall where they 
develop into the foam cells that constitute the fatty streak. 
They also suggest a role for leukocytes in the intimal smooth 
muscle cell accumulation. However, it is premature to con- 
clude that leukocyte-mediated endothelial injuryor, perhaps, 
even mononuclear leukocytes play a causal role in the initia- 
tion and progression of human atherosclerosis. It remains 
possible that mononuclear phagocytes are m rely reactive to 
another central pathogenic mechanism or may, in fact, be a 
protective/repair response. Indeed, augmentation of 
macrophage function by M-CSF administration was found to 
prevent the progression of atherosclerosis in Watanabe herita- 
ble hyperlipidemic rabbits. 17 
Leukocytes have also been implicated in the acute com- 
plications of advanced atherosclerosis. An elevated leukocyte 
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count has been established as an independent coronary risk 
factor. 18 Perhaps leukocytes provoke endothelial injury and 
trigger acute thrombosis or they undergo intravascular dhe- 
sion and aggregation leading to microvascular occlusion. 
Recently, the statins (HMG coreductase inhibitors) have been 
shown to reduce coronary events even in men with average 
cholesterol levels. I9 Interestingly, mononuclear leukocyte 
adhesive responses have b en reported to be reduced in 
patients during statin therapy, 2° raising the possibility that the 
statins' cardioprotective effects may in part be antiinflamma- 
tory by inhibiting leukocyte adhesion/emigration rather than 
lipid-lowering. 21 
John Harlan, MD 
University of Washington 
Seattle, Wash. 
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THE ROLE OF MACROPHAGES AND TISSUE 
FACTOR 
Disruption of a vulnerable or unstable plaque (type IV and Va 
lesions of the AHA) with a subsequent change in plaque 
geometry and thrombosis (type VI lesion) may result in acute 
occlusion or subocclusion with clinical manifestations of an 
acute coronary syndrome (ACS). 
Plaque disruption and macrophages 
Vulnerable plaques tend to be relatively small, but soft or 
vulnerable to "passive" disruption because of the high lipid 
content. In addition, a better understanding of an "active" 
phenomenon of plaque disruption is evolving. Thus, recently, 
atherectomy specimens obtained from patients with ACS 
revealed high macrophage-rich areas. Macrophages are capa- 
ble of degrading extracellular matrix by phagocytosis or by 
secreting proteolytic enzymes uch as plasminogen activators 
and a family of matrix metalloproteinases (MMPs; collagenas- 
es, gelatinases,.and stromelysins) that may weaken the fibrous 
cap, predisposing it to rupture. Specifically, we have observed 
that hmnan monocyte-derived macrophages grown in culture 
are capable of degrading cap collagen, and they do simultane- 
ously express MMP-1 (interstitial collagenasc) and induce 
MMP-2 (gelatinolytic) activity in the culture medium, a 
process that can be prevented by MMP inhibitors. 
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Thrombos is  and  macrophages  
Different human atherosclerotic plaques (AHA lesion 
classification) were exposed to flowing blood at high shear 
rate and their thrombogenicity evaluated. The lipid core 
abundant in cholesterol ester, displayed the highest thrombo- 
genicity and the most intense tissue factor (TF) staining. 
Colocalization analysis of coronary atherectomy specimens 
from patients with an ACS demonstrated a strong relationship 
between TF and macrophage-rich areas. As a result, we are 
investigating whether TF activity in the atheromatous gruel is 
mediated by macrophages, thus suggesting a cell-mediated 
thrombogenicity in patients with ACS. Thus far we have 
observed that thrombus formation in lipid-rich plaques can be 
prevented by recombinant TF pathway inhibition. 
Thrombos is  and  hyper l ip idemia  
On the basis of pathologic and MRI observations, we 
postulated that when high LDL cholesterol is reduced thera- 
peutically with statins, efflux from the plaques of the liquid or 
esterified cholesterol, and also its hydrolysis into cholesterol 
crystals in the vessel wall, predominate over the influx of LDL 
cholesterol. Consequently, there is a decrease in the softness 
of the plaque and so, presumably in the "passive" phenome- 
non of plaque disruption; in addition, the fibrous cap thick- 
ens. These stabilized lesions appear to represent the type Vb 
lesions (AHA classification), which until recently were poorly 
understood. 
Furthermore, when low HDL cholesterol is increased 
experimentally, there is partial decrease in the number and 
activity of the macrophages and so, presumably, stabilization 
of the "active" phenomenon ofplaque disruption and throm- 
bus formation. In addition, under conditions of lipid lower- 
ing with statins, we and others have also found a significant 
decrease in systemic thrombogenicity and the question is 
whether the maderlying platelet and/or  coagulation system 
versus the circulating monocyte-tissue factor activity become 
modified by lipid pharmacologic strategies. 
Valentin luster, MD, PhD 
Mount Sinai Medical Center 
New York, N.Y. 
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MACROPHAGES 
The blood monocyte and differentiated tissue macrophage 
(Me) have moved centerstage in the study of inflammatory 
responses to vascular injury and repair. They form a major com- 
ponent of the cellular infiltrate and interact with modified 
lipoproteins, other plasma components, extracellular matrix, 
and other cells (endothefium, platelets, smooth muscle, fibro- 
blasts and T lymphocytes) in a complex, dynamic inflammato- 
ry process. They express a r nge of membrane molecules impli- 
cated in monocyte-specific recruitment, adhesion, and reten- 
tion, and respond to extracellular igands by local secretion of a 
range of cytokines, neutral proteinases, and cytotoxic products, 
including reactive oxygen metabolites, which promote the 
inflammatory process or bring about its resolution. In this 
paper, we review studies that deal with lmown candidate mole- 
cules already implicated in experimental and natural atherogen- 
esis (scavenger receptor, SR-A and CD68/macrosialin) and 
introduce several new molecules produced by Me as further 
candidates for Me-restricted functions in inflammation, with 
particular reference to the vessel wall. 
The  class A scavenger eceptor (SR-A)  
There are collagenous receptors expressed almost exclusive- 
ly by Me and involved in the recognition and uptake of a wide 
range of polyanionic ligands including chemically modified 
lipoproteins and oxidized low-density lipoproteins. Originally 
identified as "scavenger receptors" and implicated in Me foam 
cell formation by Brown and Goldstein, the SR-A I and II iso- 
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forms were cloned by Krieger, Kodama,' and colleagues. Their 
structures and relationship to a distinct cotlagenous gene prod- 
uct (Marco) and comparison with structurally unrelated scav- 
enger eceptors (SR-B,C) are summarized in a recent review. 1 
SR-A message mad protein have been detected in foamy Mo in 
mouse, rabbit, and human. A specific antimurine mAb, 2F8, was 
raised in our laboratory by Fraser et al.2 on the basis of inhibi- 
tion of divalent cation-independent adhesion of Mo in vitro. 
Antihuman SR-A ab proved difficult o isolate, but this became 
possible when Suzuki and colleagues produced an SR-A k.o. 
mouse strain, 3 which has )Selded antihuman SR-A with broad 
species reactivity (RJ. Gough, unpublished). 
The SR-A k.o. mouse whcn crossed with Apo E k.o. mice, 
showed -50% reduction ha foam cell lesions, even on normal 
diets. Double k.o. with LDL receptor-deficient mice showed a 
smaller eduction of lesions. These studies establish a partial 
role for SR-A in experimental atherogenesis. 
More complete inhibition of lesion development was found 
when CSF-1, a Mo-specific growth and differentiation factor, 
was eliminated in combination with apollpoprotein E deficien- 
cy (W.J.S. de Vllliers, unpublished). The osteopetrotic (op/op) 
natural mutation results in marked reduction of several, but not 
all, tissue Mo populations, as well as of monocytes and Mo in 
atherogenic lesions. The absence of vascular foam cells is par- 
ticularly striking in the face of high blood lipids, and remaining 
Mo in liver, spleen, gut and elsewhere do accumulate lipid. 
These findings wcrc complemented bycell culture studies 
that demonstrated that CSF-1 is a potent and selective npregu- 
lator of SR-A expression by murine Mo in vivo. 4 This can be 
contrasted with inhibition by tgf-b and by TNFa. Intriguingly, 
expression of SR-A by Mo also plays an important role in TNFa 
production by Mo; in SR-A ko mice, MO cannot limit TNFa 
secretion, especially after an immtmologic Th-1 type priming 
stimulus uch as BCG infection. These mice become xtraordi- 
narily sensitive to endotoxin (LPS) challenge and septic shock. 5 
A potcntial intracellular regulatory step for SR-A expres- 
sion and function has recently been discovered. 6 A novel 
splice variant, third isoform of SR-A has been shown to act as 
a dominant negative receptor; it is synthesized by primary and 
cellqine Mo but does not reach the surface. On cotransfection 
it downregulates SR-A I or II expression and function. 
Apart from its endocytic and adhesion functions, SR-A can 
also mediate phagocytosis ofapoptotic thymocytes 7 and possi- 
bly other cells, in vitro, and of synthetic particulate ligands. It 
is not known how, or whether, cellular signaling isdifferential- 
ly regulated by different scavenger receptors. Surface-bound 
ligands, such as ~ amyloid fibrils, trigger a respiratory burst, 
but the role of specific receptors in these and other signaled 
responses such as TNFa release, remains unclear. 
Human CD68/mouse macrosialin 
Macrosialin is a pan-Mo (and dendritic-cell) membrane 
glycoprotein, related to the lysosomal associated membrane 
protein (lamp) family; a mucin-like xtracellular domain is 
only present in Mo. 8 The molecule is almost exchisively found 
in late endosornes with very little on the plasma membrane or 
in lysosomes. It has many complex O- and N- linked sugars, 
including lactoside chains, and the glycoform expressed by 
Mo in different tissues correlates with phagocytosis, mediated 
by specific receptors, as well as with inflammatory stimulation 
(R.P. da Silva and S. Gordon, submitted). 
The particular interest in macrosialin grew when Steinberg 
and his colleagues identified it as a "receptor" for oxidized 
LDL. We have confirmed this with rat Kupff~r cells. 9 The sig- 
nificance of this finding is still unclear--acrosialin/human 
CD68 is clearly abundant in experimental nd natural athero- 
sclerosis where it serves as an excellent Mo marker. However, 
there is contradictory evidence concerning its possible role in 
oxLDL uptake, as opposed to intracellular binding after 
uptake. The role of glycoform modulation i  oxLDL binding 
is unlmown. Ligands for macrosialin other than wheatgerm 
agglutinin, which binds readily to the inflammatory/phago- 
cytic glycoform, remain to be discovered. 
The high level, tissue-restricted pattern of expression has 
made DNA gene sequences derived from CD68 and 
macrosialin attractive candidates to direct reporter gene 
expression (including CD68 itself) in murine Mo in vitro. 
(D.R. Greaves, C. Quinn, R Gough, unpublished). Trans- 
genic experiments o evaluate the efficiency and selectivity of 
various CD68 constructs are in progress. 
New candidates for Mo-restricted functions in 
inflammation and athcrogcnesis 
It is a particular challenge to discover new molecules 
expressed by or acting on Mo, to account for important func- 
tions, especially of a call-specific nature. The newly discovered 
chemoldne fractalkine is unusual in that it is cell-associated 
with a stalk attachment which would localize its action. 1° 
Experiments are in progress to assess its possible contribution 
to monocyte-recruitment in experimental therosclerosis, and 
in naturally occurring human disease. 
The method of differential display PCK has the potential 
to generate novel cDNAs, expressed by Mo, and possibly rel- 
evant o inflammation or atherogenesis. Drs. J. A. Mahoney 
and A.J. McKnight in our group have isolated new Mo- 
expressed cDNA sequences using various cell-restriction and 
cytokine-treatment cri eria. Two molecules were selected for 
further study because of their homology to other molecules 
broadly relevant to inflammation and vascular disease. The 
first is a novel carboxypeptidase, the other a homologue of 
apolipoprotein L. Studies are fia progress to produce specific 
reagents to detect heir presence in Mo in disease states and 
to establish their functions. 
Conclusion 
Methods are now available to identify Mo molecules and 
their in situ role in inflammation and atherosclerosis. The role 
of lipid loading to generate foam cells, with a more or less dis- 
tinctive phenotype, needs further study. Many of the features of 
vascular injury are common to that in other sites, and it will be 
important to search for disease-specific as well as site-specific 
modifications of Mo. Even if such selectivity isunfikely, it may 
be possible to isolate particular cell populations anatomically, in 
a region of arterial wall, and thus to manipulate MO selectively, 
e.g. by gene therapy. Otherwise, the obvious problem will be 
how to avoid undesirable side effects of systemic treatments. 
The role of the Mo in fipid homeostasis is not yet fully made> 
stood and may involve a range ofcytokines, enzymes and mem- 
brane modifications which ultimately underlie the behaviour of 
the cell, physiologically and in disease. 
Siamon Gordon, MD 
University of Oxfbrd 
Sir William Dunn School of Pathology 
Oxford, United Kingdom 
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RESTENOSIS  AND RELATED PROL IFERA-  
T IVE  VASCULOPATHIES  
ADVENTIT IAL  REMODEL ING ASSOCIATED 
WITH RESTENOSIS 
Postangioplasty restenosis i one of the major problems con- 
fronting cardiology today. While cellular proliferation after 
balloon injury is the most likely mechanism for the develop- 
rnent of clinical post angioplasty restenosis, there is contro- 
versy regarding the degree of the proliferative response. 
Endothelial denudation of peripheral vessels using a Fogarty 
catheter on rats and rabbits induces smooth muscle cell pro- 
liferation and development of a neointima has been used 
extensively as a model for postangioplasty restcnosis. In these 
models cell proliferation begins in the media within 48 hours 
after injury; after a week these cells migrate across the inter- 
nal elastic lamina to form an intimal mass of actively prolifer- 
ating cells. Consequently, the major focus of efforts to pre- 
vent postangioplasty restenosis up to this time has been on 
regulating cell proliferation in the intima or media with very 
little consideration about how other vascular layers may con- 
tribute to the problem. In this presentation, I would like to 
suggest hat the advcntitia may also play an important role in 
lesion formation after angioplasty by contributing to vascular 
remodeling and the growth of the neointimal mass. 
Adventitial myofibroblasts proliferate and 
migrate i n to  the  res tenot ic  lesion 
Recent experiments suggest that myofibroblasts in the 
advendtia proliferate after angioplasty and may migrate into 
the neointima, where they appear as smooth muscle 
actin-containing cells. 10 Domestic juvenile swine underwent 
injury to the left anterior descending and circumflex coronary 
arteries with standard clinical angioplasty balloon catheters, 
and proliferation was followed by BrDU immunohistochem- 
istry. The time course of cell proliferation was similar to that 
seen previously in other models beginning between 24 and 48 
hours after injury. However, in pigs the greatest number of 
proliferating cells at this time was found primarily in the 
adventitia extending circumferentially around the vessel and 
not in the medial wall. By 1 wcek after angioplasty the great- 
est number of proliferating cells was found in the ncointima. 
These data suggest that the adventitia may be important with 
respect o the first wave of growth after angioplasty of coro- 
nary arteries with later growth of the lesion occurring in the 
neointima. 
Immunohistochemical analysis was performed to identify 
the proliferating adventitial cells as well as the cells which 
formed the neointima. Immunohistochemical analysis using 
antibodies against alpha smooth muscle actin, smooth muscle 
myosin, h-caldesmon or desmin consistently labeled smooth 
muscle cells in the medial wall of normal arteries but did not 
stain adventitial cells prior to angioplasty. Double-label 
immunohistochemical analysis on arteries from animals inject- 
ed with BrDU 2 to 3 days after angioplasty and killed on day 
3 indicated that the proliferating adventirial cells lacked 
smooth muscle specific markers but contained vimentin and 
were therefore probably fibroblasts. 
Two weeks after angioplasty smooth muscle alpha actin 
staining was found to extend into the surrounding adventitial 
space well beyond the medial wall including regions where 
the proliferating cells had been found on day 3. Double-label 
immunohistochemistry with the alpha actin and BrDU anti- 
bodies on vessels from animals which received BrDU betwccn 
days 2 and 3 and were killed on day 14 indicated that the pre- 
viously actin-negative adventitial cells which had proliferated 
on day 3 now showcd strong alpha actin staining. In the 
neointima almost all of the BrDU-positive cells showed 
smooth muscle alpha actin and vimentin staining. These data 
suggest a phenotypic switch of the adventitial cells that are 
responding to balloon injury by increasing alpha actin con- 
tent, which is the basis for identifying these cells as myofi- 
broblasts. Proliferation and phenotypic modulation of myofi- 
broblasts in the adventitia t the angioplasty site have been 
observed by other groups.ll, 12 
The observation of a phenotypic modulation of the 
adventitial cells with respect o actin expression between days 
3 and 14 is similar to the phenotypic hanges occurring in 
myofibroblasts associated with wound healing or tumor for- 
mation. Recent data indicate that vascular emodeling, as 
indicated by a constriction of the external elastic lamina after 
angioplasty, may contribute to restenosis.1, 7-9 Experimental 
angioplasty studies in rabbits and pigs indicate that after bal- 
loon angioplasty the size of the intima does not explain the 
loss in lumenal diameter measured morphometrically or by 
angiography.7, 9 Recent clinical data support these observa- 
tions and suggest that clinical restenosis i  associated with a 
constrictive remodeling occurring outside of the injured ves- 
sel.5,6, 8 The presence of myofibroblasts in the adventitial 
JOURNAL OF VASCULAR SURGERY 
Volmne 27, Nttmber 6 Special Communication 1163 
space surrounding injured coronary arteries and the upregu- 
lation of contractile proteins in thcsc cells may play a rolc in 
vascular emodeling by constricting the vessels from the 
adventitial side, thus contributing to late lumen loss associat- 
ed with postangioplasty restenosis. 
Pu lse  labe l ing  o f  advent i t ia l  cells w i th  BrDU or  
PKH26 suggests  that  the  pro l i fe ra t ing  advent i -  
t ia l  cells migrate  in to  the  neointima 
The finding of increased cell proliferation and growth 
factor synthesis in the advcntitia relative to the medial wall at 
early times after angioplasty suggested that the adventitia 
may play a role in the formation of the subsequent vascular 
lesion. To determine the fate of the proliferating adventitial 
cells we labeled this cell population at an early time point 
with BrDU and then examined the distribution of these cells 
once the neointima was fully formed. Animals were injured 
on day 0, injected with BrDU between days 2 and 3 (time of 
maximal adventitial labeling), and the distribution of BrDU- 
positive cells was examined on day 14 without subsequent 
BrDU injection. Because the adventitial cells comprise the 
major population of proliferating cells on day 3 we expected 
that this would enable us to determine whether these cells 
had migrated from their position in the adventitia nd con- 
tributed to the cellular mass in the neointima. This approach 
had been used previously to follow the migration and subse- 
quent proliferation of medial cells into the neointima in the 
rat carotid injury model using 3H-thymidine labeling. 2 Two 
weeks after angioplasty a large nmnber of cells labeled with 
BrDU between days 2 and 3 were still found in the adventi- 
tia surrounding the injured vessel; however, 43.1% _+ 3.3% 
(mean _+ SEM) of the neointimal cells were BrDU-positive as 
well. Because the largest proportion of cells incorporating 
BrDU at the timc of BrDU injection between days 2 and 3 
is in the adventitia, this suggested that some of the neointi- 
mal cells must be the daughter cells derived from the adven- 
titial cells which incorporated BrDU and migrated into the 
lesion across the external elastic lamina. However, because 
the labeling clearly included some medial cells as well, it was 
not possible to determine xactly how many adventitial 
myofibroblasts came into the neointima. 
To further test the hypothesis that adventitial cells migrate 
and contribute to the formation of the neointimal mass after 
balloon overstretch injury, adventitial cells from pig femoral 
arteries were labeled in situ with PKH26 by bathing the adven- 
titia surrounding surgically exposed arteries with a PKH26 
solution. PKH26 is a red fluorescent molecule that is incorpo- 
rated into file lipid bilayer of the cell membrane by selective 
partitioning. 4 Once incorporated into the cell membrane the 
dye does not affect cell function but remains associated with 
the cell for an extended period f time (more than 2 weet~) 
allowing for the continued study of the labeled cell popula- 
tions. 3The vessels were then subjected to balloon overstretch 
injury immediately afterwards, and the distribution of labeled 
cells was examined 2 weeks later. Proximal uninjured but fluo- 
rochrome-labeled segments were used as controls. In arteries 
which were labeled with PKH26 and not injured, PKH26 
labeling remained in the adventitia. In arteries ubjected to 
balloon injury where the internal elastic lamina was not broken 
and the medial wall was intact, no PICH26-1abeled adventitial 
cells crossed the external elastic lamina. In arteries that were 
labeled with PKH26 and subjected to balloon overstretch 
injury that broke the medial wall and exposed the external elas- 
tic lamina, PKH26-1abeled cells were detected in the neointi- 
ma, suggesting that those cells migrated from the advcntitia to 
that site. The present results uggest that tearing of the medi- 
al wall and exposure of the external elastic lamina stimulates 
the migration ofadventitial myofibroblasts into the neointima. 
This is the same ldnd of injury that occurs in clinical angio- 
plas~ or atherectomy and suggests that the clinical restenosis 
lesion is composed not only of smooth muscle cells but may be 
made up of adventitial myofibroblasts a  well. These data chal- 
lenge the dogma that medial smooth muscle cells are the pri- 
mary source of cells in the restenotic lesion. 
Advent i t ia l  react ions  af ter  ba l loon  denudation- 
type ang iop las ty  o f  rat  carot id  arter ies  
Recent experiments were designed to study the adventi- 
tial responses to mechanical injury of the rat carotid artery 
(De Leon, Griendling, and Wilcox, unpublished observa- 
tions). To avoid any direct manipulation of the adventitia and 
perivascular tissues, balloon angioplasty of the rat carotid 
artery was performed with a Fogarty 2F balloon catheter 
introduced through the right superficial femoral artery of 
Sprague-Dawlcy rats. Immediately after angioplasty an 
intense inflammatory esponse was seen in the adventitia sur- 
rounding the injured vessel consisting primarily of neu- 
trophils. Neutrophils rapidly accumulated throughout the 
adventitial space of the injured artery and can be seen to 
occlude the small vessels of the vasa vasorum 6 hours after 
injury. Three days after injury a highly cellular "neoadventi- 
tia" layer was seen surrounding the carotid in the space where 
the neutrophils had been. The neoadventitia exhibited an 
extensive proliferative response while relatively fewer BrDU 
positive cells were found in the media and adventitia t this 
time. Five days after angioplasty BrDU-positive cells were 
observed in the neoadventitia and the media. By 7 days, pro- 
liferation in the neoadventitia decreased but some BrDU-pos- 
itive cells were observed in the media nd in the developing 
neointima. The cells in the neoadventitia differentiate and 
take on a spindle-shaped morphology at this time and stain 
positively for alpha smooth muscle actin. Fourteen days after 
angioplast T the neoadventitial l yer had almost vanished, its 
cellularity decreased but the adventitial remained thickened. 
At this time point, most BrDU-positive cells were present in 
the well-developed neointima with few scattered positive cells 
in the media and adventitia. In summary, the rat carotid artery 
responds to vascular injury in the same way as the porcine 
coronary arteries and generates a highly cellular and prolifer- 
ative neoadventitia layer after angioplasty, whose role in vas- 
cular remodeling and the generation of the neointima remains 
to be elucidated. 
Conclusions 
The studies reported here suggest that the adventitia may 
play a role in vascular lesion formation by proliferating and 
contributing to the cellular mass of the neointima. In addi- 
tion, the adventitia may contribute to vascular emodeling 
and constriction of the external elastic lamina through an 
accumulation of myofibroblasts containing alpha smooth 
muscle actin in the adventitia surrounding the injury site. 
Additional work will have to be directed at a more detailed 
examination of the response of adventitial cells to balloon 
injury in the setting of atherosderosis. 
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CMV 
Our current investigative efforts relating to a potential role of 
infection in restenosis and atherosclerosis were stimulated by 
the fact that although such factors as hypertension, smoking, 
hypcrcholesterolemia, and diabetes have been identified as 
important risk factors in the development of atherosclerosis, 
many patients with atherosclerosis lack known risk factors, 
and no risk factors had been consistently identified for 
resrenosis occurring after coronary angioplasty. 
Our first study was designed to attempt o identify new 
etiologic mechanisms that might contribute to the develop- 
ment of restenosis and atherosclerosis. We initially focused on 
restenosis, which occurs in 25% to 35% of patients after coro- 
nary angioplasty. Although rcstenosis is a complcx process 
that is influenced by multiple mechanisms, morphologic evi- 
dence indicates that one of the critical components of lesion 
devclopment is smooth muscle cell accumulation. We wanted 
to determine what mechanisms might contribute to that 
increased accumulation. 
When we initiated this study several years ago, wild-type 
p53 had been identified as a tumor suppressor gene. Its gene 
product can block progression of cells through the cell cycle, 
and modulates an important apoptotic pathway. Each of these 
functions protects against he inheritance of damaged DNA 
by cell progcny. Mutations of this gene, found in more than 
50% of human cancers, eliminate the cell cycle suppressor and 
apoptotic functions of p53. This, in turn, can lead to the accu- 
mularion of multiple mutations of various genes, which ulti- 
mately leads to malignant transformation of the cell accumu- 
lating these mutations. We reasoned that if a mutated p53 
gene were present in SMCs, in the abscnce of mutations in 
other gcnes, the resulting impairment of p53 function could 
lead to an increase in SMC accumulation. 
Therefore, the first hypothesis we examined was "p53 
dysfimction, caused by an isolated mutation in the p53 gene, 
contributes to the excessive accumulation of smooth muscle 
cells in patients developing restenosis." 
We examined this hypothesis by obtaining restenosis tissue 
from patients who were undergoing atherectomy to treat 
restenosis. Although we did not find mutant p53, we did find 
elevated levels of wild-type p53 in almost 40% of lesions. The 
elevated levels of p53 we thought could be explained by the 
work of several oncology laboratories, which observed similar 
findings in certain transformed cells. The investigators demon- 
strated that these cells had been infected with certain DNA 
tumor viruses that expressed proteins that bound to and inacti- 
vated p53, as well as to other suppressor proteins uch as Rb 
and Rb-related proteins. The survival value to the virus of such 
a program is based on the fact that to complete their own life 
cyde, viruses must infect a host cell, drive it to replicate, and 
then capture its replicative machinery. The binding of p53 with 
these viral proteins, usually prolongs its half-life, leading to 
increased steady-state l vels. We therefore postulated that the 
elevated p53 levels we saw in the restenosis lesions might be 
due to the presence of a virus that had similar cffects as the 
DNA tumor viruses. We considered various candidate viruses 
that might be responsible for our results. 
HCMV was chosen because of many prior studies that 
suggested that this herpesvirus may play a causal role in the 
genesis of atherosclerosis: 
• Marek's disease virus, an avian herpesvirus, produces 
lesions in chickens very similar to those seen in human ath- 
erosclerosis 
• High percentage of individuals over age 50 years are 
infected with HCMV 
• Evidence of  HCMV sequences in the wall of athero- 
sclerotic arteries 
• Causal role of HCMV in the development of accelerat- 
ed coronary atherosclerosis in cardiac transplant patients 
We then reexamined the restenosis lesions--we amplified 
the DNA by PCR using primers unique for CMV DNA to 
determine whether viral sequences were present. Approximately 
half of the lesions contained CMV DNA. 
Because CMV is so common in the general population, it
might be present just as an innocent bystander and play no 
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causal role. The results of our study, however, suggested it
was not just an innocent bystander. Thus we found that: 
• HCMV is more common in lesions with elevated levels 
o fp53 
• Cultured SMCs derived from the restenosis lesions 
express HCMV immediate arly (IE) gene products 
• HCMV infection of  SMCs increases p53 levels 
• IE2-84 and important  IE gene product  of  HCMV 
binds to p53 and inhibits its transcriptional ctivity 
We and others also found that HCMV infection, through 
pathways modulated by its IE gene products, increases prolif- 
eration and ecreases apoptosis, which together could lead to 
an increase in smooth muscle cell accumulation. Such effects 
could contribute to the development of restenosis and ather- 
osclerotic lesions. 
In addition to the accumulation of SMCs, immune and 
inflammatory processes, as well as thrombotic processes, are 
believed to contribute to atherosclerosis. The questions can 
therefore be asked: 
• What is the inciting event for this proinf lammatory/  
prothrombotic environment? 
• Could infection at least in a subset of  patients, be such 
an event? 
Of note, in vitro and in vivo, HCMV is proinflammatory 
and prothrombotic, suggesting it could contribute to resteno- 
sis/atherosclerosis (although probably not unique, as many 
other infectious and noninfectious agents can cause similar 
changes). 
The hypothesis we first examined was: Prior HCMV 
infection predisposes to the development ofrestenosis. I f this 
hypothesis were correct, we would predict that: HCMV 
seropositive patients undergoing angioplasty would have a 
higher rate of restenosis than HCMV seronegative patients. 
This prediction was tested in a prospective study of 
patients undergoing atherectomy-angioplasty. HCMV anti- 
body levels were determined just before angioplasty, and the 
presence or absence of rcstenosis was determined at follow-up 
angiography, performed approximately 6 months after the 
angioplasty procedure. The major finding of dais study was 
that there is a significantly higher ate ofrestenosis (43% vs 8%; 
p = 0.002) in the seropositive patients. There was no evidence 
ofacutc infection (no change in anti-CMV IgG antibody titers 
and no anti-CMV IgM antibodies). We conduded that prior 
infection with HCMV is a strong independent risk factor for 
restenosis. 
To determine whether the association of HCMV with 
rcstenosis established in the first two studics may rcflcct a
causal role of the virus, we used the rat carotic artery injury 
model to study a more direct test of causality. We found that 
CMV infection augments the response to vascular injury. Thus 
CMV does have the genetic program that evokes from the host 
a response that leads to an increased accumulation of SMCs in 
response to vascular injury. 
Because restenosis hares many pathophysiologic similar- 
ities with atherosclerosis, we initiated the second major area 
of investigation i our laboratory: the potential role of infec- 
tion (HCMV) in the genesis of atherosclerosis. 
Given the probable role of scavenger receptors in the 
excessive upraise of oxLDL with the subsequent development 
of the foam cell and fatty streak, the earliest morphologic 
lesions associated with atherosclerosis, we examined the effects 
of HCMV on scavenger receptor activity. We found that: 
• CMV infection of  SMCs increases modified LDL uptake 
and stimulates class A SR gene mRNA expression 
• This effect is caused by the IE gene products of  
HCMV 
• Cotransfection of  an IE72 but not in IE84 expression 
plasmid and a plasmid containing an SR-A promoter /  
reporter gene construct enhances SR promoter activity 
Because increased oxLDL uptake is believed to play an 
important role in arteriosclerosis, these results provide a 
link between HCMV infection and arteriosclerotic plaque 
formation. 
Our next question focused on the issue of how HCMV 
gets into the vascular wall. Although it could primarily infect 
the vessel, HCMV known to be present in a latent state in cir- 
culating monocytes. Therefore, the virus could establish per- 
sistent infection of myelocyte precursors in bone marrow and 
thereby infect monocytes. Monocytes could act as "Trojan 
horses," delivering virus to the site of injury or inflammation. 
I f  the virus is indeed delivered to areas of vascular injury as 
part of the inflammatory response, we examined whether con- 
stituents of the vessel wall, namely, endothelial cells, smooth 
muscle cells and oxidized LDL, have the capacity to reactivate 
latent virus within monocytes. We found this to be the case. 
Thus the monocyte may deliver latent HCMV locally to the 
site of vascular injury, where constituents of the vessel wall can 
enhance HCMV IE gene expression and thereby contribute 
to viral reactivation and/or replication. The virus could then 
contribute to the immune and inflammatory components of 
the vessel pathobiology that are already present. 
We also have undertaken studies in an attempt o learn 
more about the interactions between HCMV and its host cell, 
which might result in the identification of potential therapeu- 
tic targets. We were particularly interested in identifying a 
response that could activate NFB. This pleiotropic transcrip- 
tion factor is activated in response to stress, and it in turn leads 
to the expression of numerous cellular genes, including those 
involved in the immune and inflammatory esponses. This fac- 
tor could therefore be viewed as modulating one of the cell's 
defense mechanisms in response to a stress. One of the path- 
ways by which NFB is activated is reactive oxygen species 
(ROS)-dependent. 
We found that: 
• HCMV infection of  SMCs rapidly generates ROS 
* HCMV infection of  SMCs activates NFB 
• Antioxidants inhibit HCMV-induced NFB activation 
• HCMV-induced ROS are necessary for IE1 expression 
and viral replication 
We further found that aspirin (which has antioxidant 
activity) also inhibits HCMV-induced ROS generation, 
HCMV-induced NFB activation, IE1 expression, and HCMV 
replication. These results are compatible with the concept 
that aspirin treatment for viral infections may not only be 
symptomatic, but may also have some therapeutic effect. 
Moreover, if HCMV contributes to atherosclerosis, this 
action of the drug provides another mechanism whereby 
aspirin may reduce the progression of atherosclerosis and the 
incidence of atherosclerotic-related events. 
If HCMV is eventually proven to be causally related to vas- 
cular disease, it will be neither a necessary nor a sufficient fac- 
tor, but rather will constitute another isk factor. Moreover, if 
infection does contribute to vascular disease, the contribution 
undoubtedly will not be through one unique agent. For exam- 
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pie, two additional candidate pathogens for which there is 
increasing evidence that they may play a role in atherosclerosis 
are Chlamydia pneumoniae and Helicobacter pylori. Thus it is 
possible future studies will prove that multiple infectious 
agents, perhaps through the immune and inflammatory 
responses they evoke, will contribute to the development of 
vascular disease. 
Stephen E.Epstein, MD 
National Heart, Lung, and Blood Institute 
National Institutes of Health 
Bethesda, Md. 
CHLAMYDIA PNEUMONIAE AND ATHEROSCLE-  
ROSIS 
Chlamydia pneumoniae became the third species of the 
Chlamydia in 1989. It is an important cause of pneumonia 
and other respiratory infections. 
Several characteristics of the organism make it at least 
plausible that it could be involved in the pathogenesis of ath- 
erosclerosis. It has been shown that virtually everyone is infect- 
ed during their lifetime and that reinfection continues into old 
age. Population prevalence specific C. pneumoniae antibody is 
infrequent under the age of 5 years but thereafter raises quick- 
ly, reaching 50% by 20 years. Despite the usual oss of antibody 
3 to 5 years after infection, the prevalence continues to rise in 
adults reaching about 80% in males and 70% in females after 
70 years of age. 
Another characteristic of infection with Chlamydia 
species is chronicity. The eye disease, trachoma, and infertili- 
ty from scarring and occlusion of the fallopian tube arc both 
due to immunopathology after rcinfections with C. tra- 
chomatis and chronic persistent infection. Most natural animal 
infections with C. psittaci are chronic and may be lifelong. 
The biologic plausibility of Chlamydia invading cardiovas- 
cular tissue is supported by human infections. All three 
Chlamydia species have been shown to cause myocarditis and 
endocarditis. Chlamydia elementary body particles have also 
been demonstrated in damaged heart valves. 
Seroepidemiology 
The initial study that indicated an association between C. 
pneumoniae nd coronary artery disease was seroepidemiolog- 
ic and was reported from Finland in 1988. Patients with coro- 
nary artery disease were significantly more likely to have sero- 
logic evidence of past infection with C. pneumoniae than were 
population-matched controls, and the association was inde- 
pendent of known risk factors. The original finding was 
extended in a larger nested case-control study involving 
patients enrolled in the Helsinki Heart Study. Investigations in 
Seattle found a similar association between C. pneumoniae IgG 
antibody and coronary artery disease in two studies involving 
patients with angiographically demonstrated disease. 
There are now 16 seroepidemiologic studies from 12 dif- 
ferent groups of investigators all of whom found an associa- 
tion between antibody evidence of past C. pneumoniae infec- 
tion and atherosclerotic disease. The studies come from seven 
countries in Europe, Hong Kong, and the United States. 
All but two of these studies were directed at coronary artery 
disease. One study concerned carotid artery thickening and the 
other cerebral infarction and transient ischemic attacks. The 
cases in both more frequently had C. pneumoniae ntibody. 
Perhaps the most impressive finding from the seroepide- 
miologic studies is the frequency with which the association 
has been found. Although different designs, different anti- 
body measurements, different populations, different laborato- 
ries were used, 16 studies found an association between sero- 
logic evidence of prior C. pneumoniae infection and different 
expressions of atherosclerotic disease. 
D i rec t  demonst ra t ion  o f  C. pneumoniae 
in atherosclerotic lesions 
C. pneumoniae has been found in lesions of coronary 
arteries and other large vessels that get atherosclerotic disease. 
While the organism has been demonstrated primarily by 
immunocytochemistry (ICC) and the polymerase chain reac- 
tion (PCR), it has also been shown by electron microscopy 
(EM) and now by isolation of the organism. The pear-shaped 
elementary bodies of C. pneumoniae are unique among the 
Chlamydia and provided the method for the original pre- 
sumptive identification of the organism in atheromata of 
coronary arteries. The observation was made by Dr. Alan 
Shor in South Africa. Using ICC and PCR with his material 
we showed that the structures were C. pneumoniae. Our 
Seattle laboratories have completed eight studies of a total of 
324 persons inwhich the organism has been sought in athero- 
matous lesions of coronary, carotid, and femoral/popliteal 
arteries and the aorta. The tissues tudied came from autopsy, 
surgery, and atherectomy. The populations studied came from 
South Africa and from throughout the United States, includ- 
ing Alaska. Persons studied included Caucasians, Blacks, 
Asians and Alaska Natives. C. pneumoniae was present in 
athemmata of all these populations and in both genders. The 
organism was found in beginning lesions in young persons 
and in well developed and calcified lesions of older persons. 
Overall 55% of developed lesions were positive for C. pneu- 
moniae. The organism was never found in normal artery spec- 
imens. However, true matched control persons without ath- 
erosclerosis were available only in the study of young persons 
(15 to 34 years of age) from the U.S. multicenter PDAY study 
where 31 individuals without evidence of atherosclerosis in 
the studied coronary artery failed to show C. pneumoniae. 
Eleven other laboratories have now reported the finding of 
C. pneumoniae in atherosclerotic ssue. Five studies used ICC 
or direct IF staining of tissue and reported from 69% to 100% 
of the coronary and aorta lesions studied to be positive for 
Chlamydia. Six laboratories looked for C. pneumoniae in 
atheroma by PCR only. A lower percentage positive and more 
variability were reported, from 2% to 7I%. The lower percent 
positive in three of the studies may be related to the PCR tests 
used or to PCR inhibitors in tissue. 
The results with the more sensitive ICC method are usu- 
ally based on observation of a single 4 mm section of tissue. 
When we studied a number of sections made at different 
depths through aa~ atheroma, often some were positive and 
some negative. This tendency of the organism to be irregu- 
larly distributed through the lesion has also been observed by 
EM. These findings suggest that despite the high percentage 
of atheromatous lesions with C. pnesmoniae demonstrated by
ICC, the reported results may be an underestimation f the 
true frequency. An interpretation of these data is that most 
arterial atheroma have some C. pneumoniae in the lesion. 
The first isolation of C. pneumoniae from an atheroscle- 
rotic lesion was accomplished from an atherosderotic coro- 
nary artery. Three separate laboratories culturing this speci- 
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men obtained an isolate. We have succeeded in isolating C. 
pneumoniae from a carotid artery plaque r moved at surgery. 
Recently isolation and propagation of five C. pneumoniae iso- 
lates from 60 coronary endarterectomy specimens has been 
reported from Germany. 
To investigate the possibility that C. pneumoniae may 
persist in cells indefinitely and not cause disease, the innocent 
bystander hypothesis, a study was undertaken of tissue from 
39 routine autopsies and 33 surgically removed granulomas. 
The organism was found much more frequently in car- 
diovascular tissue (-35%) than in liver, spleen, bone marrow, 
or lymph node (5% to 10%) or even lung (13%). When the 
organism was detected in noncardiovascular tissues, it was 
usually in association with its detection in the coronary artery 
of that patient. C. pneumoniae was detected in only three of 
the granuloma specimens from a variety of disease conditions. 
The three positives were from five skin lesions of sarcoidosis. 
These studies uggest aspecificity of the organism for arte- 
rial atheroma nd while not ruling out the innocent bystander 
possibility, provide evidence against hat hypothesis. 
Laboratory  in  v i t ro  g rowth  o f  C. pneumoniae in
cells found  in  the artery wal l  
In vitro C. pneumonia has been shown to multiply in 
macrophages, endothelial, and smooth muscle cells. C. pneu- 
moniae is a gram-negative intracellular bacterium possessing 
llpopolysaccharide, and this multiplication was associated with 
cytokine production (TNF-a, IL- lb,  IL-6, INF-a, INF-f), 
and induction of adhesins and proteases. Recent findings of 
Kalayoglu and Byrne have potential for showing a mechanism 
for C. pneumoniae to contribute to the pathogenesis of ather- 
osclerosis. Experimenting with macrophages in vitro they 
showed that exposure of the cells to C. pneumoniae nd then 
to low-density lipoprotein (LDL) caused a large increase in 
the number of foam cells and accumulation of cholesterol 
esters. These results suggest hat C. pneumoniae can induce 
foam cell formation a hallmark of early atherosclerosis. 
Etiologic studies 
Observational studies cannot prove that C. pneumoniae 
causes atherosclerosis. Evidence from animal model studies 
and human treatment trials will allow more direct inference of 
causality. 
Animal model studies 
Two prefiminary reports of C. pneumoniae infection of New 
Zealand white rabbits suggest hat following resph'atory tract 
inoculation C. pneumoniae can initiate lesions in the aorta of 
these rabbits that do not develop atherosclerosis on a normal 
diet. In one study a single intranasal inoculation was given and 
in addition to developing pneumonitis, 2 of 6 animals killed at 
1 or 2 weeks after inoculation showed ither fatty streaks or 
grade III atherosclerotic lesions in the aorta. In the other stud- 
ics, the rabbits wcrc given a second intranasal inoculation 3 
weeks after the first. Six of the nine rcinfccted rabbits killed 2 to 
4 weeks after rcinoculation showed inflammatory changes con- 
sisting of intirnal thickelfing or fibroid plaques resembling ath- 
erosclcrosis. WINe the pathologic nature of these early aortic 
lesions may be undear, these experiments offer evidence that C. 
pneumoniae pulmonary infection is capable of causing aortic 
lesions where they do not otherwise occur. If these rabbit exper- 
iments can be repeated with the same results with larger ntun- 
bers and with the development of pathology observed over a 
longer period they will be even more valuable. They suggest that 
C. pneumoniae can play a role in initiation of atherosclerosis. 
Human secondary  prevent ion  ant ib io t i c  
treatment rials 
Two human antibiotic treatment trials directed at secondary 
prevention of cardiovascular events have been reported. In both, 
the subjects had suffered a coronary heart disease episode and 
were at high risk for another event. Subjects were treated with 
an azalidc or macrolide-type antibiotic and the trials were place- 
bo controlled. A significant reduction in cardiac events was 
reported in the treatment group of both studies, despite a small 
number of subjects in one and a short period of observation in 
the other. Both studies had design defects. Neither study is ade- 
quate proof that antibiotic therapy will reduce coronary artery 
events. Larger studies with longer periods of observation are 
needed and justified. Also the patient base of subjects hould be 
broadened to include persons with known coronary heart dis- 
ease but without a recent event. I f  successful such trials would 
add a new treatment method for coronary artery disease and 
would suggest that C. pneumoniae plays a role in the inflamma- 
tory process which has been associated with coronary heart dis- 
ease events. They would also suggest that antibiotic treatment 
be tested against other atherosclerotic diseases. 
Conclusion 
Although an association between C. pneumoniae nd ath- 
erosclerosis has been definitely established, it remains 
unproven whether this association is causal. A question 
remains, if C. pne~tmoniae is playing a pathogenic role in ath- 
erosclerotic diseases i  it in initiation of the process, accelera- 
tion of the pathologic ondition, or in the complications that 
lead to disability and death. The rabbit model results suggest 
a role in initiation of the disease, and the human treatment tri- 
als suggest a role in disease pisodes or complications of ath- 
erosclerosis. Because of the great importance to human health 
a number of scientists are investigating this association, and 
we are expecting more definitive answers in a few years. 
f. Thomas Grayston, MD 
University of Washington 
Seattle, Wash. 
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INFLAMMATORY AND IMMUNE 
VASCULOPATHIES 
The inflammatory and immune vasculopathies are a diverse 
group of conditions. Attempts at classifying these disorders 
into discrete categories have been replete with controversy 
and inconsistencies. At the heart of this controversy is a gen- 
eral lack of definitive knowledge about the mechanism and 
etiology of these maladies. An encyclopedic overview or regi- 
mented classification scheme is therefore beyond the scope of 
this chapter. Rather, we will attempt to describe the most fre- 
quently encountered vasculopathies in our tertiary referral 
practice. Our focus will be on Raynaud's syndrome as it pre- 
sents in patients with autoimmune disease, namely the con- 
nective tissue diseases, a population which we have studied 
intensely for over 25 years. 
Giant cell (temporal) arteritis 
Giant cell (temporal) arteritis is predominantly a disease of 
elderly females. Involvement of the brachiocephalic, temporal, 
and ophthalmic arteries has been well documented historical- 
ly. It was recently pointed out, however, by the group at the 
Mayo Clinic that the incidence of thoracoabdominal aortic 
aneurysm and dissection ismarkedly increased in this group of 
patients. 1 Aneurysms of the thoracic aorta developed in 11 of 
96 patients at a median of 6 years after diagnosis of giant cell 
arteritis. Compared with an agc- and scx-matched population, 
patients with giant cell arteritis were 17 times more likely to 
have thoracic aortic aneurysm and more that twice as likcly to 
have isolated abdominal ortic aneurysm. 
The initial presentation of giant cell artcritis usually 
involves a constellation of flu-like symptoms including 
malaise, fever, headache, and myalglas. Tender temporal arter- 
ies occur in over half of patients, although involvement of the 
occipital arteries with nuchal tenderness may be present, and 
should alert the physician to the possibility of giant cell arteri- 
tis. In the untreated patient, major eye complications occur at 
an average of three months, but have been reported as early 
as three days. Biopsy of the inflamed artery remains the hall- 
mark of diagnosis. 
Corticosteroids have been traditionally used to treat giant 
cell arteritis, and have been particularly effective in the pre- 
vention of blindness. Unfortunately, in the elderly population, 
high-d0se eortieosteroid treatment is associated with an 
unusually high incidence of complications (up to 58%), 
including fractures, infections, and a complex of diabetes, 
congestive heart failure, and hypertension) Newer treatment 
regimens including lower doses of steroids combined with 
cytotoxic agents may be on the horizon. 
Takayasu's arteritis 
Takayasu's arteritis is a rare disorder occurring mainly in 
young Asian women, although the disease occurs worldwide. 
The cause is unlmown, although infectious, autoimmune, and 
hormonal etiologies have been implicated. While patients may 
present with a variety of nonspecific symptoms, most present 
with symptoms of vascular insufficiency. Typically, the aorta 
and its main branches are affected. Four types have been 
described based on sites of involvement. Type I involves the 
aortic arch and its branches. Type II involves the descending 
and abdominal aorta. Type III, which in most series is the 
most frequent ype, combines elements of types I and II. 
Type IV implies pulmonary artery involvement. Both stenot- 
ic and aneurysmal lesions may occur, but in most series 
stenotic lesions predominate. 
As with giant cell arteritis, glucocorticoid therapy remains 
the mainstay of treatment, although success has also been 
achieved with cytotoxic agents. Surgical therapy is reserved for 
patients with arterial ischemia or aneurysmal disease refractory 
to medical management. Important principles include the use 
of bypasses rather than endarterectomies, which are technically 
difficult in this patient group, avoidance of surgery during the 
active phase of disease, and taking care to originate and termi- 
nate grafts in grossly tmaffccted arteries. The largest modern 
surgical series of Takayasu's arteritis patients was recently 
reported by Robbs et al. from South Africa. a Operations were 
performed on 81 with an overall operative mortality rate of 
3.6% and no deaths after elective surgery. Surprisingly good 
intermediate-term results have also recently been reported with 
percutaneous transluminal ngioplasty oflesions in the thoracic 
and abdominal orta in patients with Tal(ayasu's arteritis. Initial 
success was noted in all patients with a life table cumulative 
patency rate of 67% in 16 patients followed up to 52 months. 4 
The largest current North American series of Takayasn's 
arteritis was rcccnfly reported by the National Institute of 
Allergy and Infectious Disease. 5 Fifty-eight patients wcrc fol- 
lowed for a mean of 5.3 years. The median age at disease onset 
was 25 years. One third had systemic symptoms, while most 
presented with vascular ischemie symptoms. Sixty percent of 
patients responded to ghicocorticoid treatment alone, while 
40% of steroid-resistant patients responded to cytotoxic 
agents. Unfortunately, half of those who achieved remission 
later relapsed. Thirty patients underwent 79 vascular proce- 
dures including bypass, angloplasty, and aneurysm repair. 
While early palliation was the norm, complications~ including 
restenosis, were common. Surgical biopsy material from 
patients with clinically inactive disease showed active arteritis in 
44%, accounting for the relapsing and virulent nauare of this 
disease. Fortunately, the mortality rate is low (2%). 
Raynaud 's  syndrome and the  connect ive  t i ssue  
d iseases  
Raynaud's syndrome is a ubiquitous malady, with an inci- 
dence in the general population up to 20% to 25% in cool, 
damp climatcs. Thc traditional c assification ofRaynaud's syn- 
drome was established in the 1930s by Allen and Brown, who 
divided the syndrome into Raynaud's disease or primary 
Raynaud's syndrome, an idiopathic form of intermittent digi- 
tal ischemia occurring in the absence of associated iseases, 
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and Raynaud's phenomenon, or secondary Raynaud's syn- 
drome, a similar symptom complex occurring in association 
with one or more of a variety of systemic diseases. However, 
as early as the 1950s, it was recognized that Raynaud's phe- 
nomenon may precede the development of an associated is- 
ease by many years, thus frequently mandating a change in 
patient classification. Gifford and Hines noted an association 
between autoimmune diseases and Raynaud's yndrome. A 
4.6% progression to a CTD was noted in 280 patients fol- 
lowed for more than 2 years. Since then, others have report- 
ed the presence of an associated isease in 40% to 80% of 
patients with RS. Several small studies also addressed the issue 
of progression to development of CTD in patients with RS. 
In patients with no clinical or serologic parameters of CTD, 
progression to a CTD occurred in up to 9% of patients. The 
results were widely varied in patients with initial clinical or 
serologic evidence of CTD, with rates of progression ranging 
from 11% to 65%. Again, these data are primarily from small 
studies with limited follow up. 
Since 1971, we have held a weekly clinic devoted to 
Raynaud's yndrome and have evaluated more than 1000 
patients to date, with a mean follow up of 3.2 years and 118 
patients followed greater than years. 6 Patients are seen annu- 
ally for physical exam, vascular lab testing, and serologic test- 
ing, and are also evaluated for CTD, other associated diseases, 
digital ulcers, and digital amputations. 
At initial presentation, serologic and vascular lab testing is 
used to divide patients into prognostic ategories. The pres- 
ence or absence of a positive antinuclear antibody or rheuma- 
toid factor defines serologic positivity and negativity respec- 
tively. Vascular lab testing, consisting of room-temperature 
digital plethysmography and cold challenge Nielsen testing, is 
used to determine whether the patient's ymptoms are primar- 
ily caused by vasospasm or fixed digital artery obstruction. 
From these tests, four prognostic groups are derived, vasospas- 
tic or obstructive KS with either positive or negative serologies 
(spas,sero-;spas,sero+;obst,sero-; obst,sero+). 
Overall, CTD were diagnosed either initially or during 
follow up in 279 patients (26.9%). At the time of initial diag- 
nosis of RS, 48.6% of the spast,sero# group and 72.9% in the 
obst,sero+ group had a concomitant diagnosis of a CTD. 
None of the sero- patients in either group initially presented 
with CTD. Subsequent development of a CTD in patients in 
whom it was not initially present occurred in 2.0% of the 
spast,sero- group, 8.5% of the obst,sero- group, 16.4% of 
the spast,sero+ group, and 30.4% of the obst,sero+ group. 
The overall prevalence of CTD diagnosed either initially or 
during follow up was 2.0% in the spast,sero- group, 8.5% in 
the obst,sero- group, 57.0% in the spast,sero+ group, and 
81.1% in the obst,sero+ group. 
In the greater than 10 year follow up group, CTD were 
diagnosed in 57 patients (48.3%) overall, including 95% of the 
patients in the obst,sero+ group, and 66.7% in the spast,sero+ 
group. This suggests that the risk of developing a CTD con- 
tinues to increase with time, particularly if initial serologic 
positivity is present. Patients without initial serologic positiv- 
ity are not at significantly increased risk of subsequent CTD 
development. 
By far the most frequently diagnosed CTD in patients 
with RS is progressive systemic sclerosis (PSS) or scleroderma. 
This was noted in 128 of the patients with CTD (45.9%) and 
was particularly common in patients with obstructive RS and 
CTD, of whom 57.7% had PSS. Other frequently diagnosed 
CTD in patients with RS include rheumatoid arthritis, 
SjOgren's syndrome, systemic lupus erythematosus, and 
mixed and undifferentiated CTD. While PSS is the most fre- 
quently encountered CTD in patients with obstructive RS, in 
patients with vasospastic RS, a more even distribution is 
noted. 
Digital ulcerations are an infrequent complication in 
patients with spast,sero- RS, occurring in only 5% of 
patients. Patients with obstructive RS have a markedly 
increased risk of RS regardless of serologic status. Greater 
than 50% of these patients exhibit digital ulcerations at some 
time during their clinical course. Among patients with CTD 
and RS, 46% develop digital ulcerations. Other diseases 
which frequently cause obstructive RS and digital ulcers 
include Buerger's disease, atherosclerosis, and rapid onset 
vascular occlusion (ROVO), felt to be a form of hypersensi- 
tivity vasculitis with immune complex deposition. 
The requirement for digital or phalangeal amputations i
exceedingly rare in patients with vasospastic RS. Again, this 
unfortunate sequela is seen almost exclusively in patients with 
obstructive RS, occurring in 10% to 20%. Ten percent of 
patients with CTD and RS require digital amputations. 
Among patients with RS followed for longer than 10 
years, the incidences of ulcerarions and amputations does not 
differ from those followed for shorter lengths of time. 
Ulcerations and amputations appear to be problems that 
occur early in the course of a patient's disease, frequently 
being the initial event hat causes them to seek medical atten- 
tion. I f  patients have had RS for greater than 10 years and 
have not had problems with ulcerations or amputations, in 
our experience it is unlikely that they will subsequently devel- 
op them. 
For most patients with RS, symptoms are easily con- 
trolled with minimal intervention and rare adverse sequelae. 
Clearly, however, a small subset of patients exists who will 
develop more severe symptoms and may require phalangeal 
amputations. The early abihty to predict which patients will 
fall into this category is important for patient counseling. 
John M. Porter, MD 
Oregon Health Sciences University 
Portland, Ore. 
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INFLAMMATORY MECHANISMS IN VENOUS 
DISEASE 
Chronic venous insufficiency (CVI) is the seventh leading 
cause of chronic disability in the United States, and it is esti- 
mated that 10% to 35% of people have some form of CVI. 1 In 
this population, venous ulceration is observed in 1% of 
patients, and the incidence increases to 4% in patients older 
than 65 years of age. 2 Chronic venous insufficiency is charac- 
terized by a dysfunctional venous ystem, which is associated 
with ambulatory venous hypertension and venous valvular 
incompetence with or without associated venous outflow 
obstruction. 3 The hemodynamic alterations observed in CVI 
may affect he superficial venous ystem, the deep venous ys- 
tem, or both. 
Veins are normally low-velocity, low-pressure, valved con- 
duits responsible for returning blood to the heart. Prograde 
flow is assisted by calf muscle pump contractions and a series 
of valves that prevent reflux. Disruption of prograde flow by 
val~alar insufficiency, calf muscle pump dysfunction, or both 
is associated with the development of venous hypertension. 
Sustained, chronic venous hypertension c stitutes an inflam- 
matory stimulus that causes alterations in the dermal micro- 
circulation and leads to leukocyte recruitment. 
Two major theories have been advanced to explain the 
cause and pathogenesis of CVI. One theory proposes that the 
less-deformable white cells are trapped in the venous micro- 
circulation of patients with CVI. 4 The resulting sluggish flow 
would favor leukocyte migration, with associated white cell 
activation, release of toxic metabolites, and eventual tissue 
damage. This particular theory was based on the observations 
that a greater percentage of leukocytes remained in the lower 
extremities of patients with venous hypertension while in the 
standing position> It was also supported by a histologic 
report of punch biopsies obtained from patients with mild sta- 
sis skin changes, lipodermatosclerosis, and active stasis ulcers. 6
The histologic study demonstrated increasing dermal euko- 
cyte infiltration associated with disease progression. Immuno- 
histochemical analysis indicated that lymphocytes and 
macrophages were the predominant leukocytes associated 
with tissue infiltration. 7 
The second major theory proposed that an oxygen diffu- 
sion barrier was responsible for the pathogenesis of CVI. The 
diffusion barrier was attributed to the presence of a pericapil- 
lary "cuff. "8 Indeed, extravasation of fibrinogen and red 
blood cells arc associated with cxtracellular matrix and inter- 
stitial alterations of the dermal microcirculation. However, 
the existence of an oxygen diffusion barrier has been experi- 
mentally refuted. The "pcrivascular cufF' represents a rela- 
tively unique extracetlular matrix alteration that is observed 
surrounding capillaries and postcapillary venules of patients 
with GVI. The perivascular cuff is composed of fibronectin, 
laminin, collagens type I and III, tenascin, and small amounts 
of fibrin. The source of these proteins is mxknown; however, 
experimental animal investigations in tumor angiogenesis sug- 
gest that the endothelial cell is the source. 9 In tumorigenesis, 
extravasated fibrinogen forms three-dimensional gels that 
attract fibroblasts, endothelial cells, and macrophages. After 
cellular penetration, the fibrinogen isreplaced by extracellular 
matrix proteins produced by endothelial cells. 
We explored the hypothesis of leukocyte-mediated injury 
ha our CVI patient population. We detected the expression of 
cell surface activation markers of circulating leukocytes using 
fluorescence flow cytometry, l° Relative to normal individuals, 
patients with chronic venous stasis ulcers had a decreased 
expression of the CD3+/DR÷ and CD3+/CD38+ markers on 
T-lymphocytes and an increased expression of CD14+/CD38+ 
markers on monocytes. Circulating neutrophils demonstrated 
no evidence of activation. Our results did not exclude the pos- 
sibility that leukocytes lodged in the microcirculation might be 
activated. 1°We also tested the possibility that monocytes might 
be dysfunctional in CVI. 11 By challenging monocytes from 
CVI patients with test mitogens, we observed a trend of dimin- 
ishing proliferative responses with clinical disease progression 
and suggested that this decreased capacity for mononuclear cell 
proliferation may manifest i self as poor and prolonged wound 
healing 11 
Although it is clear that leukocytes are involved in the 
pathogenesis of CVI, their exact fimction and the cytochemi- 
cal signaling regulating their activity is unknown. To gain 
insights, we have directed our attention more recently to 
applying ultrastructural morphometric analysis of the dermal 
microcirculation a d cytokine evaluation of tissue biopsies to 
elucidate these mechanistic relationships. 12 In contrast to the 
proposal that extravasation f macromolecules is associated 
with widened endothelial c efts, we observed uniformly tight 
junctions in patients with class 4 to 6 CVI. On the basis of this 
observation, we suggested that increased transendothelial 
vesicle transport, ransendothelial channel formation, or alter- 
ations in the glycocalyx lining the junctional cleft may be 
responsible for microedema formation. 12 Qualitative assess- 
ment of endothelial cells with electron microscopy demon- 
strated numerous ribosomes both free in the cytoplasm as well 
as on the endoplasmic reticulum and also demonstrated 
euchromatic nuclei. These ultrastructural data suggest active 
gene transcription and protein production. 12 
The distribution and type of cells observed in association 
with the perivascular cuff support a tissue remodeling and 
injury response hypothesis. In our study, the predominant 
inflammatory cells observed surrounding these structures 
were mast cells and macrophages, 12 as opposed to lympho ~ 
cytes and macrophages. 7 The role of mast cells in CVI patho- 
physiology isunknown; however, they may function as a con- 
trol point in the regulation of tissue remodeling and extracel- 
lular matrix protein production. Mast cells of the human cell 
line HMC-I  spontaneously adhere to proteins that make up 
the perivascular cuff, such as fibronectin, laminin, and colla- 
gen type I and III, in vitroJ 3 The mast cell enzyme chymase 
is a potent activator of matrix metalloproteinase-1 and -3 
(collagenase and stromelysin).14,15 Chymase also causes 
release of latent TGF-1 secreted by activated endothelial cells, 
fibroblasts, and platelets from extracellular matrices in vitro. 
Importantly, latent TGF-1 is present in perivascular cuffs of 
patients with CVI, suggesting that mast cells may cause 
release and activation of TGF-1.16 Release and activation of 
TGF-1 may inflate a cascade of events in which macrophages 
and fibroblasts are recruited to wound healing sites and stim- 
ulated to produce fibroblast mitogens and connective tissue 
proteins, respectively. 
Our current studies, using semiquantitative RT-PCR in skin 
biopsy specimens obtained from CVI patients with severe tissue 
fibrosis, have documented that patients with CEAp3 class 4, 5, 
and 6 disease demonstrate a decreasing TGF-1 gene expression 
with cliNcal disease progression. To confirm or refute a possible 
association between biochemical terations and disease progres- 
sion, quantitative studies of cytokine gene expression i patients 
with earlier stages ofdisease need to be tmdertaken. 
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In summary, venous insufficiency is a disease marked by 
chronic inflammation that leads to tissue fibrosis. Chronic 
venous insufficiency is an open field for further mechanism- 
driven research. Future studies of the pathogenesis of CVI 
should address the stimuli regulating leukocyte recruitment 
and the role of the perivascular cuff. Particularly, the cellular 
source of the extracellular matrix proteins hould be identified 
and the interactions of mast cells, macrophages, endothelial 
cells, and fibroblasts and their cytochemical signaling should 
be elucidated. 
Peter J. Pappas, MD 
UMDNJ--New Jersey Medical School 
Newark, N.J. 
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RESTENOSIS  AND ACCELERATED GRAFT 
ATHEROSCLEROSIS  
CHARACTERISTICS OF TRANSPLANT 
ATHEROSCLEROSIS  
With the excellent 1-year survival rates now achieved in heart 
transplantation, chronic graft failure has emerged as the major 
problem of this procedure, limiting its long-term benefit. The 
most common characteristic of chronic cardiac graft failure is 
a striking form of vasculopathy, descriptively termed acceler- 
ated graft arteriosclerosis (AGA). 
AGA is characterized by a concentric narrowing of the 
arterial vasculature, diffusely involving large and small vessels. 
These changes can occur within several months after trans- 
plantation and are present in a high percentage of recipients 
within 1 to 2 years. Histologically, the most striking feature of 
AGA is marked thickening of the intima by an accumulation 
of smooth muscle cells, lipid-laden macrophages, and lym- 
phocytes with generally intact external and internal elastic 
laminae and the absence of plaques) These features of AGA 
contrast with those of natural atherosclerosis in patients with- 
out transplants, in whom focal eccentric atheromatous 
plaques typically require many years to develop. 
Several significant risk factors have been associated with 
AGA in cardiac transplant recipients. These include (1) donor 
organ injury, especially associated with ischemia-reperfusion 
during organ recovery, preservation, and implantation surgery; 
(2) acute rejection episodes, including those that occur after 
the first 6 months after transplantation; (3) cytomegalovirus 
(CMV) infection, especially in CMV-negative recipients of 
CMV-positive donors; and (4) risk factors for native athero- 
sclerosis, such as hypedipidemia. 
Various mechanisms of AGA have been proposed on the 
basis of clinical observations and experimental nimal models. 
Although often termed "chronic rejection" and presumed to 
be dependent on host immune reactions against donor graft 
alloantigens, the characteristic changes of AGA have been 
demonstrated in experimental models of isograft (nonallo- 
geneic) transplantation as well as transient native organ 
ischemia, indicating that AGA is not necessarily the result of 
alloimmune-mediated r jection. Indeed, it is now generally 
thought hat AGA can develop as a result of rnechaulsms that 
involve antigen-dependent a d nondependent processes. 
To study potential mechanisms of AGA, a wide range of 
animal models have been used, especially invoMng rats and 
mice. These include heterotopic heart transplants, transient 
ischemia of native organs (especially kidneys), and aortic 
grafts in line (orthotopic) or in parallel (loop) with or without 
ligarion of the parallel segment. Each of these models, 
although useful in allowing studies of proposed mechanisms, 
raise significant questions of clinical relevance for several rea- 
sons beyond those of species differences and strain-specific 
variations. In particular, the artifactual local environment of 
these models in terms of flow and pressure, which each have 
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important effects on vascular emodeling, cannot be dis- 
counted. This is most problematic n the heterotopic heart 
model, with its reverse flow kinetics andsubstantial stasis and 
clot formation, and the aortic loop model, which has asym- 
metric pressure and flow, with the added problem of stasis 
when the native segment isnot ligated. 
A general scheme for the processes leading to AGA 
involves (1) an initiating event, such as by known risk factors 
listed above; l ading to (2) an inflammatory response, by anti- 
gen-nonspecific (macrophages, granulocytes, platelets) or 
antigen-specific (T cells, B cells) inflammatory cells and their 
mediators; leading to (3) vascular cell responses, induced by 
injury or activation of endothelial nd/or smooth muscle 
cells; leading to (4) vascular emodeling, especially involving 
myointimal hyperplasia (AGA). These processes also may le d 
to interstitial and parenchymal fibrosis of the graft either 
directly or indirectly as a result of the vascular changes of 
AGA. 
Many specific links in this general scheme have beensug- 
gested by changes observed by biopsy or resection of trans- 
planted hearts with AGA. Ischemia-reperfusion injury as a key 
initiating evcnt has been identified (when severe) by function- 
al graft impairment, but more quantitatively b direct mor- 
phologic appearance on early biopsy. Several indirect manifes- 
tations of ischemia-reperfusion injury are commonly 
observed 2-5 and include (1) the release of inflammatory and 
vasoactive mediators, especially complement (C), oxygen radi- 
cals, coagulation factors (tissue factor), and nitrous oxide 
(NO); (2) the upregulation f cell surface molecules involved 
in nonspecific nflammatory cell adhesion and migration, espe- 
cially integrins (ICAM, VCAM) and selectins (P-sdectin); (3) 
the upregulation of molecules that may evoke specific immune 
responses, uch as alloantigens (MHC class I and II) and 
autoantigens (heat shock proteins; HSP); and (4) the induc- 
tion of mediators of apoptosis (e.g., Fas). These responses to 
ischemia-reperfusion njury can exacerbate or be exacerbated 
by other risk factors of graft injury and AGA such as acute 
rejection, CMV infection, and cyclosporine toxicity. 
The effect of these initiating events, either alone or in 
combination, can cause a wide variety of non-antigen-specific 
inflammatory esponses, including the activation of comple- 
ment, which can promote the local attraction and activation of 
neutrophils, macrophages, and platelets. 6 The activation of 
complement by ischemia-reperfusion injury or antibodies 
results in a cascade of inflammatory mediators including: (1) 
cell-bound fragments of early C components (e.g., Clq, C4b, 
C3b, iC3b), which serve as ligands for binding and activating 
specific inflammatory cells and platelets; (2) soluble fragments 
of intermediate components (e.g., C3a, C5a), which can stim- 
ulate leukocyte chemotaxis ndactivation; and (3) terminal C
components (e.g., C5b-C9), which can activate ndothelial 
cells to a procoagulant state, as well as activate any platelets 
and macrophages within the vicinity. 
Antigen-specific T cell or antibody responses against 
alloimmune orautoimmune antigens within the graft can lead 
to vascular injury and AGA in various models. T cells appear 
able to mediate AGA by both the cytolytic perforin a d FasL- 
induced apoptotic pathways.5, 7 Clinical and experimental 
models have demonstrated anassociation between onallo- 
graft arteriosclerosis and anti-HSP antibody and cellular 
responses. 8 The effect of these and anti-MHC specific 
responses in promoting the development of AGA may also 
involve C activation. 6 
The initiating injury and induced inflammation results in a
range of vascular responses. Endothelial cell activation results in 
the release ofvarious growth factors, including platclet-derived 
growth factor, transforming growth factors, and basic fibroblast 
growth factor, which stimulate the smooth muscle proliferation 
and fibrosis typically seen in AGA and chronic graft failure.9 
Increased Fas expression can lead to cn othelial and smooth 
muscle apoptosis, which may in turn promote vascular myoin- 
ritual proliferation. 
The role of CMV in the development of AGA may 
involve several different mechanisms, l0 Ischemic allograft 
injury promotcs CMV infection, whereas allogeneic respons- 
es are effective in reactivating latent virus. CMV infection of 
cndothelial cells can promote their injury and conversion to a 
procoagulant state, as well as expression of MHC antigens. In 
smooth muscle cells, CMV can alter lipid metabolism, induce 
proliferation directly, and potcntially inhibit p53 control of 
cell growth. 
In summary, clinical studies and experimental models to 
date have demonstrated a variety of causes of vascular and 
graft injury that lead to AGA and chronic graft failure, and 
they suggcst that scveral distinct mcchanisms may bc involvcd 
in this process. Because most of the experimental nimal 
models used to date are subject to significant physiologic dif- 
ferences from the clinical situation, the number and nature of 
pathways leading to AGA remain unclear. 
Fred Sanfilippo, MD, PhD 
Johns Hopkins Medical Institutions 
Baltimore, Md. 
REFERENCES 
1. McManus BM, Horley KJ, Wilson JE, et al. Prominence of 
coronary arterial wall fipids n human heart allografts: impfi- 
cations for pathogenesis ofallograft arteriopathy. Am J Pathol 
1995;147:293-308. 
2. Gaudin PB, Rayburn BK, Hutchins GM, Kasper EK, 
Baughman KL, Goodman SN, et al. Peritransplant i jury to 
the myocardium associated with the development of accel r- 
ated arteriosclerosis in heart transplant recipients. Am J Surg 
Pathol 1994;18:338-46. 
3. Lafond-Walker A, Chen CL, Augustine S, Wu T-C, Hruban 
RH, Lowenstein CJ. Inducible nitric oxide synthase expr s- 
sion in coronary arteries of transplanted human hearts with 
accelerated graft arteriosclerosis. Am J Pathol 1997;151:91% 
25. 
4. Labarrere CA, Nelson DR, Faulk WP. Endothelial activation 
and development of coronary artery disease in transplanted 
human hearts. JAMA 1997;278:1169-75. 
5. Dong C, Wilson JE, Winters GL, McManus BM. Human 
transplant coronary artery disease: pathological evidence for 
Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. 
Lab Invest 1996;74:921-31. 
6. Baldwin WM III, Pruitt SK, Brauer RB, Daha MR, Sanfilippo 
F. Complement in organ transplantation: c tributions to
inflammation, injury and rejection. Transplantation 1995; 
59:797-808. 
7. Fox WM III, Hameed A, Hutchins GM, Reitz BA, 
Baumgarmer WA, Beschorner WE, Hruban RH. Perforin 
expression localizing cytotoxic lymphocytes in the intimas of
coronary arteries with transplant-related accelerated arte- 
riosclerosis. Hum Pathol 1993;24:477-82. 
8. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is ath- 
JOURNAL OF VASCULAR SURGERY 
Volume 27, Number 6 Special Communication 1173 
crosclerosis an immunologically mediated isease? Immunol 
Today 1995;16:27-33. 
9. Hoscnpud JD, Morris TE, Shipley GD, Mauck 1CA, Wagner 
CIL Cardiac allograft vasculopathy: preferential regulation of 
endothelial cell-derived mescnchymal growth factors in 
response to a donor-specific ell-mediated allogeneic 
response. Transplantation 1996;61:939-48. 
10. Koskinen P, Lemstrtm K, Bruggeman C, Lautenschlager I, 
H~iyry R Acute cytomegalovirus infection induces a suben- 
dothelial inflammation (endothelialitis) inthe allograft vascu- 
lar wall: a possible linkage with enhanced allograft arte- 
riosclerosis. Am J Pathol 1994;144:41-50. 
STUDIES  IN  TRANSPLANT ARTERIOSCLERO- 
SIS USING GENE DELETIONS 
A mouse  model  o f  transplant arteriosclerosis 
Although immtmosuppression largely prevents acute rejec- 
tion of transplanted hearts, transplant-associated rteriosclerosis 
of the coronary arteries remains a major obstacle to long-term 
graft survival. It is possible to approximate human cardiac trans- 
plantation and monitor myocardial rejection and transplaaat rte- 
riosclerosis in the mouse model of heterotopic heart ransplan- 
tation, 1 but it is difficult in this model to quantify the arte- 
riosclerotic response. To assess the development of transplant 
arteriosclerosis within a single vessel in a highly reproducible mad 
quantitative manner, we developed a mouse model of accelerat- 
ed arteriosclerosis based on the transplantation of a carotid 
artery loop) 
Carotid arteries were transplanted between B.10A(2R) (H- 
2 h2) donor mice and C57BL/6J (H-2 b) recipients and com- 
pared with arteries isografted between C57BL/6J (H-2 b) mice. 
Within 7 days the allografted arterial oops developed a neointi- 
ma composed of mononudear leukocytes (CD45+) that were 
predominantly monocytes or macrophages (although CD4+ 
and CD8+ cells were present as well). By 30 days an exuberaaat 
neointima developed in the arterial oops, and mononuclear 
lcukocytes were largely replaced by smooth muscle cells. The 
mononudear leukocytes and smooth muscle cells appeared to be 
proliferating, asevidenced by abundant s aining for proliferating 
cell nuclear antigen (PCNA) at both early and late time points. 
The area of the infima in the arterial oops increased from day 7 
to day 30 (p < 0.0005), as did the number of nuclei (p = 
0.0005), but the density of the nuclei decreased (p = 0.02), sug- 
gesting the formation of extraccllular matrix. This model, which 
reproduces many of the features of human transplant arte- 
riosclerosis but at an accelerated pace, can be used to determine 
the roles of genes that code for components ofimmunologic or 
inflammatory esponses--in the recipient as well as the donor. 
Effect on  transplant arteriosclerosis o f  muta- 
t ions in genes of  the  rec ip ient ' s  immune system 
To determine the influence of the recipient's immune sys- 
tem on the arteriosclerotic response, we first performed arter- 
ial loop transplantations i to recipient mice in which the 
V(D)J recombinase (Rag-2) gene had been deleted. 3 RAN-2 
knockout animals (lacking both T cell and B cell immune 
responses) accepted allogeneic arotid artery grafts without 
forming a significant neointima. To more precisely isolate the 
components of the recipient's immune system important in 
the genesis of a neointima, we next allografted arterial oops 
into recipients deficient in helper (CD4) T cell function or 
cytotoxic (CD8) T cell function, or in the ability to produce 
specific antibody, natural killer cells, or macrophages. We 
found that CD4+ T ceils, humoral antibody, and macrophages 
were essential to the concentric neointimal proliferation char- 
acteristic of transplant arteriosclerosis. In contrast, CD8+ T 
cells and natural killer cells were not involved. Although arter- 
ies allografted into Rag-2 knockout mice showed almost no 
neointimal proliferation, those grafted into mice deficient only 
in helper T cells, humoral antibody, or macrophages developed 
small neointimas. In these small neointimas and in the large 
neointimas of arteries grafted into immunocompetent con- 
trois, inflammatory cell number was similar; however, smooth 
muscle cell number and collagen deposition were lower in the 
small neointimas, Thus the smaller neointimas in arteries allo- 
grafted into mice deficient in helper T cells, humoral antibody, 
or macrophages were apparently due to a decrease in smooth 
muscle cell migration or proliferation. 
Effect on  transplant arteriosclerosis o f  muta- 
t ions in genes o f  the arterial loop donor  
To determine the roles of the donor's MHC I gene 
(important for presenting antigen to CD8 cells) and MHC II 
gene (important for presenting antigen to CD4 cells) in the 
arteriosclerotic response, we grafted carotid artery loops from 
C57BL/6 wild-type mice or C57BL/6 mice deficient in the 
gene for MHC I or MHC II into inbred CBA mice. Donor 
loops carrying the MHC II deletion showed a significant 
decrease in neointimal size in comparison with wild-type 
loops. In contrast, donor loops carrying the MHC I deletion 
showed a significant increase in neointimal size. These obser- 
vations indicate the importance of antigen presentation via 
the donor's MHC II molecules in the initiation of transplant 
arteriosclerosis. We were surprised to find a significant 
increase in neointimal size in donor loops carrying the MHC 
I deletion. Although we do not have a completc answer for 
this unexpected finding, it is tempting to speculate that in the 
absence of the donor's MHC class I molecules, the normal 
recipient's cytotoxic T cells could not recognize and attack 
the donor's smooth muscle cells. As a consequence, smooth 
muscle cell proliferation continued unopposed. 
Because inflammatory cells are important in the formation 
of neoinfima in transplant arteriosclerosis, we also studied the 
importance of adhesion molecules uch as ICAM-1 and P- 
selectin in inflammatory cell migration to the neointima nd its 
subsequent enlargement. We grafted carotid artery loops from 
C57BL/6 wild-type mice or C57BL/6 mice deficient in the 
gene for 1CAM-1 or P-selectin, or both, into inbred CBA mice. 
Donor loops carrying the ICAM-1 but not he P-sdectin dele- 
tion showed a significant decrease in neointimal size in com- 
parison with wild-type donor loops. Neointimal size in donor 
loops carr3~ng the ICAM-1 knockout was similar to that in 
those carrying the ICAM-1, P-selecfin double knockout. These 
data indicate the importance of donor endothelial cell ICAM-1 
expression, but not donor endothelial cell P-sdectin expression, 
ha fostering migration of the recipient's inflammatory cells and 
enlargement of the ncointima. 
A mouse model  o f  vein graft stenosis 
Occlusion of saphenous vein grafts is the primary limita- 
tion to the long-term success of coronary artery bypass 
surgery. Unfortunately, the pathogenesis ofvein graft disease 
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is not clear. Like the artetiosclerosis that follows transplanta- 
tion, the arteriosclerosis that follows vein grafting is accelerat- 
ed. To apply genetically modified mice to the analysis of this 
problem, we developed a model of vein graft disease in which 
an autogenous patch taken from the external jugular vein of a 
mouse is attached to a surgically created efect in its ipsilater- 
al carotid artery. This procedure results in the rapid and high- 
ly reproducible formation of a neointima that lies over the 
vein patch and its junction with the artery. 
The vein patch neointima occupied 37% + 4.6% of the ves- 
sel lumen at 7 days after surgery and grew to occupy 66% _+ 5.7% 
of the lumen after 20 days. The proliferative index, as measured 
by PCNA staining, was 50.6% _+ 3.64% of all cells after 7 days 
and 15.2% -+ 1.97% after 20 days. Alpha-actin-positive smooth 
muscle cells accounted for 9.9% + 1.1% ofthe intimal area at day 
7, and their share increased to 40.9% _+ 2.6% of the area at day 
20. Collagen deposition, however, accounted for only 6.76% _+ 
0.68% of the intimal area at day 7 and 20.2% + 1.4% of it at day 
20. Formation ofneointima was similar in mice of the C57BL/6 
(H-2b), B6/129 (H-2b), and mixed genetic backgrounds. Thus 
neiointima formation in this model appears to be independent 
of genetic background. Because the procedure can be per- 
formed in mice beating deletions of genes thought to be impor- 
tant in vein graft disease, the model should improve our under- 
standing of this form of vascular remodeling as well. 
Conc lus ion 
Our observations show how the study of a number of spe- 
cific gene mutations in a mouse model of carotid artery trans- 
plantation gives insight into the genes governing transplant 
arteriosclerosis. The problem can be approached from the per- 
spective of the donor's or the recipient's genes. Our initial 
observations in the vein patch model indicate its suitability for 
analogous investigations u ing knockout mice to gain insight 
into the pathogenesis of bypass graft stenosis. The work illus- 
trates the beginning of a search that should eventually clarify 
these two complex, multicellular processes. 
Chengwei Shi 
Nicholas E. S. Sihinga 
Arthur Mu-En Lee, MD, Phi) 
Edgar Haber 
Harvard School of Public Health 
Boston, Mass. 
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ENDOTHELIAL CELLS IN  TRANSPLANT 
ARTERIOSCLEROSIS 
Endothel ittm: at the  interface between host  and 
recipient 
In transplanted solid organs such as cardiac grafts the 
endothelial cells truly represent the frontier between host and 
donor tissues. Originating from the donor, they are direcdy 
exposed to and bear the first wave of attack of circulating 
immune competent cells, phagocytes, immunoglobulins, and a 
myriad of growth factors and cytokines produced by the recipi- 
ent. The elaboration ofsophisticated means ofimmunosuppres- 
sion have significantly improved the early survival rate of sofid 
organ grafts. However, the fimifing factor in long-term survival 
rates corresponds to the chronic rejection of the blood vessels 
that are feeding the grafted organ. Such a process of chronic 
rejection has been named accelerated graft arteriosclerosis 
(AGA). Endothelial cells are directly involved in the process of 
AGA. Whereas an intact endothelittm can be found adjacent to 
the typical AGA lesions with concentric accumulation fprolif- 
erating smooth muscle cells, proteoglycans, and lipids, lesions 
can also be juxtaposed to endothelial cells that are sparse and 
dearly injured. Such injury to endothelial cells can result in the 
loss of their ftmctional properties. The classic endothelial func- 
tions include (1) antithrombotic a tivi~, (2) control of the myo- 
genic tone, (3) control of access to inflammatory cells, (4) reg- 
ulation of smooth muscle cell proliferation, (5) modulation of 
extracellular p otein production and degradation, (6) barrier to 
lipids, circulating cytoldnes, and growth factors. Thus loss of 
endothelial cell fimction may play a pivotal role in the process of 
AGA. In addition, damage to endothelial cells can also lead to 
cell death through apoptosis. 
Endothe l ia l  cell  apoptos is :  a un ique  program o f  
cell death  
Endothelial cells are amazingly sturdy cells that can sur- 
vive for years on the luminal surface of blood vessels while 
exposed irectly to growth factors, cytokines, and infectious 
agents. The removal of damaged endothelial cells through 
apoptosis i a homeostatic process designed to ensure that the 
endothelium remains capable of providing its normal func- 
tion. An irreversibly damaged endothelial cell activates its 
intrinsic cell death program and through this process is 
washed away by the blood flow to an area downstream where 
it can be further processed by phagocytic ells. In most 
instances of tissular cell apoptosis, adjacent cells and phago- 
cytes provide the function of removal and processing of the 
apoptotic bodies. In the case of endothelial cells, however, 
because of the unique conditions of flow and associated shear, 
distant phagocytic mechanisms provide this function. This 
well-orchestrated process of endothelial cell apoptosis con- 
tributes ignificantly to the homeostasis of the endothelium, 
In certain pathologic onditions this process of endothe- 
lial cell apoptosis may become detrimental: (1) because of a 
reduced level of shear downstream from an arterial narrowing 
within atherosclerotic vessels, apoptotic endothelial cells 
might persist at the luminal surface of the vessel, 1 preventing 
new endothelial cells from replacing them and promoting the 
development of vessel spasms; adhesion and aggregation of 
platelets; accumulation ofmacromolecules such as proteogly- 
cans, lipids, and inflammatory cells; and proliferation of 
smooth muscle and other cells of the vessel wall; or alterna- 
tively, (2) excessive ndothelial cell apoptosis could lead to an 
abnormally accelerated turnover of endothelium, and because 
endothelial cells in a proliferative phenotype are not capable 
of providing normal physiologic functions, such a process 
could be detrimental to the vessel wall. In addition, when the 
process becomes chronic, certain areas of the vessel wall may 
become denuded from their endothelium and inner layers of 
the vessel wall are directly exposed to the blood content. The 
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latter pathologic process can be found within the coronary 
arterics of transplanted hearts. 1
Mechan isms o f  endothe l ia l  ce l apoptos i s  in  
acce lerated graf t  a therosderos i s  
It is frequently postulated that much of the injury that 
takes place in AGA is mediated by free radical generation at 
the time of transplantation. We have studied exposure of 
human aortic endothelial cells to free radicals in two condi- 
tions. In the first condition, generation of free radicals within 
endothelial cells was produced by exposing the cells to hypox- 
ia (down to 10 Torr, for 4 hours) then reoxygenation. 2 This 
has been shown to induce the production of free radicals by 
endothelial cells. However, superoxide and other oxidant 
generation did not affect the survival of endothelial cells. 
Instead, the r oxTgenation phase (associated with production 
of superoxide) led to the rapid polymerization facrin into fil- 
aments; such polymerization probably aims at protecting actin 
subunits from the damaging effect of oxidant stress. 2 
We have also studied the xposure of endothelial cells to 
oxidants by overexpressing the constitutively activated iso- 
form of the small GTP binding protein Rac 1, using replica- 
tion incompetent adenovirus gene transfer techniques. 
Activated Rac 1 overexpressing cells, and in particular 
endothelial cells, produced heightened levels of superoxide, 3 
above and beyond the levels of superoxide that were achieved 
in endothelial cells infected with a replication incompetent 
adenovirus coding for the nuclear isoform of beta-galactosi- 
dase used as a control.3, 4 In spite of the increased production 
of superoxide, the endothelial cells remained intact. As we 
had detected in cells exposed to hypoxia and reoxygenarion, 
polymerization of actin in the activated Rac 1 overexpressing 
cells was also evident. We conclude from these studies that 
oxidants, by themselves, are unlikely to be capable of injuring 
endothelial cells to the point observed in AGA. 
As endothelial cells from the donors' vessels are directly 
exposed to circulating and infiltrating monocytes and other 
ceils from the host with cytolytic activity, we have investigat- 
ed the role of death receptor-activated pathways in apoptosis 
of endothelial cells. The perforine/granzyme diated killing 
does not seem to be playing a major role in vascular cell injury 
associated with AGA. In contrast, we and others have found 
that the Fas/Fas-ligand pathway of apoptosis might be high- 
ly relevant to AGA. 
Fas -med ia ted  apoptos i s  o f  endothe l ia l  c lls 
Fas is a receptor member of the TNF receptor family and is 
found in relatively high density on the surface of endothelial 
cells. Cross-linldng of Fas with Fas ligand results in the activa- 
tion of a death program in susceptible c lls. Although many cells 
express Fas, Fas ligand is usually expressed by cells with killing 
activity (cytolytic T cells, phagocytes, etc.). We have analyzed 
the response of human aortic endothelial cells exposure to Fas 
cross-linking, either using an antibody that cross-links Fas mol- 
ecules or using recombinant Fas ligand molecules caffolded 
themselves by a Fas ligand cross-linker. We have used endothe- 
lial cells originating from the aorta of either C57BL6 mice (B6), 
or mice with the same background (C57BL6) but carrying the 
lpr mutation, (Fas-/-) in ahomozygous fashion (B6-MLR). Fas 
cross-linldng, by itself, did not induce detectable increase in 
endothelial cell apoptosis, either in endothelial cells from B6 or 
MLR-B6 mice. Interestingly, Fas cross-linking was associated 
with overexpression f thc antiapoptotic protein Bcl-2. Such 
response was seen selectively in endothelial cells originating from 
Fas expressing B6 mice. There was no Bcl-2 response detected 
in the endothelial cells originating from B6-MLR mice, indicat- 
ing that the response required aFas receptor pathway. 
We postulated that Bcl-2 overexpression would tilt the bal- 
ance between proapoptotic and antiapoptotic proteins towards 
an antiapoptotic response and that by blocking this response we 
might be able to sensitize ndothelial cells to the proapoptotic 
affect of Fas cross-linking. We used either cycloheximide or 
actnomycin D to inhibit protein synthesis in endothelial cclls 
exposed to Fas cross-linking. In B6 endothelial cells treated 
with cyclohcximide or actinomycin D, we observed a marked 
increase in endothelial cell apoptosis exposed to Fas cross-link- 
ing. In contrast, there was no enhancement of apoptosis with 
endothelial cells from B6-MLR endothelial cells upon Fas 
cross-linking in the same conditions. We conclude that Fas- 
mediated apoptosis of cndothclial cells rcquires the alteration of 
thc normal endothelial cell response to Fas cross-linking, which 
involves Bcl-2 expression. Several mechanisms a sociated with 
AGA might bc responsible for sensitizing endothelial cells to 
Fas-mediated apoptosis. One of them might be the exposure of 
endothelial cells to high concentrations of immunosuppressive 
drugs. No matter what the cofactor might bc, Fas-mcdiated 
apoptosis eems to be an important aspect of endothelial nd 
other vascular cell injury in AGA. 
Acce lerated  graf t  ar ter iosc leros is  in  the  mouse  
t ransp lant  mode l  
We have investigated the role of Fas and Fas ligand interac- 
tion in the chronic rejection process in the mouse. We have 
found that the first detectable macroscopic lesion of the vessel 
wall develops within the splitting of the internal elastic lamina 
(IEL). As the internal aspect of the spliced IEL vanishes, the 
boundary between intima and media disappears, perhaps, as a 
result of production and/or activation of metalloproteinases, 
resulting in the invasion of the media by inflammatory cells, and 
in particular, monocytes. Apoptosis of smooth muscle cells 
becomes readily detectable and might represent a necessary 
injury leading to smooth muscle cell proliferation as a response 
to the injury to the tunica media. This model of mouse vascu- 
lopathy might provide us with great insights into the pathogen- 
esis of AGA in humans, and in particular, into the processes of 
endothelial cell and smooth muscle cell apoptosis n this patho- 
logic context. 
Pascal J. Goldschmidt, MD 
Ohio State University 
Columbus, Ohio 
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INFLAMMATORY AND IMMUNE MECHA- 
NISMS OF ANEURYSM FORMATION 
GENETIC DETERMINANTS IN THE 
PATHOGENESIS OF ANEURYSMS 
Features of autoimmunity are commonly present in patients 
with nonspecific abdominal aortic aneurysms (AAAs). Because 
susceptibility o another autoimmune disease of maturity, 
rheumatoid arthritis, is associated with specific MHC class II 
DR-B1 alleles, we have evaluated the hypothesis that the 
genetic basis for AAA development may also be DR-B 1 specif- 
ic. Our pilot study, based on 52 mixed North American hap- 
lotypes, suggests that 81% of patients have alleles with pheny- 
lalanine residues in the second hypervariable r gion at posi- 
tions 31 and 47 and that 35% have a double dose of the 
putative susceptibility alleles. 
Background 
The first report of familial clustering of AAA was by 
Clifton in 1977.1 In 1984 Tilson and Seashore reported fifty 
families with two or more affected first-order relatives, 2 and 
Norrygard et al.3 reported another large series of families. A 
recent study predicts that the disease is caused by an autoso- 
real dominant gene. 4
Features  o f  auto immtmi ty  in AAA disease 
Because of limitations on length of text and number of 
citations, the author will focus on findings from his own lab- 
oratory, acknowledging that several others, especially William 
Pearce at Northwestern University, have made important 
contributions. 
1. Description of Russell bodies and purification of 
immunoglobulin from AAA wall5 Although immuno- 
globulins (Igs) are detectable in the wall of atheroscle- 
rotic aortas, they are sixfold to eightfold more abundant, 
class by class, in extracts of AAA specimens. 6 
2. Quantitative description of the number and types of 
inflammatory cells present in AAA wall. Koch and 
coworkers 7 were the first to identify the fifll range of 
resident inflammatory cells immunohistochemically. 
They reported higher semiquantitative scores for CD- 
11c+ (macrophages) and CD-19+ (B-cells) in AAA 
versus occlusive disease controls. We have quantita- 
tively confirmed these findings in our laboratory by 
fluorescence-activated cell sorting (FACS). 8 
3. Identification of a prominent elastolytic activity of  
AAA wall as matrix metalloproteinases #9 (MMP-9), 
also known as type IV collagenase or gelatinase-B.9,1° 
MMPs are a family of enzymes, of which collagenase is 
a member, that are active against he major compo- 
nents of connective tissue (including collagen, clastin, 
fibronectin, laminin, and proteoglycans). MMPs are 
important mediators of tissue destruction i  most dis- 
cases of autoimmunity. Plasmin, a major activator of 
the MMPs, is also increased in AAA wall. n 
4. Identification of the cell of origin for MMP-9 as the 
macrophage, and assignment of the cells of origin for 
collagenase (MMP-1) as endothelial cells in the neo- 
vascularizing adventitia nd fibroblasts. 12Macrophages 
are prominent in the infiltrate, and among their 
numerous ecretory products are several MMPs. The 
inflammation and angiogenesis are reminiscent of 
rheumatoid pannus. 
5. Increased concentration of cytokines (IL-1 beta and 
TNF-alpha) in extracts of AAA wall33 We have isolat- 
ed leukocytes from AAA specimens by Ficol l /Paque 
separation, and we find that mononudear cells adhere 
to culture wells, remain viable for up to 2 weeks, and 
have histologic features typical of macrophages. We 
have called these c lls "AIM-cells" (for "AAA-infiltrat- 
ing monocyte/ macrophages"). We have found that 
IL-1B is initially produced by the cultured AIM cells, 
but as the cells become quiescent the level of consti- 
tutive secretion decreases. However, the cells can be 
stimulated to make IL-15 again by soluble factors 
extracted from AAA specimens) 4 
6. Patients with AAA have IgG (in both aortic wall and 
serum) that is immunoreactive with a fibrillar self-pro- 
tein in the aortic adventitia. We have recently found 
immtmohistochemically that the immunoreactive pro- 
tein is associated with collagen, not elastin. This find- 
ing was unexpected because most microfibrillar glyco- 
proteins distribute ubiquitously with elastin. 
7. Purification of an autoantigenic aortic protein in man. 
Our research group has recently reported the partial 
amino acid sequence of an aortic adventitial collagen- 
associated fibrillar protein, which appears to be one of 
the targets of an antoimmune response, is Our initial 
report suggested that the MW was approximately 80 
kDa, 16 but we have found that the 80 kDa form is 
dimeric. Thus we have named it aneurysm-associated 
antigenic protein-40 kDa (AAAP-40). It has similari- 
ties to microfibril-associated glycoprotein-36 kDa 
(MAGP-36), which was reported by Kobayashi et al)7 
to have a tissue distribution limited to the aorta in pig. 
If  AAAP-40 is the human homolog of MAGP-36, it 
would explain how an autoimmune reaction against 
this protein might have consequences more or less lim- 
ited to the aorta and its branches. The similarities of 
AAAP-40 and MAGP-36 to all three fibrinogen chains 
are significant, and the homology to fibrinogen-beta 
(FB) is particularly extensive. It is befieved that the fib- 
rinogen chains diverged from a single common ances- 
tor in the course of evolution. 18 Accordingly, AAAP-40 
and MAGP-36 have an ancient evolutionary history, 
going back before the divergence of the fibrinogens 
from their common ancestor, probably in inverte- 
brates39 AAAP-40 also has a 12 residue sequence that 
is identical to a sequence in vitronectin (VN). 
8. Cloning of eDNA for additional antigenic proteins in 
man, one of which we have found to be aorta-specific. 
An expression library was made from mRNA of 
human aneurysmal aortic adventitia nd screened with 
anti-VN and anti-FB antibodies. Two of the first five 
clones (#1 and #5) have novel features and strongly 
resemble ach other in domain structure. 2°Although 
both have some features that occur in the families of 
MAGPs and other matrix proteins (like collagen), 
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their most remarkable property is that each begins 
with a lengthy amino acid sequence (-100 residues) 
that is homologous to members of the Ig kappa fami- 
ly. The probability that the degree of similarity is a 
result of chance alone (as calculated by BlastP) is in 
the range of 1 x 10 -50. Antibody against Ig Kappa is 
strongly immunoreactive with the aortic adventitial 
fibril, whereas immunoreactivity of the antibody is less 
conspicuous in the matrix of ovary, prostate, cervix, 
liver, testis, breast, and sldn. 
9. Serum antibody titer against recombinant-clone 1 (r- 
CI-1), as measured by ELISA, may be a simple and 
dinically useful blood test for AAA susceptibility. R- 
CI-1 has been purified by elution from SDS/PAGE 
gel, and a checkerboard titration was performed to 
determine optimal concentrations of antigen and anti- 
body for ELISA. We have now studied 20 patients 
with AAAs and 10 control patients. Ninety percent of 
the patients (18 of 20) had a positive result, and none 
of the control subjects (0/10)  had a positive result. 
The differences in the means of the two groups was 
statistically significant (p = 0.0001). 21 
10. Molecular mimicry may explain interesting reports of 
associations of infectious agents with aneurysmal diseases 
in man (cytomegalovirus) and primates (herpes virus).22 
AAA is assoc ia ted  w i th  specif ic MHC class I I  
DR alleles 
Because AAAs are rare in African-Amcricans (pcrhaps 
because they require a double dose of the susceptibility gene 
to express the phenotype), we analyzed 10 DR-B1 haplotypcs 
from five patients of color. Only three alleles were observed: 
2, 12, and 13. This result had a probability of 3 x 10 .4 by 
chance alone. 
Inspection of the amino acid sequences reveals that these 
three alleles have phenylalanines (PHEs) at positions 31 and 
47 of the second hypervariable r gion. Reviewing the data on 
21 additional North American patients of mixed descent, 16 
(75%) had an allele with PHEs at positions 31 and 47, and 
five patients had a double dose of putative susceptibility alle- 
les. Thus 81% of a total of 26 patients fit the same pattern. 2a 
A former student has returned to Japan and studied 46 
native Japanese with AAAs and 50 control patients, matched 
approximately for age and sex. DR-15 (which is a subset of 
DR-2, also sharing PHEs at 31 and 47) has been found in 
59% of 46 AAAs compared with 28% of 50 control subjects (p 
< 0.005). 24 Thus in the much more homogeneous population 
of Japan, one of the same genotypes appears to be a suscepti- 
bility factor. 
M. David Tilson, MD 
St. Luke's Medical Center 
New York, N.Y. 
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ROLE OF INFLAMMATION IN THE 
FORMATION OF EXPERIMENTAL 
AORTIC  ANEURYSMS 
Aortic aneurysms exhibit inflammation and hypervascularity. 
In 1990, Samy Anidjar and coworkers (Circulation 1990; 
82:973-81) devised the elastase infusion model in rats. In 
this model, 15 to 30 units of pancreatic elastase is infused 
into the aorta of anesthetized rats. Using this method in our 
laboratory (J Vase Surg 1992;16:139-49) we found that after 
2 hours of treatment with elastase the vessels dilated 26%. 
This diameter emained constant hrough the second day. 
Then, between the second and third days, the vessels dilated 
to 4 mm, a 300% increase in dimensions, and over the next 
several days they increased up to 400% dilation. Histologic 
examination of the tissues demonstrated that immediately on 
per fusion with elastase the elastic lamellae were disrupted, 
and over the next several days the lamellae disappeared com- 
pletely. A few inflammatory cells were seen in the adventitla. 
But on the third day there were markedly increased numbers 
of inflammatory cells in the media, and these persisted for 
about 6 days. Somewhere between the sixth and twelfth days 
the inflammatory process regressed. Using immunohistolog- 
ic methods demonstrated that these inflammatory cells were 
mainly macrophages and T helper cells. Because 
macrophages were found with fractured elastic lamellae in 
these experiments, it seems likely that peptide fragments of 
elastin served to attract he maerophages. In other experi- 
ments infusion of thioglycollate plus plasmin were used as a 
nonspecific stimulant of the immune system. Unlike the 26% 
immediate dilatation after perfusion with elastase, perfusion 
with thioglycollate plus plasmin produced no immediate 
increase in diameter, nor was there the remarkable secondary 
dilatation observed after perfusion with elastase. Instead, 
there was a gradual and continual dilatation of the vessels. 
The arteries were 38% larger than in untreated control ani- 
mals after 1 day, 213% larger than in controls at 5 days, and 
288% larger than in controls on days 9 and 16. Histologic 
analysis demonstrated that there was little inflammation until 
the fifth day, at which time numerous inflammatory cells 
were found along with disrupted elastic lamellae. Immuno- 
histologic analysis demonstrated that the inflammatory cells 
were largely macrophages. These cells are known to secrete 
elastase, collagenase, and a variety of cytokines. This suggests 
that the T cells seen with elastase infusion may have been a 
response to the foreign protein comprising the elastase. 
Halpern and coworkers (J Vase Surg 1994;20:51-60) 
repeated this experiment and found that between days 3 and 
6 there were a variety of endogenous proteinases in the aortic 
tissues. Immunohistologic studies revealed proteinases with 
molecular weights between 50 and 90 kDa. Pancreatic elas- 
tase was not found demonstrating that the proteinases 
observed were not introduced by the infusate, but rather were 
endogenous enzymes released by inflammatory cells. ED-2 
positive cells were present. DC-4 positive cells were present 
on days 1 and 3. CD-8 and CD-5 positive cells were also pre- 
sent. Specimens staining positively for IgG and IgM also were 
increased on day 6. 
Newman and coworkers (Circulation 1994;90:II224-7) 
repeated the experiment to explore the source of matrix 
degrading proteinases. Dual labeling techniques demonstrat- 
ed that the inflammatory cells were macrophages and that 
MMP-9 was localized to these macrophages. Thus it appears 
that elastase caused tissue destruction and that this destruc- 
tion released polypeptides that served to attract he inflam- 
matory cells and thereby perpetuate the destructive process. 
To test this hypothesis further, we repeated the experi- 
ment using antiinflammatory agents (Ann NY Acad Sci 
1996;800:74-88). The animals were treated with 1 
mg/kg /day  methylprednisolone, or 5 mg/kg /day  cyclo- 
sporin, or saline solution injections as controls given daily 
beginning the day before surgery. All three groups of animals 
underwent perfusion of the aorta with elastase as described 
previously. Results showed that there were no statistical differ- 
ences between the groups before perfusion or 2 hours imme- 
diately after perfusion with elastase. Similarly, there was no sta- 
tistical difference 5 days after perfusion. However, at 9 days 
the diameter of the aorta in the control animals had increased 
to 4.52 mm, whereas the diameter of the methylprednisolone- 
treated animals was 3.02 mm and the diameter of the aorta of 
the cyclosporin-treated animals was 3.01 ram. Thus the two 
immtmosuppressed groups were statistically smaller than the 
saline solution-injected control groups. Histologic examina- 
tion disclosed a marked decrease in inflammatory cells in the 
methylprednisolone- and cyclosporin-treatment groups. These 
data demonstrate that the inflammatory cells play an active 
role in producing the secondary aneurysmal dilatation 
observed at 9 days for this was attenuated in animals that 
received immunosuppression. 
More specific experiments were performed by Ricci and 
coworkers (J Vase Surg 1996;23:301-7) using an anti-CD18 
monodonal antibody to inhibit lettkocyte CD18 adhesion mol- 
ecule. Some of the animals were treated with this agent. Others 
were treated with saline solution control injections. All animals 
underwent elastase infusion. The animals were reanesthetized 
on day I4. At that time, all of the animals had developed 
aneurysms that were significantly larger in the control group 
than in the animals that had received the antibody. Interestingly, 
histologic examination demonstrated that the neutrophil counts 
were not significantly different between the control and treat- 
ment groups. Thus, unlike the previously described work using 
methylprednisolone and cyclosporin, there was no reducfon in 
inflammatory ceils, but there was a reduction in inflammatory 
destruction of the connective tissues. 
Holmes and coworkers (J Surg Res 1996;63:305-9) used 
the elastase infusion experiments with indomethacin, an effec- 
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tive inhibitor of MMP expression by activated macrophages. 
This agent acts primarily through its effect on cellular 
cyclooxygenase synthase. All animals underwent elastase infu- 
sion. Six animals received saline solution as control subjects, 
and eight others received 4 mg/kg/day of indomethacin for 7 
days. Five out of the six saline solution-treated animals devel- 
oped aneurysms, whereas none of the eight indomethacin- 
treated animals did so. Substrate gel zymography demonstrat- 
ed that treatment with indomethacin decreased levels of 
MMP-9 as compared with saline solution control subjects. The 
effects on MMP-2 were inconclusive. These data demonstrate 
the inhibition of inflammation by indomethacin and suggest 
that clinical use of NSAIDs might provide a useful clinical 
treatment for small aneurysms in patients. 
Petrinek and coworkers (J Vasc Surg 1996;23:336-46) 
examined the role of doxycycline in inhibiting aneurysmal 
degeneration in the elastase perfusion rat model. Tetracycline 
antibiotics have been demonstrated to be inhibitors of metal- 
loproteinases acting by mechanisms that are separate from 
their antimicrobial ctivity. The ¢lastase infusion model was 
used in rats. After per fusion was completed, the animals were 
treated with subcutaneous injections of dox3,cycline or saline 
solution. The animals were reanesthetized, and the aorta was 
measured and excised after 0, 2, 7, or 14 days. Measurements 
demonstrated that at 7 and 14 days doxycycline prevented 
aneurysmal enlargement of the aorta. Histologic examination 
showed that both the control and treatment groups had large 
numbers of inflammatory cells; however, unlike the control 
group, which exhibited estruction of the elastic lamellae, 
doxycycline-treated animals possessed intact elastic lamellae. 
This is comparable with what was observed earlier with 
methylprednisolone and cyclosporin, with monoclonal anti- 
body and with indomethacin i  that the difference in dimen- 
sions between and control groups both occurred 7 days or 
longer after perfusion with ¢lastase. It is this time when the 
enlargement occurs due to the influx of inflammatory cells, 
chiefly macrophages. Because 92 kD and 72 kD gelatinases are 
elastolytic metalloproteinases produced uring the course of 
experimental aneurysms, the effect of doxycycline treatment 
on the level of these enzymes in the wall also was examined. 
On day 7, 92 kD gelatinase was markedly reduced as com- 
pared with the saline solution-treated lastase-infusion control 
animals. Thus as seen in the preceding experiments, treatment 
with MMP-inhibiting doxTcycline inhibited the development 
of aneurysms in the elastas¢ per fusion model and appeared to 
block the expression of MMP by inflammatory cells. 
The precise stimulus for the influx of inflammatory cells is 
not known. Nackman and coworkers (Surgery 1997;122:39- 
44) examined adventitial ngiogenesis, a related phenomenon. 
In this experiment, he investigators perfused one of several 
substances: (1) 2 ml of pancreatic elastase as described in the 
previous experiments; (2) 2 ml of normal saline solution; or 
(3) a repeating hexapeptide, val/gly/val/ala/pro/gly. This 
hexapeptide is a breakdown product ofelastin. Seven days after 
perfusion the animals were killed, and the aortas were excised. 
Histologic examination demonstrated a 100-fold increased 
number of vessels per high-powered field in the aortas per- 
fused with elastase or with the hexapeptide. In addition, the 
hexapeptide perfused animals had a 26% increase in diameter, 
not quite sufficient to achieve statistical significance, and cer- 
tainly not of aneurysmal proportions. This may have been 
achieved if the investigators had waited longer than 7 days. 
However, this study demonstrated that infusion of this elastin 
degradation product produced a histologic feature seen in 
experimental nd human aneurysmal disease. This shows that 
the hexapeptide breakdown product may act as a stimulus elic- 
iting the hypervascularity and possibly the inflammatory 
response seen in aneurysms. 
Philip B. Dobrin, MD, PhD 
VA Medical Center 
Salt Lake City, Utah 
CHRONIC INFLAMMATION, MATRIX METALLO- 
PROTEINASES, AND MEDIAL SMOOTH MUSCLE 
CELL APOPTOSIS: INTERRELATED FACTORS IN 
THE PROGRESSION OF ABDOMINAL AORTIC 
ANEURYSMS 
Abdominal aortic aneurysms (AAAs) represent a chronic 
inflammatory disease of the aortic wall associated with local- 
ized connective tissue d terioration. Elastin and collagen are 
normally responsible for the tensile strength, resilience, and 
structural integrit 3, of the vessel wall; consequently, ancurys- 
real dilatation and rupture are a result of mechanical failure of 
these fibrillar extracellular matrix proteins. It is now clear that 
several distinct but interrelated processes contribute to the 
changes observed in human AAA tissues, including chronic 
inflammation, elevated production of matrix metallopro- 
teinases (MMPs), and depletion of medial smooth muscle 
cells (SMCs).I, 2 
Chron ic  in f lammat ion  
Mononuclear phagocytes and T-lymphocytes are prevalent 
withhl established AAA tissues. In contrast to occlusive athero- 
sclerosis, the distribution of inflammatory cells in AAA occurs 
in a rransmural fashion with dense localized infiltrates often 
centered within the elastic media. Because the density of 
inflammatory cells appears tocorrelate with the extent of medi- 
al degeneration, this proccss is thought o be closely related to 
the connective tissue destruction responsible for aneurysmai 
dilatation and rupture. 
Although the initial events responsible for recruiting inflam- 
matory cells into the aortic media are unhlown, they may be 
signaled by hemodynamic stress on medial SMCs, ischemia 
within the infrarenal aortic media, autoimmune proccsses tar- 
geting elastic fiber components, or an extension of intimal ath- 
eroselerosis. Once established, a number of chemotactic pep- 
tides produced in AAA tissue might serve to amplify thc 
mononuclear inflammatory rcsponse. These include the 
chemoldnes, monocyte chemoatrractant protein-1 and inter~ 
leuldn-8, and biologically active products released uring matrix 
destruction, such as elasthl degradation peptides and fragments 
of laminin. Other peptides produced within the aneurysm wall, 
such as granulocyte/monocyte-colony stimulating factor (GM- 
CSF), may promote monocyte diffkrentiation tomatrix-degrad- 
ing phenotypes. GM-CSF may be particularly important in this 
regard, both because it is markedly elevated in AAA tissues and 
because it is known to induce macrophage expression of hmnan 
macrophage metalloelastase (MMP-12) in vitro. 
Mononudear phagocytes are believed to play an impor- 
tant role in AAA primarily through their elaboration of 
matrix-degrading proteinases, a The tissue environment of 
AAA includes inflammatory cytokines capable of stimulating 
macrophage MMP expression, such as tumor necrosis factor- 
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(TNF-~) and interleukin-1]3 (IL-l[5). Direct cell-to-cell 
interactions may be another mechanism for amplifying local 
macrophage MMP production. Activated T-lymphocytes 
bearing cell surface CD40 ligand, for example, may interact 
with mononuclear phagocytes that express CD40. This inter- 
action is known to dramatically enhance macrophagc produc- 
tion of MMPs, including MMP-9, in vitro. 
Vigorous medial neovascularization accompanies the 
inflammatory esponse in AAAs. 4 Because capillary endothe- 
lial cells must degrade elastin-rich matrices during this 
process, the metalloenzymes they produce likely contribute o 
clastin degradation. The microvascular channels associated 
with neovascularization may also provide an essential route 
for mononuclear cell infiltration and transmigration into the 
elastic media. This view is supported by the observation that 
inflammatory cells are typically found in dense perivascular 
cuffs in aneurysm tissues. 
Given the importance of chronic inflammation i  AAAs, 
antiinflammatory d ugs have been proposed as one strategy by 
which to suppress aneurysnaal degeneration in vivo. Dobrin 
and colleagues have shown that both glucocorticoids and 
cyclosporin-A suppress thedevelopment of elastase-induced 
AAA in the rat, and Ricci et al. have demonstrated similar 
effects with leukocyte-depicting (anti-CD18) monoclonal 
antibodies. Using the same rodent model, Holmes et al. s have 
demonstrated inhibition of AAAs with indomethacin, a on- 
steroidal antiinflammatory agent. These studies indicate th  
indomethacin acts through pharmacologic blockade of PGE 2 
synthesis to suppress macrophagc expression of MMPs and 
thereby limit elastin degradation, s 
MMPs 
MMPs represent a family of structurally-related n utral 
proteinases with the capacity to degrade a wide spectrum of 
matrix proteins. 6 Four members of the MMP family exhibit 
elastolytic activity in vitro: MMP-2, MMP-7, MMP-9, and 
MMP-12. Previous studies have shown that MMP-2 is 
expressed in normal aorta, occlusive atherosderosis, and AAA 
tissues as a constitutive product of fibroblasts, vascular SMCs, 
microvascular endothelium, ononuclear phagocytes, and T- 
lymphocytes.3, 6 MMP-9 is not generally produced in normal 
aorta, but it is found in atherosclerotic plaques, where it may
contribute to plaque instability and rupture. MMP-9 is also 
more uniquely elevated in human and experimental ortic 
aneurysm tissues than MMP-2, at both protein and mRNA lev- 
els, where it is produced predominantly by aneurysm-infiltrat- 
ing macrophages.3, 6 
Recent data indicate that MMP-12, another elastolytic 
MMP, may play an even more important role in human 
aneurysms than either MMP-2 or MMP-9. 7 Thus MMP-12 is 
overexpressed in AAAs compared with normal aorta and ath- 
erosclerotic tissues, and by immunohistochemical an ysis the 
22-kD active enzyme is localized to elasfin fber fragments 
throughout the degenerative media. The unique association 
of MMP-12 with its pathologically relevant substrate repre- 
sents the strongest evidence to date that MMPs participate in 
aortic elastin degradation i  human AAAs, and it implicates a 
singular ole for MMP-12 in this process. Consistent with 
these findings, MMP-12 binds to insoluble lastin with a
higher affinity than any other elastase present in human AAA 
tissues. 
The expression of MMPs in AAAs exhibits ubstantial 
regional heterogeneity. For example, MMP-12 is readily 
localized to a subset ofmacrophages in areas of active elastin 
degradation, but is not found in areas of intense inflamma- 
tion where MMP-9 predominates. Examination of aortic 
specimens from the proximal transition zone of AAA, a site 
where aneurysm disease might be observed in its earliest 
stages, also reveals large amounts of MMP-12 associated with 
elastic fibers, whereas MMP-9 is absent. The local regulato- 
ry factors underlying these heterogeneous patterns remain to 
be elucidated, but they may include differential concentra- 
tions of cytoldncs and other mediators, or specific cell-to-cell 
interactions. 
In addition to factors that influence cellular production of 
MMPs and their secretion as proenzymes, this family of 
enzymes is regulated at several different levels by ocal factors 
in the pericellular environment. 6 For example, the activation of 
proMMPs may require additional proteinases that have been 
identified in AAAs, such as plasmin, uroldnase-type plasmino- 
ten activator, r stromclysin (MMP-3). A second mechanism 
of proMMP activation may reside in their association with 
membrane-type MMPs (MT-MMPs) on cell surfaces. MT- 
MMP-1 on fibroblasts thereby binds and activates proMMP-2 
and it serves to protect the enzyme from naturally occurring 
inhibitors, such as tissue inhibitors of metalloproteinases 
(TIMPs). This process may explain how cell-associated MMPs 
might still be responsible for matrix degradation despite the 
elevated tissue concentrations of TIMPs present in human 
AAAs.3, 6 
The importance of MMPs in aneurysmal degeneration 
suggests that they may serve as a target for rational pharma- 
cologic intervention. This was first demonstrated in the elas- 
tase-induccd rat model using doxycycline, a tetracycline 
antibiotic with potent MMP-inhibiting activity, s The use of 
doxycydinc in these experiments prevented aortic elastin 
degradation without diminishing the inflammatory response, 
and it effectively prevented the development of aneurysmal 
dilatation, s Further studies have demonstrated quivalent 
effects using chemically modified tetracyciines devoid of 
antibiotic activity. 9 To elucidate whether one of the elastolyt- 
ic MMPs is necessary or sufficient for aneurysmal degenera- 
tion, current s udies are directed toward the use of MMP- 
selective inhibitors with the elastaseqnduced ro ent model 
and the use of a similar model in genetically-engineered mice 
deficient in specific MMPs. 
Media l  SMC apoptosis  
Aortic elastin is produced by vascular SMCs early in 
development, and SMCs are normally the dominant ceils of 
the elastic media. SMCs are therefore functionally capable and 
ideally positioned to mediate connective tissue repair within 
the aneurysm wall. Although fibroproliferative repair m ght 
help to stabilize the aortic wall during aneurysm develop- 
mcnt, recent studies demonstrate hat established AAAs are 
characterized by a pronounced depletion of medial SMCs. 1° 
The depletion of medial SMCs in human AAAs appears to be 
caused in part by a process of apoptosis, as illustrated by ultra- 
structural changes, in sire localization of fragmented DNA, 
and SMC accumulation f p53 and p21 proteins. 10 Although 
SMC apoptosis is also prevalent within atherosclerotic plaques 
and experinaental neointimal lesions, the distribution ofapop- 
totic cells throughout the elastic media is much broader in 
AAAs. The factors that initiate SMC apoptosis n AAAs are 
unresolved, but like SMC apoptosis n vitro they likely involve 
signaling molecules uch as nitric oxide, TNF-ct, IL-1]], and 
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interferon-gamma, which are all prevalent in AAA tissue. 
Alternatively, SMC apoptosis may also be mediated by cellu- 
lar immune responses through the Fas/Fas ligand system. 
Thus SMCs that express Fas may be susceptible to either Fas 
ligand on T-lymphocytes or soluble Fas ligand released into 
the local environment by the action of metalloproteinases. 
Summary  
Descriptive studies on end-stage human aneurysm tissues 
have documented pathologic relationships in this disease 
between chronic inflammation, MMP activities, and medial 
SMC apoptosis. Ascertaining the temporal sequence of events 
that underlies progressive aneurysmal degeneration has proven 
to be more difficult. Thus one of the important goals for the 
near future will be to understand how the critical cellular and 
molecular changes in tissue composition correspond with pro- 
gressive aneurysm expansion. New experimental pproaches 
will be needed to help resolve some of these questions, partic- 
ularly those that use representative models of AAAs in rodents 
and transgenic mice. Additional challenges that will face inves- 
tigators in this field will include identification of common fac- 
tors that underlie these various processes, determining how 
they affect the dynamics of aneurysm growth and rupture in 
vivo, and translation of this knowledge into novel forms of ther- 
apy for clinical application. 
Rober~ W. Thompson, MD 
Washington University School of Medicine 
St. Louis, Mo. 
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MMP-2 REGULAT ION BY MACROPHAGE-  
LYMPHOCYTE INTERACTIONS 
The problem 
Although some degree of atherosclerosis is present in the 
distal aorta of most adults, severe cases result in one of two dis- 
tinct but equally devastating dinical problems. In atheroscle- 
rotic occlusive disease (AOD), atherosclerotic plaque progres- 
sively narrows the lumen, which may lead to thrombosis and 
lower extremity gangrene. This blockage is the typical clinical 
pattern of atherosclerosis of the coronary arteries, which 
results in myocardial infarction. In abdominal aortic 
aneurysms (AAAs), the aorta dilates beyond twice its normal 
diameter through a complicated remodeling processes that 
culminates in rupture and exsanguination. The anatomic 
dichotomy between AAAs and AOD suggests ftmdamental dif- 
ferences in matrix metabolism. 
Inflammation 
It is well known that inflammatory cells are capable of 
elaborating proteolytic enzymes and cytokines that modulate 
the expression of matrix proteins and protcolytic enzymes by 
mesenchymal cells) Inflammation is a prominent feature of 
aortas that are affected with either occlusive or aneurysmal 
disease. The locations of the inflammatory cells in AAAs and 
AOD are similar (intima/plaque and adventitia), as are the 
cell types (macrophage and lymphocyte). The inflammation 
in AAAs and AOD differ in that B cells are seen more com- 
monly in AAAs. 2 Adventitial inflammation, a feature observed 
only with advanced atherosclerosis,  always seen in AAAs. 
The entity called "inflammatory aneurysm" appears to repre- 
sent the extreme on a continuum of the periadventitial 
inflammation found in all AAAs. 
That this inflammation may have a causal role in AAAs has 
been suggested by two experimental aneurysm models. 
Aneurysms can be created reliably in the rabbit carotid artery 
and aorta by applying calcium chloride to the adventitia. This 
produces atransmural chemical injury that isassociated with the 
same type of periadventitial lymphocyfic infiltrate that is found 
in human AAAs. Aneurysm formation ccm'red only after the 
inflammatory response was present. Anidjar ct al. have shown 
that elastase infusion under superphysiologic pressures produces 
aneurysms in the rat aorta. The dilation corresponds temporal- 
ly, not with the early clastin degradation, but with the enming 
inflammatory esponse and the expression of both matrix metal- 
ioproteinase (MMP)-9 and MMP-2. Furthermore, blocking 
either the inflammatory esponse or the MMP activity prevents 
aneurysm formation, s These observations support he hypothe- 
sis that the inflammatory cells and subsequent expression of the 
MMPs have a causal role in aneurysm formation. 
Proteolysis 
The MMPs are a family of zinc endopeptidases that func- 
tion in the turnover and remodeling of the extracellular 
matrix. Several MMPs have been identified in AAA tissue, 
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including MMP-1, MMP-2, MMP-3, and MMP-9. 
Thompson et al.4 assayed media conditioned for 72 hours by 
aortic tissue explants. AAA explants produced more MMP-9 
than normal or AOD-conditioned media. Vine and Powell 
found no increase in gelatinase activity in AAAs compared 
with AOD using a radiolabeled gelatin substrate. By zymog- 
raphy, the majority of this gelatinase activity localized to a 
broad band around 92 kDa. The studies of Vine and Powell 
and Thompson et al. are especially noteworthy for their 
including a relatively large AOD group. Studies of tissue 
mRNA by McMillan et al. 7 found no differences in MMP-9 
mRNA between AAA and AOD. 
MMP-2 may have greater potential to regulate matrix 
than other proteinases for several reasons. In addition to its 
ability to degrade clastin, it also has been shown to be capa- 
ble of degrading intact fibrillar collagen. Moreover, its prima- 
ry source is thc same mesenchymal cells (smooth muscle ceils 
and fibroblasts) that produce elastin and collagen. Although 
MMP-2 expression by certain cell lines is not responsive to 
stimuli known to upregulate other MMPs, recent work sug- 
gests that it is regulated in neoplastic cells and stromal cells of 
the uterus. There is evidence that it is also regulated in the 
aorta, because MMP-2 levels are consistently increased in the 
diseased aorta (AAA and AOD) as compared with normal 
aorta. Freestone t al.5 reported increased MMP-2 in small 
aneurysms compared with AOD and McMillan et al.7 found 
increased MMP-2 mRNA in AAAs compared with AOD. 
More recently, immunohistochemical analysis by Knox et al.6 
suggested that MMP-2 expression may be increased in 
AAAs. 6 Taken together, there is accumulating evidence of an 
important role for MMP-2 in AAAs. 7 
Previous work cited above suggested a role for MMPs in 
AAAs and suggests hat both elastolytic and collagenolytic a tiv- 
ity are required. 8 We used RT-PCR to screen an RNA library 
derived from normal (n = 6), AOD (n = 6), and AAA (n = 6) 
infrarenal ortic tissue. We initially assessed expression of MMP- 
1 (interstitial collagenase), MMP-2 (72 kDa gelatinase), MMP- 
3 (stromelysin), and MMP-9 (92 kDa gelatinase). After repeat- 
ed analysis, only MMP-2 appeared to be expressed at consis- 
tently higher levels in AAA than in AOD. We further 
investigated the protein levels of MMP-2 and MMP-9 using 
zymography. This was initially done in the salt-soluble MMP 
extracted from the tissue. We fomad no differences in MMP-2 or 
MMP-9 levels between the AAA mad AOD groups. Using two 
additional solvents, DMSO and urea, we were able to investigate 
MMP/matrix binding associated with the flbronectin domain 
(disrupted with DMSO) and covalent tissue binding (disrupted 
with urea). The high yield of additional MMP removed with 
these solvents demonstrated that there is significant MMP bind- 
ing in the aorta. When salt-soluble and matrix-bound MMP 
were taken together, analysis uggests more MMP-2 in AAA 
than in AOD, corroborating the mRNA data. 9 This work was 
done through our collaboration with Dr. Hidea!d Nagase at the 
University of Kansas. In addition, we found increased matrix 
binding and an increased proportion of active (62 kDa) MMP- 
2 bound to matrix in AAA compared with AOD. 
Ce l lu la r  source  and  locat ion  o f  MMP-2  
expression 
We went back to tissue to determine the cellular source 
and location of the increased MMP-2 expression found in 
AAAs. Using immunohistochemical analysis of adjacent sec- 
tions, we identified macrophages as the source of MMP-9. 
MMP-2 did not colocalize with macrophages or T-lympho- 
cytes but was expressed by spindle-shaped ceils in the outer 
media and adventitia, which appeared to be SMCs and fibrob- 
lasts on hematoxylin and eosin-stained sections. MMP-2 
expression was greatest in these mesenchymal cells when they 
were surrounded by inflammatory cells. 
SMC regulation of  MMP-2 in vitro 
The increase in MMP-2 expression noted in AAAs corre- 
lated with inflammatory infiltrates consisting of macrophages 
and lymphocytes. Although MMP-2 was generally thought o 
be constitutively expressed, our immunohistochemical analy- 
sis suggested that macrophages and lymphocytes can regulate 
MMPs through specific interactions. The next experiments 
were designcd to examine this interaction and its role in 
MMP-2 regulation i  vitro. Early passage (P-4) human aortic 
SMC (actin-positive) lines derived from normal aorta were 
grown to confluence prior t  exposure to conditioned media 
from human inflammatory cells obtained by elutriation of 
peripheral blood. Monocytes were allowed to differentiate 
into macrophages by culturing them for 7 days in MCSF. 
Lymphocytes and macrophages were stimulated with PHA (1 
gg/ml) and LPS (5 gg/ml), respectively, for 24 hours. After 
washing cells to remove the activator, media was conditioned 
for an additional 24 hours and collected and frozen. Because 
interactions between lymphocyte membrane receptors and 
macrophages have been shown to be important, macrophages 
were also exposed to activated and inactivated lymphocytes. 1° 
After reaclfing confluence, SMCs were exposed to media con- 
ditioned by activated and inactivated macrophages and 
rnacrophages stimulated irectly by inactivated or activated 
lymphocytes. Whereas media from LPS-stimulated 
macrophages did not change SMC MMP-2 expression, media 
from macrophages xposed to activated human lymphocytes 
resulted in MMP-2 upregulation. 
Conclusion 
RNA and protein analysis uggests an increasc in MMP-2 
expression and activation in AAA tissue extracts. Immuno- 
histochemical studies identify the medial SMCs and adventitial 
fibroblasts as the source of MMP-2 and suggest upregulation 
in areas of inflammatory infiltrates. Finally, SMC MMP-2 pro- 
duction appears to be regulated by macrophage-lymphocyte 
interactions. 
B. Timothy Baxter, MD 
University of Nebraska Medical Center 
Omaha, Neb. 
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INFLAMMATORY AND IMMUNE REAC-  
T IONS TO VASCULAR IMPLANTS 
INFLAMMATORY CELLS AND HEALING 
OF VASCULAR BIOMATERIALS 
The inflammatory and healing responses to vascular biomate- 
rials are characterized by the development of a foreign body 
reaction consisting of macrophages and foreign body giant 
cells (FBGCs) at the tissue/biomaterial interface. To better 
understand the mechanism of formation of the foreign body 
reaction and its potential role in the success or failure of vas- 
cular biomaterials, we have carried out studies on lymphokine- 
induced FBGC formation on biomaterials. These studies 
address the hypothesis that the monocyte/macrophage is the 
major cellular component that controls the tissue/material 
inflammatory and healing responses and that biomedical poly- 
mers can selectively affect the activation, function, and 
cytokine production of tissue macrophages. 
We have recently demonstrated that differential lym- 
pho!dne regulation of macrophage fusion leads to morpholog- 
ic variants of multinncleated giant cells. Interleukin (IL)-4 and 
IL-13 have been shown to independently promote mono- 
cyte/macrophage fusion to form FBGCs, whereas interferon- 7 
has been demonstrated to form Langhans-type giant cells.l, 2 
IL-4 and IL-13 are secreted predominantly b Th2 lympho- 
cytes and suggest a role for lymphocytes, present during the 
transient chronic inflammatory response, in the development of 
FBGCs. In vivo studies using the rat cage implant system and a 
polyurethane together with IL-4-nentralizing antibodies and 
recombinant mnrine IL-4 demonstrated a role for IL-4 in 
FBGC formation. 3 Confocal immunofluorescent studies 
demonstrated the npregulation of the macrophage mannose 
receptor (MMR) activity by IL4 or IL-13. 4 IL-4-induced 
macrophage fusion and giant cell formation was prevented by 
competitive inhibitors of MMR activity, that is, cz-mannan, or
inhibitors of glycoprotein processing thatrestrict MMR surface 
expression. 
Confoeal microscopy studies were undertaken to charac- 
terize the dynamic temporal organization of the monocyte 
cytoskeleton and adhesive structures during macrophage 
development and FBGC formation in the in vitro culture sys- 
tem5 Punctate filamentous F-actin structures appeared along 
the ventral cell membrane ofadhcrent macrophagcs and were 
identified as the core ofpodosomc adhesive structures by the 
distinctive ring staining ofvinculin, talin, and paxillin around 
the F-actin. Cytokinc-induced FBGCs were charactcrizcd by 
a restriction of podosomes to thc extreme periphcry of the 
ventral cell surface. In the FBGCs, significantly morc F-actin 
was located within i btm of the ventral plasma membrane 
when compared with F-actin i  macrophages. 
Silane-modified glass surfaccs were used in the IL- 
4-induced FBGC culture system to examine the effect of bio- 
material surface chemistry on the adhesion, motility, and 
fusion of human monocytes and macrophages. 6 The adhesion 
of monocytes and macrophages was surface independent, 
whereas the IL-4-induced FBGC density was strongly influ- 
enced by the surface carbon and silicone content. In contrast, 
contact angle and surface nergy displayed no correlation with 
FBGC formation. Studies using glass surfaces modified with 
alkyl chains or PEO oligomcrs have demonstrated a chain 
length or molecular weight dependence on FBGC formation. 
These and other molecular engineercd surfaces are b ing used 
as probes or models to determine the relationships between 
lympholdnc-mediated signal transduction, macrophagc 
cytoskeletal and adhesion structural organization, and 
macrophagc membrane receptor/material su f ce interactions 
in the foreign body reaction. It is anticipated that results from 
these studies will provide newdesign criteria for biomaterials 
that can modulate the foreign body reaction. This work was 
supported under NIH Grants HL-33849 and HL-55714. 
James M. Anderson, MD, PhD 
Case Western Reserve University School of Medicine 
Cleveland, Ohio 
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MOLECULAR DETERMINANTS OF ACUTE 
INFLAMMATORY RESPONSES 
TO BIOMATERIALS 
Although biomaterials commonly used for implantation are 
generally nontoxic, relatively inert, and nonimmunogenic, 
implants often trigger acute and chronic inflammatory reactions. 
These inflammatory responses, reflected by the accumulation of 
JOURNAL OF VASCULAR SURGERY 
1184 Special Communication June 1998 
implant-adherent macrophages and neutrophils, may be associ- 
ated with subsequent fibrotic reactions around the implant and 
with implant degradation and failure. We have been investigat- 
ing the basic question of why such inert and nontoxic materials 
should trigger inflammatory esponses. The following repre- 
sents a short summation of our present understanding of this 
phenomenon. 
On contact with the proteinaceous fluids of the body, bio- 
materials rapidly acquire a layer of host protein. The adsorbed 
proteins ubsequently undergo a process of "denaturation," 
probably involving progressive dehydration of the proteins on 
the usually very hydrophobic surface of the biomaterial. This 
denaturation is reflected in the fact that after a few hours, a 
majority of the adsorbed protein cannot be removed by deter- 
gents such as sodium dodecylsulphate. 
It has been our working assumption that this layer of 
adsorbed and partially denatured protein powerfully influ- 
ences or even dictates ensuing host responses. This is partly 
because the appearance of cells (such as phagocytes and 
fibroblast-like cells) on implant surfaces occurs much later 
than does the almost immediate adsorption of host protein. 1 
However, before some of the work reviewed below, no link 
had been established between types of adsorbed protein and 
conformational changes thereof with acute inflammatory 
responses to biomaterial implants. 
Experimental approach 
To investigate the mechanisms of biomaterial-mediated 
inflammatory responses, we developed a simple animal impl - 
tation model. Biomaterial films (usually of polyester terephtha- 
late, which in woven form is called Dacron) are cut into 1.2 cm 
diameter disks. After repetitive washes ith ethanol, the disks 
are precoated with various types ofproteins and then implant- 
ed in the mouse peritoneal cavity for 16 to 18 hours (in this 
model, the time of maximal phagocyte accumulation2). The 
surface-associated activities ofmyeloperoxidase and nonspecific 
esterase are measured to estimate the numbers of adherent eu- 
trophils and macrophages/monocytes, respectively2, 3 
Effects of adsorbed protein type 
Taking advantage of the fact that surface-adsorbed proteins 
tend to become "irreversibly" ound, we experimentally deter- 
mined the possible role of various plasma proteins--precoated 
on implant surfaces--in itiating biomaterial-mediated inflam- 
matory responses. In agreement with many previous reports, 
we found that albumin will "passivate" biomaterials, greatly 
diminishing inflammatory (and thrombogenic) responses) We 
subsequently found that adsorbed immunoglobulins al o are 
not essential to acute inflammatory esponses to implants. 
Experimental implants i  mice with severe combined immun- 
odeficiency that have extremely low plasma immunoglobulin G 
levels (<1 btg/ml vs 4 mg/ml in normal, otherwise syngeneic, 
animals) show a "normal" inflammatory response to uncoated 
PET disks, as evidenced bythe recruitment ofboth neutrophils 
and macrophages. 2 Furthermore, it would appear that the 
acute inflammatory esponse is independent of complement/ 
complement activation. Complement-depleted mice (pretreat- 
ed with cobra venom factor) exhibit normal recruitment of
inflammatory cells to implant surfaces. 2 
Importance of adsorbed fibrinogen 
By elimination, the preceding results raised the possibili- 
ty that fibrinogen, also present in large amounts on implant 
surfaces, 4 might be the host protein most important in trig- 
gering inflammatory eactions. This was supported by a sur- 
prising observation: serum-coated surfaces, like albumin- 
coated surfaces, fail to prompt inflammatory esponses, a The 
major difference between plasma and serum is that plasma, 
but not serum, contains flbtinogen. Indeed, serum that con- 
tains added fibrinogen (in physiologic oncentration), when 
used to coat experimental implants, caused the recruitment of 
as many phagocytes as did disks coated with fresh, minimally 
heparinized plasma. In fact, we observed that fibrinogen 
alone was sufficient o trigger inflammatory esponses; PET 
disks preincubated with purified human (or murine) fibrino- 
gen also attracted large numbers of both neutrophils and 
macrophages. 3 
The requirement for fibrinogen adsorption to the surface 
of PET implants would appear to hold in vivo as well. Mice 
having undetectable plasma fibrinogen were produced by 
repetitive injections of ancrod. Ancrod-treated mice (having 
undetectable fibrinogen at the time of implantation) show 
almost no phagocyte accumulation untreated disks, but do 
so if the disks are precoated with purified murine fibrinogen. 3 
Proinflammatory epitopes exposed by adsorbed 
fibrinogen 
In view of the foregoing, we reasoned that the adsorbed 
fibtinogen probably displayed one or more epitopes normally 
occult in the soluble protein but exposed by surface-mediat- 
ed "denaturation" of the protein. Using purified plasmin- 
generated fragments of fibrinogen, we localized the proin- 
flammatory activity to the 'D' fragment. Altieri and col- 
leagues ~ had earlier found that a small peptide in the 'D' 
domain, g190-202 (P1), is critically important in mediating 
phagocyte-fibrinogen interactions. We therefore synthesized 
P1 and a Pl-based scrambled peptide and covalently linked 
these to human albumin (which has been used widely as a car- 
rier to enhance cellular responses to peptides). Implant sur- 
faces precoated with P1 peptide but not with the scrambled 
peptide induced substantial phagocyte accumulation, roughly 
equivalent to that caused by fibrinogen-coated surfaces. 
Because the PI cpitope is within the D domain, which is very 
susceptible to conformational changes, we now believe that 
the interaction between fibrinogen and surfaces mediates th  
conformational changes of the D fragment causing exposure 
of P 1. As a result, otherwise inert and unreacrive surfaces that 
display this epitope are recognized by phagocytes. 
Phagocyte CD11b/CD18 (Mac- l )  interacts 
with adsorbed fibrinogen 
Earlier investigators had shown that the critical 
fibrin(ogen) epitope, P1, is recognized by Mac-1. s As a par- 
tial test of this hypothesis, we used recombinant eutrophil 
inhibitory factor (NIF), which blocks CDllb-dependent 
binding of Mac-1 to fibtinogen (which presumably occurs 
through the P1 epitope) without affecting other Mac-1 inte- 
grin functions uch as binding to coagulation factor X. 6 
Indeed, when mice were given repetitive injections of NIF 
before and during implantation, phagocytes failed to accumu- 
late on fibrinogcn-coated surfaces. Further support for the 
importance of Mac-1 in these phagocyte-implant interactions 
derives from recent experiments inanimals that lack this inte- 
grin. In CD11b knockout (KO) and CD18 KO mice, the 
"normal" accumulation of phagocytes on implant surfaces 
fails to occur.; Interestingly, this impairment of phagocyte 
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accumulation is not caused by decreased phagocyte recruit- 
ment: the numbers of macrophages and neutrophils in peri- 
toneal avage fluids after implantation i both types of KO 
animals are roughly equivalent to those in wild type controls .7 
Thus the Mac-1 integrin appears to be crucial in the 
adhesion of inflammatory cells to implant surfaces. However, 
unstimulated phagocytes normally express only low levels of 
surface Mac-l, and most of this is in the "low-affinity" state. 
This raises the question of what factors might prompt the 
apparent upregulation ofthis phagocyte integrin. Earlier stud- 
ies indicated that TNF-~ is a potent stimulator of the expres- 
sion of Mac-1 on cell surfaces. Furthermore, TNF-a is pre- 
sent in peritoneal lavage fluids from implant-bearing mice 
within 4 hours after implantation. This suggests that TNF-c~ 
might be critical in upregulating Mac-1 integrin expression 
on incoming phagocytes. In at least partial support, adminis- 
tration of neutralizing anti-TNF-ix antibodies to implant 
bearing mice blocks phagocyte accumulation on implant sur- 
faces. Furthermore, as was the case with the Mac-1 KO mice 
described above, we find that neutralizing antibodies against 
TNF-c~ do not affect the extent of phagocyte recruitment to
the site of the implant because the numbers of recruited cells 
are roughly equivalent in treated and control animals. 8 
Chemokines  and phagocyte recruitment 
to imp lants  
In the peritoneum of an animal implanted approximately 
16 hours previously, about 20% of total neutrophils and about 
50% of total macrophages are found on the implant surface (as 
opposed to being recovered in peritoneal lavage). Inasmuch as 
the implant may represent only about 2% of the total intraperi- 
toneal surface, phagocytic ells are obviously preferentially 
accumulated on the implant. We have assumed that certain 
chemokines might participate in attracting incoming phago- 
cytic cells toward implant surfaces. Using reverse transcript 
polymerase chain reaction to estimate levels of chemoldne 
mRNA produced by implant-adherent cells, we have observed 
high levels of mRNA production for two particular 
chemokines: macrophage inflammatory protein-la (MIP-la) 
and monocyte chemoattractant protein-1 (MCP-1), both of 
which appear to be involved in phagocyte-implant interactions. 
Neutralizing antibodies to both MIP-la and MCP-1, but 
not to MIP- lb or MIP-2, block 70% to 90% of the accumu- 
lation of both macrophages and neutrophils on implant sur- 
faces. However, the numbers of recruited phagocytes do not 
differ amongst control and treated groups. 8 Therefore, it is 
likely that the reduction in numbers of adherent phagocytes i  
caused by impairment of directed phagocyte migration 
(although other interpretations are possible at the moment). 
Invo lvement  o f  mast cells and histamine in 
phagocyte  recruitment 
We and others have observed that the tissue surrounding 
biomaterial implants is often hyperemic and edematous, fea- 
tures of a classical histanainic response. To test the possible 
involvement of histamine, we administered the histamine 
receptor antagonists pyrilamine (an H1 receptor antagonist) 
and famotidine (an H2 receptor antagonist) o animals that 
received implants. Combined treatment of implant recipients 
with both H1 and H2 receptor antagonists significantly 
reduced the numbers of phagocytes on implant surfaces and 
the numbers of macrophages and neutrophils recruited e 
novo to the peritoneal cavity (down to values of 50% and 40% 
of untreated controls, respectively). 9 We tentatively conclude 
that histamine enhances the transmigration of phagocytes 
through the endothelial barrier via both H1 and H2 receptors. 
Mast cells are the most likely source of the histamine that 
may be involved (although macrophages also are reported to 
produce and release histamine). We therefore tested the pos- 
sible importance of mast cells in phagocyte recruitment using 
mast cell-deficient mice. 7 After intraperitoneal implantation 
for 16 hours, far fewer PMN (<50% of normal) and 
macrophages/monocytes (<30% of normal) accumulated on 
implant surfaces in mast cell-deficient mice than in their con- 
genie controls. Furthermore, aswas the case with normal ani- 
mals treated with combined histamine receptor antagonists, 
the reduction of the numbers of adherent phagocytes i  
accompanied by greatly decreased recruitment of phagocytes 
to the peritoneum. 
Conclus ion 
Although typically inert, nontoxic, and nonimmunogenic, 
tissue contact biomatefials often prompt a variety of unwanted 
host responses. Overall, our results indicate that acute inflam- 
matory responses to biomaterial implants are triggered by the 
precedent adsorption/denaturation of fibrinogen, mast cell- 
dependent, histamine-dependent, a dchemokine-dependent 
recruitment of phagocytes to the area of the implant and 
phagocyte-surface dherence mediated by interactions between 
Mac-1 and the PI epitope displayed by adsorbed fibrinogen. 
Despite this small progress, we still know very little of the bases 
of inflammatory esponses to biomaterial implants. This igno- 
rance of the mechanisms involved in implant-mediated host 
responses hinders the rational development of more biocom- 
patible materials. 
John W. Eaton, PhD 
Baylor College of Medicine 
Houston, Tex. 
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ROLE OF INTEGRINS IN THE REGULATION 
OF MATRIX DEPOSITION 
Cell interactions with other cells and with extracellular matrix 
molecules are essential in the regtflation of growth, differenti- 
ation, migration, and death. Adhesive interactions also support 
the development and maintenance of the immune system, 
inflammatory processes, and wound healing. Aberrant cell-cell 
and cell-matrix interactions may underlie the volution of 
pathologic host responses. Among the cell surface receptors 
responsible for these pivotal adhesive interactions are the car- 
bohydrate-binding selecting the immunoglobulin superfamily 
members, and the integrins, all of which coordinately orches- 
trate recruitment, attachment, and signaling at sites of inflam- 
mation.i, 2 The fundamental importance of these interactions 
has made them prime targets for blocldng immune/inflamma- 
tory pathogenesis; thus this highly dynamic area of research 
offers exciting possibilities for therapeutic intervention. 
Recent work in our laboratory and others has focused 
specifically on the role of integrins in attachment and signal- 
ing and as targets for intervention. The integrins are glyco- 
protein heterodimers composed of noncovalenfly associated 
ox and: subunits of which many have now been described) -3 
As an example, members of the :1 integrin family bind corre- 
sponding ligands on other cells and may also interact with 
appropriate recognition sequences found in extracellular 
matrix molecules. Ligand-induced adhesion transduces infor- 
mation across the plasma membrane that engages appropriate 
signal transduction pathways. 
Several of the :1 integrins recognize the extracellular matrix 
molecule, fibronectin, and by blocking ligand-integrin binding 
interactions with either integrin-specific antibodies or with sol- 
uble synthetic peptides derived from this glycoprotein, adhe- 
sion and signaling can be disrupted in vitro 4 and in vivo. 5-7 
Leukocytes that express D1 integrins bind to fibronectin 
substrata, which results in cytoskeletal-based morphologic 
changes, adhesion, and signal transduction. Recent vidence 
indicates that monocyte adhesion to fibronectin enhances the 
monocyte signaling response to the Thl lymphocyte-derived 
cytokine, interferon-~ (IFN-II/),4 which amplifies and propa- 
gates immune processes. Although monocyte adhesion to 
fibronectin does not change basal evels of the IFN-~ signal- 
ing cascade constituents, fibronectin-integrin interactions 
markedly augment signaling and activation of monocytes in 
response to IFN-~. Whereas binding of IFN-~ to the IFN-~ 
receptor normally stimulates monocytes to express the Fc 
immunoglobulin receptor (Fc~R1), monocytes adherent to 
fibronectin before b ing exposed to IFN-g exhibit a signifi- 
cant increase in IFN-~-induced steady state levels of RNA for 
Fc~R1. This provides a mechanism whereby integrin mediat- 
ed adhesion may amplify cytoldne stimulated signaling path- 
ways important for monocyte activation. 
In the signaling cascade leading to FeaR1 mRNA expres- 
sion, IFN-~ rapidly activates a DNA-binding activity referred 
to as FcRF~s, and it is this newly formed complex of proteins 
that translocates to the nucleus, where it binds to an area on 
the promoter egion of IFN-responsive genes and induces 
their transcription. Fibronectin adhesion causes a marked 
enhancement of the IFN-~g-induced formation of the FcRF~g 
DNA binding complex in monocytes as detcrmined by clcc- 
trophoretic mobility shift assays. Not only is intact fibronectin 
effective at augmenting IFN-~g signaling, but immobilized 
RGD-containing fibronectin peptides, which retains integrin- 
binding activity, induces optimal enhanccmcnt of the IFN- 
~g-induced signals. The RGD peptidc sequence may be cleaved 
from fibronectin matrices at sites of inflammation and is rec- 
ognized by 0~5~1 and other integrin rcceptors to initiate sig- 
naling events. Moreover, monocytes which intcract hrough 
their a4~1 integrin receptors to bound CS-1 synthetic peptide 
also exhibit enhanced IFN-~g induced activation. 
Further evaluation of the signaling pathways triggcred by 
ligand-0~4[~l or ligand-aSI31 interaction and thcir intersection 
with IFN-~g signal transduction reveals crosstalk between the 
two pathways. The transcription factor, p91 (STAT1), is a 
component of the IFN-~g-stimulated signaling cascade, and 
assembly of the FcRFgr DNA binding complcx is dependent 
on tyrosine phosphorylation f p91.8 In those cells adherent 
to either fibronectin or RGD-containing peptides, a marked 
enhancement is evident in the ability of IFN-~g to stimulate 
thc tyrosine phosphorylation f p91. 4 Furthcrmorc, both 
JAK1 and JAK2 kinases, upstream components of the IFN-~I/ 
signaling pathway, demonstrate enhanced tyrosinc phospho- 
rylation. These data suggest that the integrin and IFN-~g 
intracellular signaling pathways converge at or immediately 
distal to receptor dimerization and phosphorylation. Whercas 
adhesion to immobilized fibronectin matrices or its derivative 
cell-binding peptides activates these pathways, soluble 
fibronectin or RGD has no enhancing effect on IFN-~g medi- 
ated signaling. Not only do these data suggest that integrin 
clustering is an important aspect of augmentation of the 
cytokine-induced signaling pathways, but they also provide 
cvidence that soluble peptides might compete for integrins, 
inhibiting subsequent adhesion and its attendant signal gen- 
eration. In support of this hypothesis, we find that pretreat- 
mcnt of monocytes with soluble pcptidcs reverses their sus- 
ceptibility to fibronectin-mediated augmentation of IFN-xg 
activation, providing evidence for a possible antiinflammatory 
role for these agents. 
Extending these studies from in vitro observations to in 
vivo applications has revealed that similar disruption of adhe- 
sion and signaling in inflammatory diseases ameliorates the 
disease process.I, s-7 Using the TGF-[31 null mouse, in which 
the gene for TGF-~I has been inactivated by homologous 
recombination, as a model we explored the potential ability of 
synthetic fibronectin peptides to influcncc the characteristic 
disease that develops in the absence of TGF-~I. In these ani- 
mals, T cell activation is associated with constitutive cytokine 
release, including IFN-gO5 and the development of mnltifocal 
autoimmune-like T cell lesions in multiple organs.9, l° ThI- 
like immune foci with c3,coldne secretion, macrophage activa- 
tion, and disease appear within weeks after birth, ultimately 
rcsulting in dcath of the animals of autoinduced cardiopul- 
monary failure. One of the first predictors of impending dis- 
case is leukocyte adhesion to the vessel walls in vulnerable tis- 
sues, cspccially heart, lung, and salivary glands. 7 After these 
adhesive ¢vcnts, leukocytcs transmigrate across the vessel wall 
and cxtraccllular matrix, accumulating in apparcntly uncon- 
trolled numbers within the adjacent tissues. 
The association of elevated adhesion with spontaneous 
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IFN-~¢ production prompted us to explore whether the 
fibronectin-augmented IFN-q¢ signaling pathways detected in 
vitro were operative in the pathologic lesions of the TGF-[~I 
null mice. Indeed, constitutive activation of the IFN-~ path- 
way is apparent in the null mice as comparcd to control itter- 
mates (Wahl et al., in preparation). These observations raise 
thc potential for disrupting this insidious cyclc of leukocyte 
adhesion, recruitment and activation with the antiinflammato- 
ry soluble fibronectin peptides. To this end, the mice were 
treated systemically with synthetic peptides (RGD, CS1, FN- 
C /H- l ,  and FN-C/H-V),  and the evolution of leukocyte 
accumulation and activation was monitored in target issues. 
As reported,6, 7 leukocyte adhesion and recruitment is marked- 
ly attenuated in the animals treated with the active peptides 
but not the corresponding scrambled peptidcs: Moreover, 
diminished IFN-g¢ production and disruption of fibronectin 
adhesion moleculc binding arc associated with changcs in the 
phosphorylation events characteristic of the IFN-g signaling 
pathway. These observations support he notion that disrup- 
tion of integrin-mediated adhesion and signaling events can 
suppress inflammation-based pathogenesis. Development of 
specific adhesion-disrupting drugs should lead to the Success- 
ful treatment of disorders related to both acute and chronic 
inflammation. 
Sharon Wahl, PhD 
National Institute of Dental Health 
National Institutes of Health 
Bethesda, Md. 
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SURFACES AND INFECTION 
Foreign materials, biomaterials, are nowadays implanted for 
temporary or permanent use in many different parts of the 
human body. Materials used are polymers, metals, and ceram- 
ics. Commonly used graft materials are polytetrafluoroethylene 
(PTFE) and Dacron. Criteria for evaluation of biomaterials are 
tissue compatibility, end-use functioning, and for materials in 
contact with blood, antithrombogenicity. In recent years, 
complement activation has been recognized as a serious com- 
plication, and microbial infections. The latter are significantly 
more frequent i  skin-penetrating devices, and members of the 
normal skin microflora, such as Staphylococcus epidermidis and 
other species of coagulase-negative staphylococci, and 
Propionibacterium aches are common etiologic agents. 
Within the first second after introduction of a biomateri- 
al into the body, host proteins and glycosaminoglycans d orb 
to its surface. Physicochemical properties of the biomaterial 
and whether the implant is exposed to host fluid during per- 
fusing or stand-still conditions influence the initial adsorp- 
tion. Adsorption of the quantitatively dominating protein is 
initially maximal. 1 Protein-protein teractions, for example, 
between fibronectin and collagen, fibronectin and fibrinogen, 
or collagen and vitronectin, contribute to formation of a mul- 
tilayer of proteins and to the exposure of different proteins 
over the next 3 to 4 days after insertion. Postadsorptional 
changes of configuration, also determined by physicochemical 
properties of the biomaterial surface, cause exposure of dif- 
ferent domains of the proteins. Because binding of thrombo- 
cytes, complement factors, and eukaryotic ells, as well as 
binding of Staphylococcus aureus is identified in specific 
domains of fibrinogen, fibronectin, vitronectin, and other 
plasma proteins, exposure of distinct domains of several of 
these proteins influence the outcome of a biomaterial 
implant. 2 Furthermore, thrombospondin a d von Willebrand 
factor may be released from adherent thrombocytes, a 
Whenever a microbe is in the vicinity of a solid surface, for 
example, during circulation in the blood stream, they seek to 
adhere to the surface, either to proteins or to glycosaminogly- 
cans already adsorbed, or to naked biomaterial surface. After 
adhesion they turn down their metabolism and grow slowly as 
microcolonies. In about 6 hours synthesis of glycocalyx, a
polysaccharide substance, can be detected. This forms part of 
the biofilm on the surface, which prevents ignals to the host 
immune system and penetration ofphagoc)mic cells and antibi- 
otics as well as impairs diagnosis of the colonization/infection. 
In this way bacteria may remain in a silent, dormant form for 
weeks, months, and even years. Mechanisms which make the 
microbial colonization to "flare up" are unknown. 
Interactions of microbes with extracellular matrix (ECM) 
and plasma proteins have been most thoroughly studied in S. 
aureu 6 where specific binding of fibronectin, fibrinogen, vit- 
ronectin, laminin, collagen, thrombospondin, and heparan sul- 
phate has been described. 4 Interestingly, S. epidermidis has 
been shown to bind these proteins in immobilized form to the 
same or higher extent than S. aureus. S This may indicate that 
coagulase-negative staphylococci recognize a domain which 
preferentially is exposed when the proteins are immobilized on 
surfaces. Fibronectin has been proposed to mediate adhesion of 
staphylococci to surfaces. 6 Also, thrombospondin a d yon 
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Willebrand factor have been shown to bind to S. aureus and 
have been proposed to mediate adhesion of these bacteria in 
the blood stream.a, 7 
Microbial colonization of a biomaterial surface may pre- 
vent exposure of protein domains that mediate adhesion of 
eukaryotic cells, the Arg-Gly-Asp sequence, present in all ECM 
and plasma proteins, thereby impairing tissue integration. By 
expression of binding of vitronectin microbes may prevent this 
protein from inhibition of insertion of the final C5-9 compo- 
nent of the complement, resulting in increased complement 
activation. 8 Fibrinogen is a "sticky" molecule that exerts pecif- 
ic and nonspedfic interaction with microbes and other mole- 
cules. Intact fibrinogen may expose domains mediating binding 
of thrombocytes, inflammatory response, and lenkocytes. 9 
These interactions may lead to serious complications per se, like 
dogging, but also create anew locus for microbial colonization 
and proliferation. 
In recent years a number of studies on various modifications 
of biomaterial surfaces to prevent microbial colonization have 
been presented, like coating with disinfectants orantimicrobials. 
Certainly, this i  a correct approach since treatment of surfaces 
to eliminate microbial colonization generally is in vain. 
However, the rapid adsorption of host proteins to any inserted 
biomaterial occludes most surface coatings. One of the few sta- 
ble surface coating is heparinization using the end-point attach- 
ment technique since this is a "self-new generating" surface, l0 
Heparinization was introduced as an antithrombotic surface and 
has later been shown to induce complement activation to a low 
extent. 11 The heparinized surface is also interesting fi'om the 
point of view that it may bind hepafin-dependent growth fac- 
tors, thereby enhancing tissue integration. On the other hand, 
we have identified binding of basic heparin-dependent a d 
platelet-derived growth factor by S. aureus and coagulase-nega- 
tive staphylococci, which shows that microbial colonization may 
impair tissue integration i a specific way.12 Surfaces coated with 
antibiotics may impair bacterial colonization i itially. However, 
these surfaces carry the risk of spreading bacteria that are resis- 
tant to the antimicrobial gent used and of inducing allergic 
reactions. The latter complication is also valid for surfaces coat- 
ed with disinfectants, The risk of spread of antibiotic-resistant 
bacterial strains s higher for skin-penetrating devices than for 
biomaterials in inner organs. Certainly this is an important area 
for future development ofantiadhesive surfaces. 
Torkel Wadstr6m, MD 
University of Lund 
Lund, Sweden 
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POSTER SESSION 
P53 GENE TRANSFER TO THE INJURED RAT 
CAROTID ARTERY DECREASES INTIMAL 
HYPERPLASIA 
Purpose: We studied the effect of adenovirus-mediated g ne 
transfer of p53 protein on the injured rat carotid artery to deter- 
mine its ability to decrease the formation ofintimal hyperplasia. 
Methods: In vivo gene transfer was used in isolated segments of 
balloon injured rat carotid arteries. Genetically modified aden- 
ovirus encoding for wild-type p53 protein (AdWTp53) was 
appfied in three different concentrations. Control rats received 
either adenovirus null (AdNuU), 8 x 1010 pfu/ml or M-199 
medium solution (vehicle). Expression of p53 was determined 4 
days after gene transfer by Westem-blot. Intimal hyperplasia was 
assessed after 14 days by harvesting carotid arteries and deter- 
mining the intima/media ( I /M) ratio by cross-sectional area 
measurement. Simultaneously, immunohistochemical analysis 
was done to detect he presence of p53 on smooth muscle cell 
nuclei. 
Results: p53 expression was confirmed by Western-blot. 
There was a significant reduction in intimal hyperplasia on all 
treated animals as compared with controls. The highest dose of 
AdWTp53 resulted in a near total arrest of intimal hyperplasia 
(mean of 97% reduction). A dose-response curve was observed. 
The immunohistochemical an lysis was positive for the presence 
of p53 in rats infected with AdWTp53. The AdWTp53 groups 
have three different concentrations: #1, 8 x 10 ~0 pfu/ml; #2, 
1.6 x 1010 pfu/ml; and #3, 8 x 109 pfu/ml. 
Conclusions: Adenovirus-mediated gene transfer of p53 
protein significantly decreases the formation of intimal hyper- 
plasia in the rat carotid injury model h~ a dose-response manner. 
This may represent a potential therapy for restenosis inhumans. 
Marcel Scheinman, MD 
Enrico Ascheg MD 
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MONOCLONAL ANTIBODY AGAINST CD 18 
REDUCES INTESTINAL AND PULMONARY 
INJURY IN A MODEL OF RUPTURED 
ABDOMINAL AORTIC ANEURYSM 
Purpose: Rupture of an abdominal aortic aneurysm (RAAA) 
is associated with significant morbidity and mortality due to 
multiple organ failure after successful repair. Because neu- 
trophils are thought o play a pivotal role in the generation 
of ischemia-reperfusion injury, the purpose of this study was 
to determine the role of neutrophils in the generation of 
local (intestinal) and remote (pulmonary) injury after the 
combined insults of shock and supramesenteric aortic clamp- 
ing in a model simulating RAAA repair. 
Methods: Sprague-Dawley rats (450 to 550 g) were 
hemorrhaged to a mean arterial pressure of 50 mm Hg for 1 
hour, followed by 45 minutes of supramesenteric aortic 
clamping. Animals were given anti-CD18 (4 mg/kg) or con- 
trol antibody (4 mg/kg) 55 minutes into shock and 5 min- 
utes before clamp placement. Intestinal permeability was 
determined by measuring I125-1abeled albumin loss into an 
isolated, perfused segment of small intestine. Pulmonary per- 
meability (LPI) to albumin-1125 was determined by bron- 
choalveolar lavage. Intestinal and puhnonary myeloperoxi- 
dase (MPO) activity and F2-isoprostane l vels were mea- 
sured as indexes of neutrophil sequestration and oxidative 
stress, respectively. 
Results: In shock plus clamp (S+C) animals there was a 
significant increase in intestinal plasma protein loss from 7.36 
_+ 2.14 to 33.66 +_ 5.90 mg/g  dry intestine (p < 0.05). 
Intestinal MPO activity also increased from 0.684 +_ 0.157 to 
4.10 _+ 0.787 units/rag protein (p < 0.05). Treatment with 
anti-CD18 decreased intestinal protein loss to 11.98 + 4.34 
mg/g  dry intestine (p < 0.05) and decreased intestinal MPO 
activity to 0.597 + 0.159 units/mg protein (p < 0.05). Lung 
permeability index also increased from 0.014 _+ 0.005 to 
0.047 _+ 0.008 (p < 0.05) in the S+C animals; and pulmonary 
MPO activity and F2-isoprostane levels significantly 
increased from 2.38 _+ 0.334 to 5.19 _+ 0.614 units/rag pro- 
tein (p < 0.05) and from 90.0 + 15.0 to 843.27 _+ 231.24 
pg/mg protein (p < 0.05), respectively. Treatment with anti- 
CD18 significantly reduced LPI to 0.025 _+ 0.005 (p < 0.05) 
and F2-isoprostane l vels to 396.66 +_ 67.5 pg /mg (p < 
0.05); however, anti-CD18 did not after lung MPO activity 
(4.27 _+ 0.228 units/mg protein). 
Conclusions: The combination of shock and suprame- 
senteric aortic clamping caused a significant intestinal and 
pulmonary injury characterized by increased capillary perme- 
ability, oxidative stress, and neutrophil sequestration. The 
administration f anti -CD 18 antibody significantly decreased 
organ injury; however, the results uggest that different neu- 
trophil-mediated mechanisms are responsible for the local 
intestinal nd remote pulmonary injury in this RAAA model. 
April J. Boyd, PhD 
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DACRON-MODIF IED LDL INHIBITS ENDOTHE-  
LLAL CELL MIGRATION: VARIABLE 
PROTECTION BY ANTIOXIDANTS 
Purpose: Graft healing is characterized by limited endothelial 
cell (EC) ingrowth at the anastomoses, but the reason for this 
is unclear. We have previously reported that Dacron graft 
material activates monocytic (U937) cells to oxidize LDL 
This study assessed the effect of Dacron-activated U937 cell- 
modified LDL (oxLDLDac/u937) on EC migration and the 
protective role antioxidants may play. 
Methods: Bovine aortic EC were grown to confluence and 
injured with a razor blade pressed into the plastic plate to mark 
a starting line, then swept forward to remove EC on one side 
of the cut. At the time of injury, LDL (200 and 400 ~tg 
Chol/ml) modified by 24 hour incubation with U937 cells 
(500,000/ml) and Dacron graft (80 mg _+ 5 mg/ml) was 
added to EC monolayers. Antioxidant protection of migration 
was assessed bypreincubating EC with antioxidants for 1 hour 
before plating test conditions. At 24 hours, EC migration was 
quantitated by image analysis. 
Results: Native LDL increased EC migration, whereas 
oxLDLDac/ug37 (400 gg/ml) inhibited EC migration by 95%, 
as did Cu2+-modified LDL. Vitamin E completely restored EC 
migration, whereas probucol and BHT did not. 
Conclusions: OxLDLDac/u937 inhibits EC migration, sug- 
gesting that oxLDL may contribute to the limited EC 
ingrowth at the anastomoses of prosthetic grafts. Vitamin E 
may have a role in promoting raft healing by protecting EC 
migration. 
John A. van Aalst, MD 
Paul L. Fox, PhD 
Linda M. Graham~ MD 
University Hospitals of Cleveland 
Cleveland Heights, Ohio 
INCREASED PLASMA LEVELS OF MMP-9 ARE 
ASSOCIATED WITH ABDOMINAL AORTIC 
ANEURYSMS 
Previous investigators have identified isease-specific eleva- 
tions of the metalloelastase, MMP-9, in aneurysm tissue biop- 
sies. We hypothesized that circulating MMP-9 might also be 
elevated in patients with aneurysms. The purpose of this study 
was to compare plasma and aortic tissue MMP-9 levels in 
patients with infrarenal aneurysms (AAA), patients with 
symptomatic aortoiliac occlusive disease (AOD), and normals 
(NA). 
Methods: Sandwich ELISA was used to measure plasma 
MMP-9 in patients with AAA (n = 22; mean age, 72.7 years), 
AOD (n = 9; 60.5 years), and NA (n = 8; 35.3 years). MMP- 
9 levels were also measured in 48-hour supematants of organ 
culture tissue explants from patients with AAA (n = 10; 66.2 
years), AOD (n = 5; 50.4 years), and organ donors (n = 7; 
48.1 years). Results were reported as mean _+ SE and analyzed 
using ANOVA with multivariate r gression. 
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Results: Plasma MMP-9 levels were significantly higher in
patients with AAA (85.66 _+ 11.64 ng/ml) than in AOD 
patients (25.75 +_ 4.159 ng/ml; p < 0.001) or NA (13.16 _+ 
1.94 ng/ml; p < 0.001). No significant difference in plasma 
MMP-9 levels between AOD and NA was identified. Patients 
with multiple aneurysms had significantly higher levels than 
did patients with an isolated AAA (134.68 + 17.5 vs 71.03 _+ 
10.7; p < 0.04). In organ culture, AAA and AOD tissue 
explants produced significantly higher levels of MMP-9 
(3218.5 _+ 1115.2 and 1283.1 _+ 310.6 ng/gm aortic tissue) 
than did NA explants (6.14 _+ 2.3 ng/gm aortic tissue; p < 
0.0001). No significant difference in MMP-9 production 
between AAA and AOD explants was identified. 
Conclusions: Plasma MMP-9 levels are significantly high- 
er in AAA patients than AOD patients or normal volunteers. 
Patients with multiple aneurysms have higher levels than 
those with an isolated AAA. Organ culture studies suggest 
that diseased aortic tissue is the source of MMP-9. 
William D. McMillan, MD 
William H. Pearce, MD 
Northwestern University Medical School 
Chicago, Ill. 
ALTERATION OF ENDOTHELIAL PERMEABILITY 
DURING HYPOXIA IS MEDIATED BY 
INTERLEUKIN-6 
Purpose: Increased endothelial permeability leads to neu- 
trophil transmigration a d tissue injury in diverse inflamma- 
tory conditions. Hypoxia has been shown to increase 
endothelial permeability and alter cellular function. These 
experiments were designed to determine which cytokines are 
released uring hypoxia and whether antibody blockade 
would prevent the observed changes in endothelial perme- 
ability. 
Methods: Endothelial cells were cultured from human 
umbilical veins. Hypoxia was maintained for 24 hours by iso- 
lating the cells in a chamber through which a 1% 02 mixture 
was insufflated (30 minutes at 1 L/rain). The production of 
three cytokines (IL-1, IL-6, and TNF-0Q was quantitated by 
enzyme-linked immunosorbent assay (pg/ml). Changes in 
permeability were measured by transendothelial electrical 
resistance (TEER; ohms cm 2) in that decreasing TEER repre- 
sents increased permeability. 
Results: TNF-0~ and IL-lc~ were not altered over 24 
hours of hypoxia. IL-6 secretion increased over 18 hours, 
peaking at 140 -+ 5 pg/ml. Addition of anti-IL-6 mAb (0.3 
mg/ml) before hypoxia attenuated the decrease in TEER 
(hypoxia 63% +_ 3% of control; hypoxia+anti-IL-6 8 % _+ 4%; 
p < 0.05). 
Conclusions: IL-6 is produced by endothelial cells during 
prolonged hypoxia. Antibody blockade of IL-6 ablates the 
hypoxic increases in HUVEC permeability. This data supports 
the hypothesis that IL-6 is an important mediator of the 
changes in permeability associated with hypoxic tissue injury. 
Mir H. All, BA 
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FAS/FAS LIGAND-MEDIATED APOPTOSIS AS A 
MECHANISM OF VASCULAR SMOOTH MUSCLE 
CELL LOSS IN ABDOMINAL AORTIC 
ANEURYSMS 
A common histologic characteristic of AAA is the decrease in 
SMC density that may contribute to dilatation by preventing 
repair of damaged elastic fiber matrix. It is known that fas- 
expressing cells can undergo apoptosis when bound by fasL, 
and there is evidence for this process in atherosclerotic 
plaque. We have used immunohistochemical analysis to iden- 
tiff/the presence of fas and fasL expression within aortic 
aneurysms. Formalin-fixed paraffin-embedded s ctions treat- 
ed with saponin (Sigma) from AAA, aortas with occlusive ath- 
erosclerotic disease (AOD), and normal aortas from trans- 
plant patients were probed with affinity-purified rabbit anti- 
fas and anti-fasL antibodies (Research Diagnostics). Urea 
extracts of AAA, AOD, and NA tissue and a lysate of AAA 
SMC explant culture were separated on a 12% acrylamide gel, 
blotted onto nitrocellulose, and probed with monocloual 
mouse anti-fas antibodies (Transduction Labs). By Western 
blotting for fas, 5/5 AAA extracts, 1/1 Aneurysm SMC 
explant lysate, 1/1 AOD, and 0/1 NA were positive for a 
45kDa band, which corresponded to a band in a known con- 
trol lysate. In AAA tissue, we were able to identify fas express- 
ing SMC in focal areas of media where SMCs were most con- 
centrated, frequently these colocalized with mononuclear 
cells which stained positively for fasL. The neovascular 
endothelinm within the media of AAA specimens were reac- 
tive with both antibodies. Staining of medial cellular elements 
in AOD or NA was rare. These results offer preliminary evi- 
dence that ligation of fas on SMCs within the media of AAA 
results in apoptotic stimuli and loss of the normal medial 
SMC population. 
John A. Curci, MD 
Robert W Thompson, MD 
Washington University School of Medicine 
St. Louis, Mo. 
MOLECULAR PRECURSORS TO FLOW-INDUCED 
AORTIC ENLARGEMENT 
We have previously demonstrated the incrcased expression of 
growth factors (TGF-~ and bFGF) and c-los a growth factor 
regulator, in animal models of increased blood flow (BF). 
These precursors may be responsible for arterial enlargement. 
To demonstrate platclct derived growth factor-~ (PDGF-]3) 
expression i  response to increased BF and correlation with c- 
los expression i  vivo, aortocaval fistulae (ACF) werc created 
in mice using a needle puncture method. After ACF creation, 
mice were killed at 1, 3, and 7 days. Controls consisted of 
sham operated animals (no fistula). BF by micro-Doppler 
vclocimetry, aortic diamcter (AD), and WSS were calculated. 
Transcription ofproximal aorta beta-actin (BA) and PDGF-B 
was investigated by RT-PCR using mouse specific primers. 
Expression of c-los was determined by b-galactosidasc activity 
of aortas from transgenic mice harboring the c-los gene con- 
nected to a lacZ reporter gene. BF immediately after fistula 
creation was 4.4 _+ 0.6 ml/min and continued to increase after 
7 days to 8.6 ~ 1.6 ml/min (p < 0.05). AD increased by 50% 
after 7 days (p < 0.05). Expression of c-los was observed after 
1 day and ecreased after 3 days. Appropriate-sized BA bands 
were detected in all aortic samplcs. No PDGF-B mRNA was 
detected in control, 1, or 3 day aortas, but was detected in 
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liver (positive control). PDGF-13 expression, contrary to TGF- 
[3 and bFGF, is not upregulated with increased BF acutely 
before enlargement. Expression of c-los may not regulate arly 
transcription of PDGF-13. We have developed a reproducible 
mouse ACF model to study molecular markers responsible for 
arterial adaptation to increased BF. 
Andrew J. Krystkowiak, BS 
Quang ~ Vo, BS 
Tej M. Singh, MD 
Raul J. Guzman, MD 
Christopher K. Zarins, MD 
Stanford University School of Medicine 
Palo Alto, Calif. 
F IBRONECTIN INCORPORATION INTO EXTRA- 
CELLULAR MATRIX OF RAT CAROTID ARTERIES 
AFTER BALLOON INJURY 
Intimal esions after vascular injury are believed to result from 
medial layer smooth muscle proliferation, migration, and 
ECM synthesis. However, adventitial cells have recently been 
implicated in the development of these lesions. Fn, a major 
glycoprotein component of ECM, may play a role in the 
pathogenesis of intimal hyperplasia (IH). To investigate the 
role of Fn in IEt, we characterize an ex vivo whole carotid 
assay of adventitial Fn incorporation using a rat carotid bal- 
loon injury model. Carotid arteries were harvested and tied at 
each end. Arteries were then incubated in Fn-deficient MEM 
containing 1.0 gg/ml of I12a-Fn. After incubation for various 
time intervals, the carotids were washed, weighed, and placed 
in 1% deoxycholate o extract soluble I125-Fn (pool I), which 
is attached to cell-associated matrix assembly sites, from insol- 
uble, polymerized I12S-Fn (pool II). In rats undergoing vas- 
cular injury, a 2F balloon catheter was used to denude the 
artery of endothelium before the matrix incorporation assay. 
Adventitial I12~-Fn matrix incorporation i to pool II demon- 
strated a temporal increase, which plateaued by 6 hours (4.74 
± 0.23 ng/mg carotid). Pool I was relatively unchanged over 
the incubation period (0.81 _+ 0.01 ng/mg). To determine 
whcthcr Fn is prefercntially incorporated into the adventitial 
or intimal ECM, I12S-Fn incorporation by everted (luminal) 
and noneverted (adventitial) carotids after a 6 hour incuba- 
tion was compared. There was significantly ess uptake of1125- 
Fn on the luminal surface of the carotid artery when com- 
pared to adventitial uptake for both pools I (0.73 ± 0.19 vs 
0.24 + 0.05; p < 0.01) and II (3.38 _+ 0.76 vs 0.58 ± 0.19; 
p < 0.001). To assess the effect of vessel injury induced by 
endothelial denudation on I]2S-Fn incorporation i to the 
adventitial ECM, pools I and II were measured on days 0, 2, 
and 7 after injury. Significantly ess Fn incorporated into pool 
II of the adventitial ECM 7 d~ys after endothelial balloon 
injury. These studies demonstrate hat Fn incorporates to a 
greater extent in the adventitial layer as compared with the 
intima of carotid arteries and that this adventitial incorpora- 
tion is decreased 7 days after balloon injury. 
Claude Roland, MD 
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TISSUE INHIB ITOR OF METALLOPROTEINASE IS 
INCREASED IN THE SAPHENOFEMORAL 
JUNCTION OF PATIENTS 
WITH VARICOSITIES IN THE LEG 
To examine the role of matrix metalloproteinase (MMP) activ- 
ity in the development of varicose disease, we studied MMPs 
and their inhibitors (TIMPs) in vein segments from patients 
with and without varicosities. Vein segments of normal caliber 
from the saphenofemoral junction were harvested from 13 
patients: at saphenous ligation for varicosities in 7 and at har- 
vest for bypass graft in 6. A portion of the specimen was mount- 
ed for immunohistochemical analysis, and the remainder was 
processed for the recovery of protein. Twenty micrograms of 
each specimen was electrophoretically separated on 10% poly- 
acrylamide gels containing elatin (zymography), or without 
gelatin for Western analysis using monoclonal ntibodies direct- 
ed against MMP-2, MMP-3, MMP-9, and TIMP-1 and -2. 
Signals were quantified by scanning densitometry and normal- 
ized to the signal of 20 pg of HT1080 fibrosarcoma cell line 
media (positive control). Immunohistochemical analysis was 
performed using the same antibodies and quantified with image 
analysis software. TIMP-1 is increased in vein segments from 
patients with varicose disease and MMP-2 levels were higher in 
veins from patients without varicosities. No differences were 
noted in MMP-3, MMP-9, TIMP-2, gelatinolytic activity, or 
on immunohistochemieal analysis. When analyzed by gender, 
there was no difference between men and women. TIMP-I lev- 
els in veins from patients with varicose disease are increased, 
whereas MMP-2 levels are decreased. These findings in the 
proximal saphenous vein implicate alterations in matrix metal- 
loproteinase activity in the etiologic mechanism ofvenous vari- 
cosities. 
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OPIOID GROWTH FACTOR DECREASES 
NEOINT IMA FORMATION IN THE RAT 
CAROTID ARTERY 
Purpose: [Met~]enkephalin is an opioid growth factor (OGF) 
that has been found to inhibit cellular proliferation i  various 
cell lines. The aim of this study was to determine whether 
OGF also decreases vascular intimal hyperplasia in the rat 
carotid artery injury model. 
Methods: After undergoing balloon injury of the common 
carotid artery, rats were given daily intraperitoneal injections of 
either OGF ([MetS]enkephalin, 10mg/kg/d),  naltrexone (30 
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mg/kg/d),  the competitive OGF receptor antagonist, or saline 
solution. Carotid arteries were serially harvested at 1, 2, 4, 7, 14, 
and 28 days. Morphometric analysis and computerized planime- 
try was used to measure the cross-sectional area of the intima 
and media. Statistical comparisons were performed by ANOVA. 
Results: Neither OGF or naltrexone had a significant 
effect on intimal proliferation at day 1, 2, or 4. OGF success- 
fully inhibited intimal hyperplasia, s measured by the ratio of 
cross-sectional area of the intima to the media ( I /M),  by day 
7, and this effect persisted throughout the follow-up period. 
Naltrexone promoted intimal proliferation during the same 
time periods. Conclusions: [Met5]enkephalin inhibits intimal 
hyperplasia in balloon-injured rat carotid arteries. Because 
naltrexone caused intimal proliferation, the effects 6f OGF 
appear to be receptor-mediated. 
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